
<html lang="en"     class="pb-page"  data-request-id="6ea3ef1c-3cf1-4df7-acca-736695d27873"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00736;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes" /></meta><meta name="dc.Creator" content="Xinyu  Chen" /></meta><meta name="dc.Creator" content="Junjie  Fu" /></meta><meta name="dc.Creator" content="Feng  Zhou" /></meta><meta name="dc.Creator" content="Qimeng  Yang" /></meta><meta name="dc.Creator" content="Jialing  Wang" /></meta><meta name="dc.Creator" content="Hui  Feng" /></meta><meta name="dc.Creator" content="Wen  Jiang" /></meta><meta name="dc.Creator" content="Luofan  Jin" /></meta><meta name="dc.Creator" content="Xuelin  Tang" /></meta><meta name="dc.Creator" content="Neng  Jiang" /></meta><meta name="dc.Creator" content="Jian  Yin" /></meta><meta name="dc.Creator" content="Jing  Han" /></meta><meta name="dc.Description" content="Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity. Hypoglycemic agents capable of improving β-cell function and reducing body weight therefore are gaining in..." /></meta><meta name="Description" content="Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity. Hypoglycemic agents capable of improving β-cell function and reducing body weight therefore are gaining in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 30, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00736" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00736" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00736" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00736" /></link>
        
    
    

<title>Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00736" /></meta><meta property="og:title" content="Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0014.jpeg" /></meta><meta property="og:description" content="Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity. Hypoglycemic agents capable of improving β-cell function and reducing body weight therefore are gaining increasing interest. Though glucagon-like peptide 1 receptor (GLP-1R)/cholecystokinin 2 receptor (CCK-2R) dual agonist ZP3022 potently increases β-cell mass and improves glycemic control in diabetic db/db mice, the in vivo half-life (t1/2) is short, and its body weight reducing activity is limited. Here, we report the discovery of a series of novel GLP-1R/CCK-2R dual agonists. Starting from Xenopus GLP-1, dual cysteine mutation was conducted followed by covalent side chain stapling and albumin binder incorporation, resulting in a stabilized secondary structure, increased agonist potency, and improved stability. Further C-terminal conjugation of gastrin-6 generated GLP-1R/CCK-2R dual agonists, among which 6a and 6b showed higher stability and hypoglycemic activity than liraglutide and ZP3022. Desirably, 6a and 6b exhibited prominent metabolic benefits in diet-induced obesity mice without causing nausea responses and exerted considerable effects on β-cell restoration in db/db mice. These preclinical studies suggest the potential role of GLP-1R/CCK-2R dual agonists as effective agents for treating diabetes and related metabolic disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00736"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00736">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00736&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00736&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00736&amp;href=/doi/10.1021/acs.jmedchem.0c00736" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12595-12613</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01035" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00813" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Stapled and <i>Xenopus</i> Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xinyu Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinyu Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinyu++Chen">Xinyu Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junjie Fu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junjie Fu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junjie++Fu">Junjie Fu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2741-7469" title="Orcid link">http://orcid.org/0000-0002-2741-7469</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Zhou">Feng Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qimeng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qimeng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qimeng++Yang">Qimeng Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jialing Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jialing Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jialing++Wang">Jialing Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Feng">Hui Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wen Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen++Jiang">Wen Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luofan Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luofan Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luofan++Jin">Luofan Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuelin Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuelin Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuelin++Tang">Xuelin Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neng Jiang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neng Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#dab9aaafb0b4b29aebece9f4b9b5b7"><span class="__cf_email__" data-cfemail="22415257484c4a621314110c414d4f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neng++Jiang">Neng Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Yin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Yin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#1e74777f706777705e74777f7079707f70307b7a6b307d70"><span class="__cf_email__" data-cfemail="53393a323d2a3a3d13393a323d343d323d7d3637267d303d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Yin">Jian Yin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2284-1666" title="Orcid link">http://orcid.org/0000-0002-2284-1666</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jing Han</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, PR China</div><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a4ccce959d9c92909690e4ced7cad18ac1c0d18ac7ca"><span class="__cf_email__" data-cfemail="177f7d262e2f21232523577d64796239727362397479">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Han">Jing Han</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5605-1868" title="Orcid link">http://orcid.org/0000-0001-5605-1868</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00736&amp;href=/doi/10.1021%2Facs.jmedchem.0c00736" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12595–12613</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 May 2020</li><li><span class="item_label"><b>Published</b> online</span>30 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00736</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12595%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXinyu%2BChen%252C%2BJunjie%2BFu%252C%2BFeng%2BZhou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c00736%26title%3DStapled%2Band%2BXenopus%2BGlucagon-Like%2BPeptide%2B1%2B%2528GLP-1%2529-Based%2BDual%2BGLP-1%252FGastrin%2BReceptor%2BAgonists%2Bwith%2BImproved%2BMetabolic%2BBenefits%2Bin%2BRodent%2BModels%2Bof%2BObesity%2Band%2BDiabetes%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12613%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00736"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1134</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00736" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xinyu&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Junjie&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Qimeng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jialing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Wen&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Luofan&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Xuelin&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Neng&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Han&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12595-12613&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00736&quot;},&quot;abstract&quot;:&quot;Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity. Hypoglycemic agents capable of improving β-cell function and reducing body weight therefore are gaining increasing interest. Though glucagon-like peptide 1 receptor (GLP-1R)/cholecystokinin 2 receptor (CCK-2R) dual agonist ZP3022 potently increases β-cell mass and improves glycemic control in diabetic db/db mice, the in vivo half-life (t1/2) is short, and its body weight reducing activity is limited. Here, we report the discovery of a series of novel GLP-1R/CCK-2R dual agonists. Starting from Xenopus GLP-1, dual cysteine mutation was conducted followed by covalent side chain stapling and albumin binder incorporation, resulting in a stabilized secondary structure, increased agonist potency, and improved stability. Further C-terminal conjugation of gastrin-6 generated GLP-1R/CCK-2R dual agonists, among which 6a and 6b showed higher stability and hypoglycemic activity than liraglutide and ZP3022. Desirably, 6a and 6b exhib&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00736" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00736&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00736" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00736&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00736" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00736&amp;href=/doi/10.1021/acs.jmedchem.0c00736" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00736" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00736" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00736%26sid%3Dliteratum%253Aachs%26pmid%3D33125843%26genre%3Darticle%26aulast%3DChen%26date%3D2020%26atitle%3DStapled%2Band%2BXenopus%2BGlucagon-Like%2BPeptide%2B1%2B%2528GLP-1%2529-Based%2BDual%2BGLP-1%252FGastrin%2BReceptor%2BAgonists%2Bwith%2BImproved%2BMetabolic%2BBenefits%2Bin%2BRodent%2BModels%2Bof%2BObesity%2Band%2BDiabetes%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12595%26epage%3D12613%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity. Hypoglycemic agents capable of improving β-cell function and reducing body weight therefore are gaining increasing interest. Though glucagon-like peptide 1 receptor (GLP-1R)/cholecystokinin 2 receptor (CCK-2R) dual agonist ZP3022 potently increases β-cell mass and improves glycemic control in diabetic db/db mice, the in vivo half-life (<i>t</i><sub>1/2</sub>) is short, and its body weight reducing activity is limited. Here, we report the discovery of a series of novel GLP-1R/CCK-2R dual agonists. Starting from <i>Xenopus</i> GLP-1, dual cysteine mutation was conducted followed by covalent side chain stapling and albumin binder incorporation, resulting in a stabilized secondary structure, increased agonist potency, and improved stability. Further C-terminal conjugation of gastrin-6 generated GLP-1R/CCK-2R dual agonists, among which <b>6a</b> and <b>6b</b> showed higher stability and hypoglycemic activity than liraglutide and ZP3022. Desirably, <b>6a</b> and <b>6b</b> exhibited prominent metabolic benefits in diet-induced obesity mice without causing nausea responses and exerted considerable effects on β-cell restoration in db/db mice. These preclinical studies suggest the potential role of GLP-1R/CCK-2R dual agonists as effective agents for treating diabetes and related metabolic disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There are over 400 million people with diabetes globally, and the prevalence of diabetes continues to rise.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Type 2 diabetes mellitus (T2DM) accounts for ∼90% of diabetic cases worldwide, and the number of T2DM has doubled in the past decades, with a particularly rapid increase among adolescents and children.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As a complex metabolic disorder characterized by β-cell dysfunction and insulin resistance, T2DM patients may ultimately need insulin treatment due to pancreatic function deterioration.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, T2DM is closely associated with obesity as approximately over 80% of T2DM patients are overweight or obese.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Although the causal relationship between T2DM and obesity is not fully elucidated, elevated saturated free fatty acids and low-grade inflammation as seen in individuals with obesity have been proposed to exert a negative effect on pancreatic β-cell function.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, it is desirable if an antidiabetic therapy not only controls blood glucose but also reduces body weight and benefits β-cell function. In this regard, traditional antidiabetic agents such as thiazolidinediones and sulfonylureas suffer from some drawbacks such as weight gain.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Among the approved antidiabetic agents, glucagon-like peptide 1 receptor (GLP-1R) agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors are the only ones that could achieve effective glycemic control and modest weight reduction.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> GLP-1 is an incretin hormone produced from intestinal endocrine L cells. Intriguing physiological effects of GLP-1 include improving glycemic control, inhibiting gastric emptying, reducing appetite, preventing β-cell apoptosis, and increasing β-cell proliferation.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Importantly, GLP-1R agonists are able to achieve a 3–6% reduction in body weight.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Currently, seven GLP-1R agonists have been approved, including exenatide, liraglutide, semaglutide (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), etc.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In 2014, the high dose version of liraglutide (3 mg) was approved for the treatment of obese individuals with overweight-related health conditions.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of liraglutide, semaglutide, ZP3022, <b>1</b>, <b>2</b>, <b>3</b>, and their dual cysteine mutants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Beyond these approved GLP-1 agents, combining the bioactivity of GLP-1 and additional gut hormones to generate unimolecular multitargeting hybrid peptides is known to achieve superior therapeutic benefits and represents the next generation of gut-derived peptide agonists. For example, multifunctional peptides capable of activating not only GLP-1R but also other gut hormone receptors, such as glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon receptors, have recently been developed.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Owing to the synergistic effects of GLP-1 agonists and other gut hormones, these dual or triacting peptides were found to be effective therapeutics for T2DM and obesity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Gastrin is a gastrointestinal peptide belonging to the family of neuroendocrine peptides and is secreted from gastroendocrine G cells during meal ingestion. Gastrin-17 and gastrin-34 are the major forms, while gastrin-6 and gastrin-14 have also been identified.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Gastrin stimulates gastric acid secretion through activation of the cholecystokinin 2 receptor (CCK-2R, also referred as the gastrin receptor). Evidence suggests that gastrin and CCK-2R are implicated in fetal pancreas development. Moreover, it has been reported that in rodent models of pancreatic regeneration, gastrin increases β-cell mass, suggesting the potential utility of gastrin for diabetes treatment.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Previous research studies proved that coadministration of gastrin with GLP-1, exendin-4, or epidermal growth factor in the rodent model of diabetes restored normoglycemia and increased β-cell mass via islet neogenesis.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> In 2013, Zealand Pharma has developed ZP3022 (exendin-4 (1-28)-8Ado-8Ado-gastrin-6, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as a GLP-1R/CCK-2R dual agonist. ZP3022 is an exendin-4 analogue, which potently increases β-cell mass and improves glycemic control in diabetic db/db mice.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> To date, ZP3022 is the only reported GLP-1R/CCK-2R dual agonist. Although preclinical studies of ZP3022 indicated its potential to be developed as a novel antidiabetic agent, rare follow-ups were found. In addition, the in vivo half-life (<i>t</i><sub>1/2</sub>) of ZP3022 is short, and its body weight reducing activity is limited.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">We therefore are highly interested in developing novel GLP-1R/CCK-2R dual agonists. It is noteworthy that nearly all reported GLP-1R agonists are based on the scaffold of human GLP-1 or exendin-4. Our previous research identified <i>Xenopus</i> GLP-1, a GLP-1 analogue from amphibians, as an alternative GLP-1R agonist.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In addition, some <i>Xenopus</i> GLP-1 derivatives were found to be long-acting GLP-1R agonists with better effects on glycemic control and body weight reduction than those of liraglutide and lixisenatide (a C-terminal modified exendin-4 analogue).<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div><div class="NLM_p">Incretin peptides such as GLP-1 and glucagon bind to their receptors in an α-helical conformation. It has been well documented that stabilizing the secondary structures of these peptides leads to increased receptor binding affinity and proteolytic stability, and this holds true for <i>Xenopus</i> GLP-1 peptides as preliminarily demonstrated in our previous work.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Based on the above premises, the following strategies were applied in the present study in search of novel GLP-1R/CCK-2R dual agonists: (1) Instead of using the GLP-1 or exendin-4-based scaffold as the GLP-1R agonist, <i>Xenopus</i> GLP-1-derived peptides were used to bind to and activate GLP-1R. (2) Covalent side chain cross-linking of <i>Xenopus</i> GLP-1 was employed to generate stapled peptides with a stabilized secondary structure, enhanced agonist potency, improved metabolic stability, and increased bioactivity. (3) A serum albumin binding motif was introduced to further optimize the pharmacokinetics profile of peptides. (4) Gastrin-6 was conjugated to the C-terminus of stapled <i>Xenopus</i> GLP-1 derivatives to construct GLP-1R/CCK-2R dual agonists. Following stepwise rounds of design, synthesis, and bioactivity screening, compounds <b>6a</b> and <b>6b</b> outperformed other candidates as novel GLP-1R/CCK-2R dual agonists with demonstrated metabolic benefits in both diabetic db/db mice and diet-induced obesity (DIO) mice.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Cys Substitutions and Bioactivity Screenings of <i>Xenopus</i> GLP-1 Analogues</h3><div class="NLM_p">Our group first reported xGLP-1 (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as a human GLP-1 analogue with demonstrated stability, in vitro GLP-1R activation potency, and in vivo hypoglycemic activity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Further extension of <b>1</b> with the C-terminus of exendin-4 and lixisenatide led to the discovery of xGLP-Ex (<b>2</b>) and xGLP-Sen (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), respectively, with improved stability and bioactivity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These three peptides were thus employed as starting materials for current research. Based on our synthetic strategy (<i>vide infra</i>), the existence of two cysteine (Cys) residues in the peptide backbone is required as the anchoring points for constructing stapled <i>Xenopus</i> GLP-1 derivatives. Therefore, a Cys scanning was performed to identify suitable residues in <b>1</b> and its analogues for Cys substitutions. In view of the fact that the N-terminus of GLP-1 analogues is highly conserved and plays an important role in receptor binding and activation, Cys substitutions were conducted through positions 11 to 30 of <b>1</b>, <b>2</b>, and <b>3</b>. The two Cys were spaced at <i>i</i> and <i>i</i> + 7 to fix two turns of the helix as this conformational restriction has been widely used to form α-helices in many gut hormones, such as OXM, exendin-4, and GLP-2.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a></div><div class="NLM_p">In addition, previous research revealed that introducing Gly at the position 8 improved the dipeptidyl peptidase IV (DPP-IV) stability of GLP-1; however, its affinity for the GLP-1R was reduced. The introduction of Aib at the position 8 was the only Ala substitution that resulted in both high GLP-1R affinity and DPP-IV stability.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In 2015, Novo Nordisk found that Aib<sub>8</sub>, Arg<sub>34</sub> GLP-1 (7-37) was more potent than native GLP-1. Further derivatization at Lys<sub>26</sub> with C18 diacids through various linkers on Aib<sub>8</sub>, Arg<sub>34</sub> GLP-1 (7-37) successfully leads to the discovery of semaglutide, which was the next-generation once weekly dosing GLP-1R agonist.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Inspired by these enlightening previous research studies, the Gly<sub>2</sub> in <b>1</b>, <b>2</b>, and <b>3</b> was replaced with Aib. A total number of 39 dual cysteine mutants (<b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, and <b>3a</b>–<b>3m</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) were designed based on the above rules and were synthesized by solid-phase chemistry on Rink amide MBHA resin. Crude products were purified by semipreparative reversed-phase high-performance liquid chromatography (RP-HPLC), and the purified products were characterized by HPLC and ESI-MS (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Tables S1–S3</a>).</div><div class="NLM_p">The dual cysteine mutants were screened for their GLP-1R activation ability by the cAMP activity assay. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S1</a>, although weakened after Cys substitution, all mutants remained full GLP-1R agonists with subnanomolar EC<sub>50</sub> values. Most mutants derivatized from <b>2</b> (<b>2a</b>–<b>2m</b>) and <b>3</b> (<b>3a</b>–<b>3m</b>) showed low subnanomolar EC<sub>50</sub> values, indicating moderate reductions in agonism. Meanwhile, the disturbance of Cys mutations on <b>1</b> was more profound as seen from the EC<sub>50</sub> of <b>1a</b>–<b>1m</b>. In particular, we found that Cys mutations at Leu<sub>14</sub>/Glu<sub>21</sub> (<b>1d</b>, <b>2d</b>, and <b>3d</b>) or Glu<sub>21</sub>/Lys<sub>28</sub> (<b>1k</b>, <b>2k</b>, and <b>3k</b>) were well tolerated with respect to GLP-1R activation.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro GLP-1R Agonist Potency of <b>1</b>, <b>2</b>, <b>3</b>, <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, and <b>3a</b>–<b>3m</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center" char="±">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.048 ± 0.015</td><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">0.034 ± 0.011</td><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">0.024 ± 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.32 ± 0.08</td><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.05</td><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.05</td><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.12 ± 0.04</td><td class="colsep0 rowsep0" align="left"><b>3b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.49 ± 0.21</td><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.08</td><td class="colsep0 rowsep0" align="left"><b>3c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.066 ± 0.019</td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.042 ± 0.016</td><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.028 ± 0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.59 ± 0.22</td><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.08</td><td class="colsep0 rowsep0" align="left"><b>3e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.73 ± 0.29</td><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.11</td><td class="colsep0 rowsep0" align="left"><b>3f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.12 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.05</td><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.089 ± 0.035</td><td class="colsep0 rowsep0" align="left"><b>3g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.073 ± 0.024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.33 ± 0.12</td><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.05</td><td class="colsep0 rowsep0" align="left"><b>3h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.68 ± 0.23</td><td class="colsep0 rowsep0" align="left"><b>2i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.24 ± 0.04</td><td class="colsep0 rowsep0" align="left"><b>3i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.76 ± 0.31</td><td class="colsep0 rowsep0" align="left"><b>2j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.08</td><td class="colsep0 rowsep0" align="left"><b>3j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.23 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.083 ± 0.025</td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.052 ± 0.014</td><td class="colsep0 rowsep0" align="left"><b>3k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.036 ± 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.45 ± 0.07</td><td class="colsep0 rowsep0" align="left"><b>2l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.05</td><td class="colsep0 rowsep0" align="left"><b>3l</b></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1m</b></td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.27</td><td class="colsep0 rowsep0" align="left"><b>2m</b></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.12</td><td class="colsep0 rowsep0" align="left"><b>3m</b></td><td class="colsep0 rowsep0" align="char" char="±">0.23 ± 0.08</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values are shown as means ± SD. The assay was conducted in triplicate and repeated three times.</p></div></div></div><div class="NLM_p">The hypoglycemic activity of <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> were further evaluated by the oral glucose tolerance test (OGTT) in normal ICR mice to examine their in vivo GLP-1R agonist potency. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, compared with the vehicle (saline) treatment, administration of <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> resulted in significantly decreased blood glucose concentrations after oral glucose loading (<i>P</i> < 0.001). The glucose-lowering activity of <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> was comparable to <b>1</b>, <b>2</b>, and <b>3</b> and was better than GLP-1. Glucose AUC<sub>0–120min</sub> values of each group revealed a similar tendency (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Taken together, the Cys scanning study revealed mutants <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> as suitable templates for subsequent side chain cross-linking.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Acute hypoglycemic activity of GLP-1, <b>1</b>, <b>2</b>, <b>3</b>, <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> in ICR mice as assessed by the OGTT. Test peptides (each at 25 nmol·kg<sup>–1</sup>) were i.p. administered at −15 min, and glucose (3 g·kg<sup>–1</sup>) was orally loaded at 0 min. (A, C, E) Curves of blood glucose during the OGTT. (B, D, F) Corresponding glucose AUC<sub>0–120min</sub> values. Means ± SD, <i>n</i> = 6. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> GLP-1; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> GLP-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design and Synthesis of Stapled and Fatty Acid Coupled Peptides</h3><div class="NLM_p">A bis-maleimide amide molecule (referred to as BisMAL, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was used to cross-link the reserved Cys in <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> based on the specific reaction between thiol and maleimide. This cross-linker could form stable thiomaleimide adducts and has been successfully used in our previous research to construct potent dimeric <i>Xenopus</i> GLP-1 conjugates and by other research group to develop potent PEGylated dimeric exendin-4 conjugates.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> A long-chain fatty acid (palmitic acid) was further coupled with the terminal amine of BisMAL to afford peptides <b>4a</b>–<b>4f</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Fatty acid acts as an albumin binding to facilitate the physical interaction between peptide and human serum albumin (HSA), which is a well-established strategy used during the development of marketed GLP-1 analogues, such as liraglutide and semaglutide, to enhance the pharmacokinetics property.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, the introduction of a fatty acid might lead to potency loss of peptides due to the steric interfering with receptor recognition and the lipophilicity of fatty acid. We reasoned that a short spacer between the peptide backbone and fatty acid could help to alleviate the above negative impacts and provide more opportunities for structural tuning. Therefore, 8-amino-3,6-dioxa-octanoic acid (OEG), OEG-γGlu, and 2OEG-γGlu were used as spacers to conjugate the ω-amino group of BisMAL with octadecanedioic acid, giving peptides <b>4g</b>–<b>4l</b>, <b>4m</b>–<b>4r</b>, and <b>4s</b>–<b>4x</b>, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For the synthesis of <b>4a</b>–<b>4x</b>, orthogonally protected Fmoc-Cys(Mmt)-OH and Boc-His(Trt)-OH were used as the building blocks for Cys and His<sub>1</sub>. Specific Mmt deprotection was achieved using 1% TFA in CH<sub>2</sub>Cl<sub>2</sub>. BisMAL dissolved in DMF was reacted with the solid support for 1.5 h, and palmitic acid, Fmoc-OEG-OH, Fmoc-Glu-OtBu, and octadecanedioic acid, 1-(1,1-dimethylethyl) ester were added and coupled in order (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Crude products of <b>4a</b>–<b>4x</b> were purified and characterized using the same method as described above (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Table S4</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of stapled <i>Xenopus</i> GLP-1 derivatives <b>4a</b>–<b>4x</b>. (A) Sequence of selected dual Cys mutants. (B) Structures of fatty acid-modified BisMAL cross-linkers (L1–L4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route of Stapled Peptides <b>4a</b>–<b>4x</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>PG: acid labile protecting group.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of the Structures and the In Vitro Potencies of <b>4a</b>–<b>4x</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">GLP-1R activation EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center">sequence</th><th class="colsep0 rowsep0" align="center">linker</th><th class="colsep0 rowsep0" align="center">fatty acid protractor</th><th class="colsep0 rowsep0" align="center" char="±">0% HSA</th><th class="colsep0 rowsep0" align="center" char="±">4.4% HSA</th><th class="colsep0 rowsep0" align="center" char=".">ratio 4.4%/0% HSA</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liraglutide</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">γGlu</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.052 ± 0.020</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">26.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">semaglutide</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2OEG-γGlu</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.040 ± 0.012</td><td class="colsep0 rowsep0" align="char" char="±">13.5 ± 5.2</td><td class="colsep0 rowsep0" align="char" char=".">337.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.098 ± 0.016</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">18.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.12 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">18.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4c</b></td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.041 ± 0.011</td><td class="colsep0 rowsep0" align="char" char="±">0.91 ± 0.24</td><td class="colsep0 rowsep0" align="char" char=".">22.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4d</b></td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.054 ± 0.018</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">24.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4e</b></td><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.093 ± 0.015</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4f</b></td><td class="colsep0 rowsep0" align="left"><b>3k</b></td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="left">C16</td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4g</b></td><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4h</b></td><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4i</b></td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4j</b></td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">15.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4k</b></td><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4l</b></td><td class="colsep0 rowsep0" align="left"><b>3k</b></td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.12 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4m</b></td><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.059 ± 0.018</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 1.2</td><td class="colsep0 rowsep0" align="char" char=".">47.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4n</b></td><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.069 ± 0.022</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">55.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4o</b></td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4p</b></td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">8.6 ± 2.8</td><td class="colsep0 rowsep0" align="char" char=".">61.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4q</b></td><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">40.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4r</b></td><td class="colsep0 rowsep0" align="left"><b>3k</b></td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 3.2</td><td class="colsep0 rowsep0" align="char" char=".">38.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4s</b></td><td class="colsep0 rowsep0" align="left"><b>1d</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">14.5 ± 6.8</td><td class="colsep0 rowsep0" align="char" char=".">90.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4t</b></td><td class="colsep0 rowsep0" align="left"><b>1k</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">18.2 ± 5.2</td><td class="colsep0 rowsep0" align="char" char=".">95.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4u</b></td><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.025 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">108</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4v</b></td><td class="colsep0 rowsep0" align="left"><b>2k</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">16.5 ± 5.9</td><td class="colsep0 rowsep0" align="char" char=".">97.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4w</b></td><td class="colsep0 rowsep0" align="left"><b>3d</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">12.7 ± 4.5</td><td class="colsep0 rowsep0" align="char" char=".">84.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4x</b></td><td class="colsep0 rowsep0" align="left"><b>3k</b></td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="left">C18 diacid</td><td class="colsep0 rowsep0" align="char" char="±">0.034 ± 0.009</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">79.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data of the receptor potency are represented as EC<sub>50</sub> (means ± SD). The assay was conducted in triplicate and repeated three times.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro Efficacy and Circular Dichroism (CD) Spectra of Stapled Peptides</h3><div class="NLM_p">The receptor agonist potency of <b>4a</b>–<b>4x</b> was determined by the cAMP activity assay in the presence of 0% HSA or 4.4% HSA (physiological concentrations). This approach was successfully applied in the discovery of semaglutide and was a pragmatic screening plan to select peptides for animal pharmacodynamics and pharmacokinetics studies.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S2</a>, in the absence of HSA, most stapled peptides were equipotent in receptor activation to their corresponding noncross-linked peptides. To our satisfaction, stapled peptides <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> activated GLP-1R more potently than the noncross-linked counterparts. When 4.4% HSA was present in the assay, a large shift was observed between activity in the absence and presence of HSA for BisMAL cross-linkers L3 and L4 (<b>4m</b>–<b>4x</b>). This was attributed to enhanced HSA binding in vitro, an effect which will bring longer in vivo half-life, and previously observed in the discovery of semaglutide. Interestingly, the 4.4%/0% HSA ratio of semaglutide was higher than that of <b>4s</b>–<b>4x</b> with a similar linker and fatty acid protractor with semaglutide. The possible reasons were that the albumin binding affinity of our stable peptides was lower than that of semaglutide and/or the receptor activation potency of these stable peptides was improved at 4.4% HSA compared to semaglutide.</div><div class="NLM_p">Next, the α-helicity of <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> was determined by CD (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), and a prominent increase in α-helicity compared with <b>1</b> and <b>2</b> was observed at room temperature. These results suggested that the thiomaleimide bridge within the stapled peptide stabilized the α-helical segment, resulting in improved agonist potency. Paradoxically, the less potent peptides <b>4m</b> and <b>4n</b> showed the highest increase in α-helicity, indicating that the agonist activity is not solely attributed to helical content since lipidation itself was known to increase helicity.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Alpha-helicity and in vivo pharmacodynamics of stapled peptides. (A) CD spectra of <b>1</b>, <b>2</b>, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> in phosphate buffer containing 20% TFE. (B, C) Hypoglycemic effects of liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> in nonfasted male db/db mice after s.c. dosing of 25 nmol·kg<sup>–1</sup>. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Albumin Binding, Pharmacodynamics, and Obesity Ameliorating Effects of Stapled Peptides</h3><div class="NLM_p">The observed differences of the 4.4%/0% HSA ratio among liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were clearly attributed to their different albumin binding abilities. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S3</a>, under physiological conditions (in PBS pH 7.4), 83.8 ± 2.0 and 85.0 ± 1.4% of <b>4c</b> and <b>4d</b> were found to associate with albumin resin, lower than those of liraglutide (90.6 ± 3.3%) and semaglutide (97.8 ± 1.4%). For <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> with C18 diacid side chain albumin binders, the binding rates increased to 92.6 ± 2.6, 91.6 ± 2.0, 95.3 ± 1.2, and 96.7 ± 1.7% by <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b>, respectively, higher than liraglutide and still lower than semaglutide. Consistent with the previous research, increasing the length of the carbon chain was favorable for the albumin binding affinity of <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b>.</div><div class="NLM_p">We next determined whether the enhanced in vitro potency observed for <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> led to improved pharmacodynamics in vivo. The pharmacodynamics properties of <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were first evaluated in nonfasted db/db mice by s.c. injection, using liraglutide and semaglutide as the controls. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C, all the eight peptide-treated groups exhibited a similar lowest glucose level. However, the hypoglycemic duration (from the nadir to 18 mmol·L<sup>–1</sup> blood glucose) differs among each group. The hypoglycemic durations in <b>4c-</b> and <b>4d</b>-treated groups were slightly longer than that of liraglutide (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). In particular, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were able to maintain the hypoglycemic state in db/db mice for at least 24 h, comparable to that of semaglutide (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C). Interestingly, <b>4c</b> and <b>4d</b> with lower albumin binding affinities than liraglutide exhibited longer in vivo hypoglycemic durations than liraglutide, and it could be speculated that the Aib<sub>8</sub> on <b>4c</b> and <b>4d</b> protected the cleavage by DPP-IV and the increased α-helicity of <b>4c</b> and <b>4d</b> caused by stable BisMAL was the main reason for the longer hypoglycemic durations of <b>4c</b> and <b>4d</b> than liraglutide. The above results demonstrated that peptide stapling and fatty acid modification using proper BisMAL cross-linkers not only enhanced the in vitro agonist potency but also extended in vivo half-lives. Considering that liraglutide and semaglutide are dosed once daily and once weekly,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> respectively, in human, peptides <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> hold promise for being developed into long-acting hypoglycemic agents.</div><div class="NLM_p">Next, the effects of <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> to ameliorate obesity were evaluated in DIO mice and compared to those of liraglutide and semaglutide. Based on the in vivo pharmacodynamics property of each peptide, liraglutide, <b>4c</b>, and <b>4d</b> were s.c. treated twice daily while semaglutide, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were s.c. administered every 2 days. The changes in body weight, food intake, and blood glucose of DIO mice were monitored for 1 week. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B, twice daily administration of <b>4c</b> and <b>4d</b> for 1 week reduced body weight by ∼14.4 and ∼15.2%, respectively, significantly better than that of liraglutide (<i>P</i> < 0.001) with the same dosing frequent. Every 2 days s.c. administration of semaglutide, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> reduced body weight by ∼9.8, ∼13.4, ∼13.8, ∼10.6, and ∼10.2%, respectively, indicating that <b>4m</b> and <b>4n</b> exhibited better effects on body weight reduction than semaglutide (<i>P</i> < 0.001), whereas the effects of <b>4u</b> and <b>4x</b> were less pronounced. Food intakes of DIO mice revealed similar trends, and <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b> potently reduced body weight and also exhibited prominent effects on food intake reduction (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Moreover, all the stapled peptides effectively protected DIO mice from fasted hyperglycemia, superior to liraglutide and semaglutide (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E,F).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A–F) Effects of 1 week s.c. treatment of 25 nmol·kg<sup>–1</sup> liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> on body weight change (A, B), food intake (C, D), and fasted blood glucose (E, F) of male DIO mice. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> semaglutide; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> semaglutide; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> semaglutide. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Design of GLP-1R/CCK-2R Dual Agonists</h3><div class="NLM_p">Stapled peptides <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b>, which were more effective in body weight reduction, were selected to further generate GLP-1R/CCK-2R dual agonists. Native-sulfated gastrin-6 (Tyr(SO<sub>3</sub>)-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>) was previously used as a CCK-2R agonist, and more recently, Zealand Pharma introduced a nonsulfated gastrin-6 analogue (Tyr-Gly-Trp-Leu-Asp-Phe-NH<sub>2</sub>) to modify the C-terminus of exendin-4 linked by two OEG moieties.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> There is debate and inconsistence regarding the role of tyrosine <i>O</i>-sulfation in CCK-2R agonist potency. Although previous research showed that the potency (EC<sub>50</sub>) of nonsulfated and sulfated gastrin-17 is equal, the difference between nonsulfated and sulfated gastrin-6 remains unexplored.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> As a result, we decided to use both sulfated and nonsulfated gastrin-6 to clarify their bioactivity contributions. Instead of using stapled peptides <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b>, we commenced with unstapled peptides <b>2d</b> and <b>2k</b> to avoid any influence of the stapled cross-linkers on GLP-1R/CCK-2R activation potency and get a more direct insight into the role of gastrin-6. Thus, sulfated and nonsulfated gastrin-6 were coupled to the C-terminus of <b>2d</b> and <b>2k</b> through two OEG spacers, affording <b>5a</b>–<b>5d</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of <b>5a</b>–<b>5d</b> and <b>6a</b>–<b>6d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the synthesis of <b>5c</b> and <b>5d</b> containing a sulfated Tyr residue, Fmoc-Tyr(SO<sub>3</sub>-neopentyl)-OH was used, and the neopentyl-protecting group was specifically removed by aqueous ammonium acetate (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Scheme S1</a>). Crude products were purified and characterized using the same method as described above (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Table S5</a>). The activation potencies of <b>5a</b>–<b>5d</b> toward GLP-1R, CCK-1R, and CCK-2R were determined by cAMP or ERK1/2 phosphorylation (pERK1/2) functional assays, using <b>2</b> and Leu<sub>15</sub>-gastrin-17 as controls. As listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S4</a>, the EC<sub>50</sub> values of <b>5a</b>–<b>5d</b> on GLP-1R were comparable to that of <b>2</b>. The EC<sub>50</sub> values of <b>5a</b>–<b>5d</b> on CCK-2R were approximately three-fold lower than Leu<sub>15</sub>-gastrin-17, a full agonist for the CCK-2 receptor. Importantly, no activation of CCK-1R was observed with <b>5a</b>–<b>5d</b> treatments. Because <b>5a</b>–<b>5d</b> showed similar CCK-2R agonist efficacy, it indicated that both sulfated and nonsulfated gastrin-6 were suitable to confer high CCK-2R activation potency to <i>Xenopus</i> GLP-1 derivatives.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effects of <b>2</b>, Leu<sub>15</sub>-Gastrin-17, ZP3022, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> on GLP-1R, CCK-1R, and CCK-2R</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">peptide</th><th class="colsep0 rowsep0" align="center">GLP-1R</th><th class="colsep0 rowsep0" align="center">CCK-1R</th><th class="colsep0 rowsep0" align="center">CCK-2R</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">0.043 ± 0.016</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Leu<sub>15</sub>-gastrin-17</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">2.8 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">0.040 ± 0.011</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">8.3 ± 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">0.048 ± 0.018</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">9.4 ± 3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">0.038 ± 0.013</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">7.6 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">0.059 ± 0.021</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">8.2 ± 3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZP3022</td><td class="colsep0 rowsep0" align="left">0.069 ± 0.030</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">9.9 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">0.022 ± 0.008</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">7.3 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">0.041 ± 0.017</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">8.8 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">0.055 ± 0.026</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">15.2 ± 5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">0.061 ± 0.019</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">17.5 ± 6.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">HEK293 cells expressing human GLP-1R, CCK-1R, or CCK-2R were incubated with increasing concentrations of tested peptides, and potency (EC<sub>50</sub>, means ± SD) was measured as release of cAMP (GLP-1R) or pERK1/2 (CCK-1R and CCK-2R). The assay was conducted in triplicate and repeated three times.</p></div></div></div><div class="NLM_p last">Considering the easier synthetic accessibility of nonsulfated gastrin-6 than sulfated gastrin-6, stapled peptides <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b> were next C-terminally modified with the sequence Tyr-Gly-Trp-Leu-Asp-Phe-NH<sub>2</sub> using two OEGs as the linker to generate <b>6a</b>–<b>6d</b>, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The synthetic and purification procedures of <b>6a</b>–<b>6d</b> were similar to those of <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b>, respectively (see the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Table S6</a>). As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S5</a>, <b>6a</b> and <b>6b</b> activated both GLP-1R and CCK-2R more potently than ZP3022, and the EC<sub>50</sub> values of <b>6c</b> and <b>6d</b> on CCK-2R were about two-fold lower than ZP3022. The agonist potency of <b>6c</b> and <b>6d</b> was comparable to ZP3022 on GLP-1R but lower than ZP3022 on CCK-2R. No activation of CCK-1R was measured for <b>6a</b>–<b>6d</b>. Peptides <b>6a</b> and <b>6b</b> were selected for the following biological studies.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> OGTT and Insulin Secretion Test of <b>6a</b> and <b>6b</b></h3><div class="NLM_p">The hypoglycemic and insulinotropic effects of <b>6a</b> and <b>6b</b> were evaluated in db/db mice using ZP3022 as the control. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A–D, both <b>6a</b> and <b>6b</b> reduced the glucose excursion and potently improved glucose tolerance, whereas ZP3022 showed less glucose-lowering activity than <b>6a</b> and <b>6b</b>. Enhanced plasma insulin levels were observed in ZP3022-, <b>6a</b>-, and <b>6b</b>-treated groups, accompanied by declined blood glucose concentrations. Consistent with the hypoglycemic ability, <b>6a</b> and <b>6b</b> showed higher insulinotropic activity than ZP3022. The AUC values further suggested that the glucose-lowering and insulinotropic activities of <b>6a</b> were better than <b>6b</b>.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo glucose-lowering, insulinotropic, and anorectic effects and PK profiles of <b>6a</b> and <b>6b</b>. The hypoglycemic and insulinotropic effects of ZP3022, <b>6a</b>, and <b>6b</b> were measured by the OGTT in male db/db mice. Saline, ZP3022, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were i.p. injected 30 min prior to oral administration of glucose (1.5 g·kg<sup>–1</sup>). (A–D) Time–blood glucose levels, time–plasma insulin levels, and the corresponding AUC values for blood glucose and plasma insulin. Means ± SD, <i>n</i> = 6. (E) PK profiles of ZP3022, <b>6a</b>, and <b>6b</b> in male ICR mice by s.c. injection at a dose of 50 nmol·kg<sup>–1</sup>. Means ± SD, <i>n</i> = 3. (F–I) Antihyperglycemic duration and anorectic effects of ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in nonfasted male db/db mice at doses of 25 (F, G) and 100 nmol·kg<sup>–1</sup> (H, I). Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pharmacokinetics (PK) Study of <b>6a</b> and <b>6b</b></h3><div class="NLM_p">To determine the in vivo PK profiles of <b>6a</b> and <b>6b</b>, the PK assay was performed by s.c. injection of the tested peptides at 50 nmol·kg<sup>–1</sup> in ICR mice. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Table S7</a>, the PK data revealed highly enhanced in vivo <i>t</i><sub>1/2</sub> for <b>6a</b> (4.4 h) and <b>6b</b> (4.7 h) than ZP3022 (1.2 h). The absorption of <b>6a</b> and <b>6b</b> was protracted compared with ZP3022, as reflected by the higher maximum plasma concentration (<i>T</i><sub>max</sub>) values of <b>6a</b> (4 h) and <b>6b</b> (4 h) than ZP3022 (2 h). In addition, enhancements of areas under the curve from zero to infinity (AUC<sub>inf</sub>) were observed for <b>6a</b> (15,868 ng·h/mL) and <b>6b</b> (19,638 ng·h/mL), indicating better drug utilizations of <b>6a</b> and <b>6b</b> than ZP3022 (9587 ng·h/mL).</div><div class="NLM_p last">In addition, we designed two <b>6a</b> and <b>6b</b> analogues (<b>7a</b> and <b>7b</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S6</a>) only with stable BisMAL and without a fatty acid albumin binder to investigate whether BisMAL itself could also improve the stability of our xGLP-1 analogues as we observed an interesting phenomenon that the selected stapled peptides <b>4c</b> and <b>4d</b> with lower albumin binding affinities than liraglutide exhibited longer in vivo hypoglycemic durations than liraglutide, and the possible reason was BisMAL could also improve the stability of <b>4c</b> and <b>4d</b>. The in vivo PK profiles of <b>6a</b>, <b>6b</b>, <b>7a</b>, <b>7b</b> as well as the corresponding unstapled peptides <b>5a</b> and <b>5b</b> were studied in SD rats by s.c. injection (50 nmol·kg<sup>–1</sup>). As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S7 and Table S8</a>, the <i>t</i><sub>1/2</sub> values of <b>7a</b> and <b>7b</b> were longer than <b>5a</b> and <b>5b</b> and shorter than <b>6a</b> and <b>6b</b>, respectively, indicating that BisMAL itself could also improve the stabilities of our xGLP-1 analogues. The increased α-helicity brought by stable BisMAL should be the main reason of the improved stability, and another possible reason was that the stable BisMAL blocked the rapid degradation by other enzymes such as neutral endopeptidase (NEP) 24.11.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Hypoglycemic Duration and Food Intake Assays of <b>6a</b> and <b>6b</b></h3><div class="NLM_p last">The antidiabetic durations of <b>6a</b> and <b>6b</b> were examined at two doses (25 and 100 nmol·kg<sup>–1</sup>) in db/db mice under a nonfasted condition. The amount of food intake was also recorded to evaluate the anorectic effects of <b>6a</b> and <b>6b</b>. According to the PK profiles of <b>6a</b> and <b>6b</b>, liraglutide, instead of semaglutide, was selected as the positive control. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>F–I, both <b>6a</b> and <b>6b</b> exhibited dose-dependent glucose-lowering efficacy, and the duration of action of <b>6a</b> or <b>6b</b> was longer than ZP3022 and liraglutide, independent of the doses. In addition, the nadir of blood glucose levels in the <b>6a</b>- or <b>6b</b>-treated group was lower than ZP3022 and liraglutide, further proving the higher in vivo potency of <b>6a</b> and <b>6b</b> than ZP3022 and liraglutide. Food intake study revealed that <b>6a</b> and <b>6b</b> lead to prominent reductions of food intake in a dose-dependent manner. In addition, both <b>6a</b> and <b>6b</b> exhibited better anorectic effects than ZP3022 and liraglutide. Interestingly, although the half-life of <b>6a</b> was shorter than <b>6b</b>, <b>6a</b> exhibited a stronger anorectic effect than <b>6b</b>.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Gastric Emptying Study of <b>6a</b> and <b>6b</b></h3><div class="NLM_p">The concentration of acetaminophen in blood could be used as an indicator of the rate of gastric emptying as the absorption of acetaminophen in stomach was negligible and occurred completely in small intestine. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, both <b>6a</b> and <b>6b</b> potently reduced blood acetaminophen concentration, indicating a high inhibitory rate of gastric emptying. The AUC values of acetaminophen indicated that the effects of <b>6a</b> and <b>6b</b> on gastric emptying were better than ZP3022 and liraglutide. We further performed a solid-phase gastric emptying study as a direct test to strengthen our findings. The solid gastric emptying rate was obtained as the amount of food intake in the mice relative to the amount of dry stomach contents. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B, compared with the saline group, the gastric emptying rate in mice treated with <b>6a</b> or <b>6b</b> was decreased, to a more marked extent than ZP3022 or liraglutide treatment.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Gastric emptying, kaolin consumption, and toxicity assays of <b>6a</b> and <b>6b</b>. (A) Time–response curves of plasma acetaminophen and the corresponding AUC values measured by the acetaminophen absorption assay in 6 h fasted male ICR mice that received i.p. injection of saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> at −30 min followed by orally administered acetaminophen (100 mg·kg<sup>–1</sup>) at 0 min. (B) Solid gastric emptying rates in male ICR mice 4 h after i.p. injection of saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b>. (C, D) Kaolin and food intake during 24 h in male SD rats following i.p. injection of saline (containing 10% DMSO), cisplatin (3 mg·kg<sup>–1</sup>), ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>). (E, F) Daily kaolin and food consumption in male SD rats for 12 days. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day. Liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were s.c. injected twice daily. Means ± SD, <i>n</i> = 6. (G, H) Effects of liraglutide, ZP3022, and <b>6a</b> on the viability of INS-1 cells under normal (G) or glucotoxicity (H) condition. (I, J) Effects of liraglutide, ZP3022, and <b>6b</b> on the viability of INS-1 cells under normal (I) or glucotoxicity (J) condition. Means ± SD, <i>n</i> = 3. (K, L) Values of hepatotoxicity and renal toxicity indicators in male ICR mice after a 2 week s.c. dosing of ZP3022, liraglutide (100 nmol·kg<sup>–1</sup>), <b>6a</b>, and <b>6b</b> (1000 nmol·kg<sup>–1</sup>). Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Kaolin Consumption Assays of <b>6a</b> and <b>6b</b></h3><div class="NLM_p last">While <b>6a</b> and <b>6b</b> were found to potently reduce food intake, the possible side effects such as nausea could not be overlooked. To this end, kaolin consumption was used as a well-established model of nausea to investigate the biocompatibility of <b>6a</b> and <b>6b</b> in SD rats. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C,D, cisplatin potently decreased food intake, accompanied by increased kaolin consumption in a 24 h acute assay, validating the successful establishment of the rat model. Liraglutide, ZP3022, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) potently reduced food intake without eliciting kaolin intake. In the following 12 day chronic test (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E,F), liraglutide, ZP3022, <b>6a</b>, and <b>6b</b> caused food intake reduction from day 2, and no obvious increase in kaolin consumption was observed even at day 10. All the above results preliminarily indicated that peripheral administration of <b>6a</b> or <b>6b</b> did not cause prominent nausea response in rats.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Toxicity Assays of <b>6a</b> and <b>6b</b></h3><div class="NLM_p last">The in vitro toxicity of <b>6a</b> and <b>6b</b> was evaluated by the MTT assay on INS-1 cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>G,I, no impacts on cell viability were measured for both <b>6a</b> and <b>6b</b> up to a concentration of 1000 nM. Furthermore, the cell protective effects of <b>6a</b> and <b>6b</b> against glucotoxicity were evaluated. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>H,J, glucotoxicity media reduced the cell viability in the saline-treated group by ∼27%, while <b>6a</b> or <b>6b</b> treatment dose-dependently recovered cell viability. At a dose of 100 nM, the cell protective effects of <b>6a</b> and <b>6b</b> surpassed those of liraglutide and ZP3022. Additionally, a 2 week toxicity test was performed in ICR mice. Satisfyingly, even if administered at a dose (1000 nmol·kg<sup>–1</sup>) that was 10 times higher than liraglutide and ZP3022 (100 nmol·kg<sup>–1</sup>), <b>6a</b> and <b>6b</b> led to no prominent changes in hepatotoxicity or renal toxicity indicators (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>K,L), including aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine (SCr), and blood urea nitrogen (BUN). These results supported the safety of <b>6a</b> and <b>6b</b> for in vivo application.</div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Metabolic Benefits of <b>6a</b> and <b>6b</b> in DIO Mice</h3><div class="NLM_p">The metabolic benefits of <b>6a</b> and <b>6b</b> were comprehensively evaluated in DIO mice by s.c. injection twice daily and compared with equimolar doses of liraglutide (twice daily) and ZP3022 (three times a day). It was found that <b>6a</b> and <b>6b</b> significantly decreased body weight by ∼26.3 and ∼24.0%, respectively, as compared with ZP3022 and liraglutide (∼17.8 and ∼14.0%, respectively; <i>P</i> < 0.001) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B). In addition, treatment with <b>6a</b> and <b>6b</b> led to ∼32.2 and ∼30.4% reduction of body fat content, respectively, larger than those treated with ZP3022 (∼24.5%) and liraglutide (∼21.4%) (<i>P</i> < 0.001, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C). Furthermore, <b>6a</b> and <b>6b</b> exhibited more profound effects on reducing food intake than ZP3022 and liraglutide (<i>P</i> < 0.001, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D), and the effects of <b>6a</b> and <b>6b</b> on reducing fasting blood glucose (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>E and F) and improving glucose tolerance (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>G–J) were more evident than those of ZP3022 and liraglutide. Moreover, <b>6a</b> and <b>6b</b> exhibited stronger lipid-regulating ability than ZP3022 and liraglutide after a 21 day treatment, leading to decreased serum cholesterol (TC) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>K) and triglycerides (TG) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>L).</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Three week treatment effects of <b>6a</b> and <b>6b</b> in male DIO mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. administered three times a day. Liraglutide, <b>6a</b>, and <b>6b</b> were s.c. administered (25 nmol·kg<sup>–1</sup>) twice daily in DIO mice for 3 weeks. (A–L) Effects on body weight change (A, B), fat mass change (C), food intake (D), fasted blood glucose levels (E, F), glucose tolerance before (G, H) and after (I, J) treatment, serum TC (K), and TG (L) were measured. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> ZP3022; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Three Week Treatment Effects of <b>6a</b> and <b>6b</b> in db/db Mice</h3><div class="NLM_p">In a 21 day treatment in db/db mice, <b>6a</b> and <b>6b</b> caused a more profound reduction in cumulated food intake and body weight gain than ZP3022 and liraglutide (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A,B). The beneficial effects of <b>6a</b> and <b>6b</b> on fasted blood glucose and HbA1c were also found to surpass those of ZP3022 and liraglutide in db/db mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C–F). Notably, treatment with <b>6a</b> or <b>6b</b> effectively increased % β-cell area per islet, to a greater extent than ZP3022 and liraglutide treatments (<i>P</i> < 0.001, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>G). Meanwhile, <b>6a</b> or <b>6b</b> treatment decreased % non-β-cell area (α-cell, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>H), similar to ZP3022 or liraglutide treatment. Significantly increased islet areas and numbers were observed in mice treated with liraglutide, ZP3022, <b>6a</b>, and <b>6b</b>, and the increases were more evident in <b>6a</b>- and <b>6b</b>-treated groups (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>I,J). Insulin staining results further revealed that the insulin content, which was reflected by the integrated optical density (IOD) values, was remarkably increased after <b>6a</b> or <b>6b</b> treatment, larger than those of ZP3022 and liraglutide treatments (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>K). Representative H&E and insulin staining images are shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>L–P.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Glycemic, body weight, and islet benefits following a 21 day treatment with ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in male db/db mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day, and liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were s.c. injected twice daily for 21 days. (A–K) Effects on food intake (A), body weight (B), fasted blood glucose (C, D), HbA1c (E, F), percent β-cell (G) and α-cell (H) area per islet, islet area (I), islet number (J), and IOD values of insulin staining (K) were measured. (L–P) Representative H&E and insulin staining images in saline (L), liraglutide (M), ZP3022 (N), <b>6a</b> (O), and <b>6b</b> (P) groups are shown. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Long-Term Effects of <b>6a</b> and <b>6b</b> on Glycemic Control in db/db Mice</h3><div class="NLM_p">Finally, the long-term effects of <b>6a</b> and <b>6b</b> on glycemic control were investigated in db/db mice during a 12 week treatment. ZP3022 was s.c. treated three times a day, while liraglutide, <b>6a</b>, and <b>6b</b> were s.c. treated twice daily. All peptides were dosed at 25 nmol·kg<sup>–1</sup>, and the treatments lasted for 6 weeks followed by another 6 week saline treatment for each group. On days 0, 42, 56, 70, and 84, OGTTs were performed to evaluate the glucose controlling ability of each group of mice (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A–E, respectively). As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>F, the AUC values of OGTTs clearly showed a gradually impaired glucose tolerance in mice treated with saline during the first 6 weeks. However, mice treated with ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> resulted in prominent improvements in glucose tolerance, with the lowest AUC values observed in <b>6a</b>- and <b>6b</b>-treated groups. Importantly, mice treated with <b>6a</b> or <b>6b</b> exhibited long-lasting improvements in glucose tolerance during the following treatment-free period (weeks 7–12), as reflected by the AUC values, and the improvement effects were more evident than those in ZP3022- and liraglutide-treated groups (<i>P</i> < 0.001). The fasted blood glucose levels were also determined in each group, and the results showed a similar trend to that of the OGTT (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>G). Moreover, reduced HbA1c values in ZP3022-, liraglutide-, <b>6a</b>-, and <b>6b</b>-treated groups were measured on day 43, as well as on day 85, 6 weeks after the cessation of peptide treatments (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>H).</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chronic treatment effects of ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in male db/db mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day, and 25 nmol·kg<sup>–1</sup> liraglutide, <b>6a</b>, and <b>6b</b> were s.c. injected twice daily for 42 days. In the following 42 days, each group of mice was s.c. injected twice daily with saline. (A–E) Effects on glucose tolerance on days 0 (A), 42 (B), 56 (C), 70 (D), and 84 (E) during the treatment were determined by OGTTs, and (F) corresponding glucose AUC values were summarized. (G, H) Effects on fasted blood glucose levels (G) and HbA1c (H) values were also determined. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this study, we focused on GLP-1R/CCK-2R dual agonists, which we believe to have high prospect to be developed into new generation of antidiabetic agents. The sequence of <i>Xenopus</i> GLP-1, a selective GLP-1R agonist developed by us previously, was reengineered by (1) dual Cys mutation while maintaining the potent GLP-1R agonist activity, (2) side chain cross-linking to stabilize a secondary structure and achieve enhanced stability and bioactivity, and (3) gastrin-6 conjugation to gain CCK-2R agonist activity.</div><div class="NLM_p">After incorporating different serum protein binding motifs into stapled peptides linked by various spacers, <i>Xenopus</i> GLP-1 derivatives retained full GLP-1R activation potency and improved stability in rodents. Four peptides, <b>4c</b>, <b>4d</b>, <b>4m</b>, and <b>4n</b>, exhibited potent body weight reduction activity in DIO mice.</div><div class="NLM_p">After gastrin-6 conjugation, peptides <b>6a</b> and <b>6b</b> showed potent glucoregulatory effects and induced insulin secretion in a glucose-dependent manner in db/db mice. PK data showed that <b>6a</b> and <b>6b</b> had longer <i>t</i><sub>1/2</sub> than ZP3022. In db/db mice, the longer <i>t</i><sub>1/2</sub> of <b>6a</b> and <b>6b</b> contributed to better hypoglycemic activity and anorectic effects than both ZP3022 and liraglutide. It was found that <b>6a</b> and <b>6b</b> potently inhibited gastric emptying, to a great extent than ZP3022 and liraglutide, which might explain the better anorectic effects of <b>6a</b> and <b>6b</b>. Kaolin consumption assays in rat revealed that neither <b>6a</b> nor <b>6b</b> induced prominent nausea responses. Toxicity assays further indicated the safety of <b>6a</b> and <b>6b</b> in vitro and in vivo. The effects of <b>6a</b> and <b>6b</b> on weight loss, fat mass, food intake reduction, glucose tolerance, and lipid regulation in DIO mice were significantly better than those of ZP3022 and liraglutide. Importantly, <b>6a</b> and <b>6b</b> increased β-cell areas, islet areas, and amounts in db/db mice following a 3 week treatment. The 12 week study in db/db mice further proved the protective effects of <b>6a</b> and <b>6b</b> on pancreas. Preliminary docking studies of the xGLP-1 part in <b>6a</b> and <b>6b</b> (<b>6a′</b> and <b>6b′</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">Figure S8 and Table S9</a>) suggested a different binding mode between <b>6a</b> and <b>6b</b> to GLP-1R. However, further experimental data, such as the crystal structures of dual agonists and GLP-1R complexes, are required for a more accurate elucidation of the interactions of <b>6a</b> and <b>6b</b> with GLP-1R.</div><div class="NLM_p">Since the BisMAL we used was structurally asymmetric, <b>6a</b> or <b>6b</b> might exist in two forms. Although the HPLC analysis of <b>6a</b> and <b>6b</b> presented each peptide as a single peak, it may comprise an inseparable mixture of two isomers. Currently, it is difficult to identify which of the two stapled variants of <b>6a</b> and <b>6b</b> elicit the observed pharmacological effects. To circumvent this issue, a next-generation symmetrical serum-binding linker should be developed in the future to control the identity of the final stapled peptide.</div><div class="NLM_p last">Taken together, the current research contributes to the discussion whether stapled GLP-1R/CCK-2R dual agonists based on <i>Xenopus</i> GLP-1 could serve as new therapeutic agents for diabetes and obesity. Dual agonists <b>6a</b> and <b>6b</b> exhibited high metabolic efficacy in DIO mice, exerted prominent effects on β-cell restoration, and achieved long-term glycemic control in db/db mice, supporting their potential roles as therapeutical options for metabolic diseases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Materials and Animals</h3><div class="NLM_p">Liraglutide, semaglutide, GLP-1(7-36)-NH<sub>2</sub>, ZP3022, nonsulfated and sulfated gastrin-6, Leu<sub>15</sub>-gastrin-17, standard Fmoc-protected amino acids, Fmoc-Cys(Mmt)-OH, Fmoc-Tyr(SO<sub>3</sub>-neopentyl)-OH, Fmoc-Aib-OH, Fmoc-Glu-OtBu, octadecanedioic acid mono-<i>tert</i>-butyl ester, palmitic acid, and Rink amide MBHA resin were obtained from GL Biochem Ltd. (Shanghai, China). BisMAL and Fmoc-OEG-OH (Fmoc-8-amino-3,6-dioxa-octanoic acid) were purchased from Xi’an Ruixi Biological Technology Co., Ltd. (Xi’an, China) and Bachem (Bachem AG, Switzerland), respectively. The cAMP dynamic kit and AlphaScreen SureFire ERK 1/2 assay kit were acquired from Cisbio (Bedford, MA, USA) and PerkinElmer (Waltham, MA, USA), respectively. The mouse insulin ELISA kit was obtained from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). Other reagents were purchased from Merck or Sigma-Aldrich and were of an analytical grade. HEK293 cells expressing CCK-1R and CCK-2R were obtained from Cyagen Biosciences Inc. (Guangzhou, China) by transfecting the cDNA of each receptor subcloned into the pIRESneo2 expression vector (Clontech, CA, USA) into HEK293 cells.</div><div class="NLM_p last">Male C57BL/6 mice (7–8 weeks, 20–25 g), SD rats (7–8 weeks, 200–250 g), and ICR mice (6–7 weeks, 20–25 g) were acquired from Qinglongshan Animal Breeding Farm (Nanjing, China). Male BKS-Lepr<sup>db</sup>/Nju mice (db/db mice, 8–9 weeks) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). SD rats, ICR mice, and db/db mice were allowed free access to standard rodent chow, and C57BL/6 mice were fed with high-fat diet (60% calories from fat, D12492 Diets, Research Diets) for at least 18 weeks until body weight reached a plateau. The animals were kept in temperature- and light-controlled room (12/12 h light/dark cycle, 22–24 °C). All animal studies were conducted according to the guidelines of Guide for the Care and Use of Laboratory Animals (National Institutes of Health, revised 2011) and Laboratory Animal Management Regulations in China.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of Peptides</h3><div class="NLM_p last">The peptide backbones of <b>1</b>, <b>1a</b>–<b>1m</b>, <b>2</b>, <b>2a</b>–<b>2m</b>, <b>3</b>, <b>3a</b>–<b>3d</b>, <b>4a</b>–<b>4x</b>, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> were synthesized by the standard Fmoc-based solid-phase synthesis strategy and were conducted on Rink MBAH resin using a semiautomated PSI-200 peptide synthesizer (Peptide Scientific Inc., USA).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For <b>4a</b>–<b>4x</b> and <b>6a</b>–<b>d</b> with side chain cross-linkers, Fmoc-Cys(Mmt)-OH was incorporated into the cysteine modification sites, and the N-terminal position 1 was replaced with Boc-His(Boc)-OH. After accomplishment of the peptide backbones, the Mmt protection was specifically removed using 1% TFA in CH<sub>2</sub>Cl<sub>2</sub>. Then, BisMAL was dissolved in DMF, and the cross-linking reaction was conducted by incubating BisMAL with resins containing dicysteine peptides with gentle shaking for 2–3 h. After that, palmitic acid, Fmoc-OEG-OH, Fmoc-Glu-OtBu, and octadecanedioic acid mono-<i>tert</i>-butyl ester were added in order according to the structures of <b>4a</b>–<b>4x</b> and <b>6a</b>–<b>6d</b> and coupled by HBTU/HOBT/DIPEA. All the peptides were released from the Rink resin with Reagent K cocktail (EDT/thioanisole/water/phenol/TFA, 2.5:5:5:5:82.5) and precipitated in cold ether. For <b>5c</b> and <b>5d</b> containing neopentyl-protected sTyr, the crude peptides were treated with 2 M aq ammonium acetate in acetonitrile, and the mixture was kept at 55 °C for 12 h. The reaction mixture was then purified by RP-HPLC (Shimadzu LC-20AP). The purities of the purified peptides were analyzed by analytical HPLC (Agilent 1260 Infinity) with a C18 column (Shimadzu Shim-pack PREP-ODS(H) kit, 5 μm, 250 mm × 4.6 mm) with a linear gradient of 50–90% of solvent B at a flow rate of 0.8 mL/min (A, water with 0.1% TFA; B, methanol) and confirmed to be of ≥95% purity for all peptides as determined by UV absorption at 214 nm. The identity of the product was established by MS (Bruker micrOTOF Q2 or Agilent 6538 Q-TOF mass).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> GLP-1R and CCKR Activation Measurement</h3><div class="NLM_p">Using previously described methods, activation of human GLP-1R was determined by cAMP formation, and activation of human CCK-1R and CCK-2R was determined by pERK induction.<a onclick="showRef(event, 'ref21 ref33'); return false;" href="javascript:void(0);" class="ref ref21 ref33">(21,33)</a> For each assay, HEK293 cells expressing receptors were grown in DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% v/v FBS, 100 units·mL<sup>–1</sup> penicillin, 100 μg·mL<sup>–1</sup> streptomycin, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 μg·mL<sup>–1</sup> G418. HEK293 cells expressing GLP-1R were washed, resuspended in assay buffer (20 mM HEPES, 1× HBSS, 2 mM IBMX, 0.1% BSA), and plated into 96-well plates coated with 0.01% poly-<span class="smallcaps smallerCapital">l</span>-lysine before testing. Test peptides were dissolved in DMSO and diluted in medium containing 0.1% BSA and transferred to the cells. For the high HSA (4.4%) assays, peptides <b>4a</b>–<b>4x</b>, liraglutide, and semaglutide were dissolved in DMSO and diluted in medium containing HSA and transferred to the cells to reach final HSA concentration at a physiological level (4.4%). The cells were incubated for 20 min at 37 °C. Lysis buffer was added, and cAMP content was estimated using a cAMP dynamic 2 kit according to the manufacturer’s instructions.</div><div class="NLM_p last">HEK293 cells expressing CCK-1R and CCK-2R were seeded into 96-well plates coated with 0.01% poly-<span class="smallcaps smallerCapital">l</span>-lysine and kept for 2 days at 5% CO<sub>2</sub> and 37 °C. Then, cells were incubated overnight in serum-free medium (DMEM with <span class="smallcaps smallerCapital">l</span>-glutamine containing 1× nonessential amino acids and 1 mM sodium pyruvate) at 5% CO<sub>2</sub> and 37 °C. On day 3, test peptides dissolved in DMSO were diluted in serum-free medium and added into the cells at room temperature for 5 min. Then, cells were lysed, and the content of pERK was determined using an AlphaScreen SureFire ERK 1/2 assay kit (PerkinElmer). The results for cAMP and pERK were determined using an EnVision 2104 Multilabel reader (PerkinElmer). Data were normalized to maximal GLP-1 or Leu<sub>15</sub>-gastrin-17 response, and the potency (EC<sub>50</sub>) was calculated by GraphPad Prism 5.0. All experiments were performed in triplicate and repeated three times.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> OGTT in ICR Mice</h3><div class="NLM_p last">Male ICR mice (20–25 g, <i>n</i> = 6) were acclimated for 1 week and randomly divided. Mice were fasted overnight, and saline, GLP-1, <b>1</b>, <b>2</b>, <b>3</b>, <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> (25 nmol·kg<sup>–1</sup>) were injected (i.p.) 15 min before oral glucose loading (3 g·kg<sup>–1</sup>). Tail blood was collected at −15, 0, 15, 30, 60, and 120 min through cutting the tip tail (one drop). A OneTouch Sannuo handheld glucometer (GA-3, Changsha, China) was used to measure the blood glucose levels in each group.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Circular Dichroism (CD) Measurements</h3><div class="NLM_p last">CD spectra of <b>1</b>, <b>2</b>, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were recorded using a JASCO model J-810 CD spectrometer at room temperature in a path length cuvette (2 mm). Spectral data were recorded from 190 to 250 nm and averaged over 3 scans with a bandwidth of 1 nm and at a scan speed 50 nm/min. All tested peptides were dissolved in phosphate buffer containing 20% TFE to reach a final concentration of 50 μM. The signal of solvent was subtracted, and the spectra were plotted by mean residue ellipticity <i>versus</i> wavelength.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Pharmacodynamics Studies in db/db Mice</h3><div class="NLM_p last">The glucose homeostasis durations of semaglutide, liraglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were tested using nonfasted db/db mice.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In brief, male db/db mice (8 weeks, <i>n</i> = 6) were randomly divided into nine groups and acclimatized for 1 week before the study. Then, saline and 25 nmol·kg<sup>–1</sup> semaglutide, liraglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were s.c. injected, and blood glucose levels in each group were determined at 0, 2, 4, 6, 24, and 48 h using a Sannuo glucometer. Mice were allowed free access to rodent chow and water during the whole experiment.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Human Serum Albumin Binding Assay</h3><div class="NLM_p last">The albumin binding characteristics of liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were evaluated using a modified albumin binding assay by albumin-conjugated Sepharose resin, using the previously described method.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In brief, 4 mL of NHS-activated Sepharose 4FF (wet resin volume, Amersham Pharmacia Biotech (China) Ltd.) and 30 mg of HSA in 10 mM PBS (pH = 7.4) were mixed and reacted for 4 h at 25 °C by gentle shaking. After centrifugation, the recovered albumin-conjugated resin was washed by PBS three times. The HSA content in the resin used was 7–8 mg/mL wet resin. For the albumin binding assay, liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> (50 μL, 100 μg/mL in PBS) were mixed with albumin-conjugated resin and incubated at 25 °C for 2 h. The supernatant and resin were separated by centrifugation at 2000 rpm for 10 min, and the amount of unbound peptides was determined by LC–MS/MS. The albumin-free resin was obtained by inactivating the resin through hydrolysis of the NHS-active ester, and nonspecific absorption of tested peptides on the NHS-inactivated resin was determined in a similar manner.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> One Week Study in DIO Mice</h3><div class="NLM_p last">After the body weight reaching a plateau, male C57BL/6 mice (∼6 months, <i>n</i> = 6) were randomly divided into nine groups and housed individually.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Saline and 25 nmol·kg<sup>–1</sup> liraglutide, <b>4c</b>, and <b>4d</b> were s.c. injected twice daily, and 25 nmol·kg<sup>–1</sup> semaglutide, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> were s.c. injected every 2 days for 1 week. Body weight and food intake were recorded on days 1, 3, 5, and 7. Fasting blood glucose levels were determined on days −1 and 8 from mice fasted for 6 h.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> OGTT and Insulin Secretion Tests in db/db Mice</h3><div class="NLM_p last">Male db/db mice (8 weeks, <i>n</i> = 6) were randomly divided into four groups and acclimatized for 1 week before the study. Each group of mice was fasted overnight (16 h), and saline and 25 nmol·kg<sup>–1</sup> ZP3022, <b>6a</b>, and <b>6b</b> were i.p. loaded at −30 min followed by an oral loading of 1.5 g·kg<sup>–1</sup> glucose at 0 min. One drop of blood was collected at −30, 0, 15, 30, 60, and 120 min for blood glucose level monitoring. At 0, 15, 30, and 60 min, additional eight drops of blood were collected to obtain ∼10 μL of plasma. Plasma insulin levels were determined using a mouse insulin ELISA kit (Nanjing Jiancheng Bioengineering Institute, catalog no. NJB201909).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Pharmacokinetics (PK) Tests</h3><div class="NLM_p last">Pharmacokinetics studies of ZP3022, <b>6a</b>, and <b>6b</b> were performed in ICR mice using the previously described method.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Male ICR mice (20–25 g) were acclimatized until body weight reached ∼30 g. Mice were randomly divided into three groups (<i>n</i> = 12 for ZP3022; <i>n</i> = 18 for <b>6a</b> and <b>6b</b>) and fasted overnight before the experiment. On the test day, each group of mice received 50 nmol·kg<sup>–1</sup> ZP3022, <b>6a</b>, and <b>6b</b> (s.c.). At 1, 2, 4, 8, 16, and 24 h, three ICR mice were sacrificed, and ∼200 μL of blood samples was collected from fundus venous plexus and stored in ice cooled tubes containing EDTA. The plasma was isolated by centrifugation at 3000 rpm and stored at −80 °C until analysis. After thawing the plasma, two volumes of acetonitrile with 0.5% formic acid were added for precipitation of the protein. Then, the mixture was subjected to centrifugation (15,000 rpm, 10 min) to obtain a supernatant, which was analyzed by LC–MS/MS. The concentrations of ZP3022, <b>6a</b>, and <b>6b</b> were calculated using standard curves plotted by multiple reaction monitoring (MRM) signals <i>versus</i> tested peptide concentrations. Pharmacokinetics parameters were calculated using BAPP version 2.2 (China Pharmaceutical University, Nanjing, China).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Dose Response for Hypoglycemic Duration and Food Intake in db/db Mice</h3><div class="NLM_p last">The dose response studies for hypoglycemic duration of ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> were performed using nonfasted db/db mice. Male db/db mice (8 weeks, <i>n</i> = 6) were randomly divided into 10 groups and acclimatized for 1 week. On the experiment day, five groups of mice were s.c. injected with saline or 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b>, and the other five groups of mice were s.c. injected with saline or 100 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b>. The blood glucose levels were determined at 0, 4, 6, 12, 24, and 48 h. For food intake consumption recording, the rodent chows were preweighed and reweighed at 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h to calculate food intake consumption. The food spillage was also checked for accuracy.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Gastric Emptying Studies</h3><div class="NLM_p last">Two protocols were applied for the gastric emptying studies. The liquid-phase gastric emptying rate was tested by the acetaminophen absorption test.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Male ICR mice (20–25 g) were randomly divided into five groups (<i>n</i> = 6). After being acclimatized for 7 days, each group of mice was deprived for food and fasted for 6 h. Saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> were i.p. injected at −30 min. Acetaminophen solution (100 mg·kg<sup>–1</sup>) was then orally administered at 0 min. Blood samples (∼50 μL) were collected from tail vein into tubes containing EDTA. The procedures of obtaining plasma and precipitating protein were the same as described above in PK tests. The concentration of acetaminophen was determined by LC–MS/MS. To measure the rate of solid-phase gastric emptying, ICR mice were divided into five groups (<i>n</i> = 6) and housed individually. Mice were fasted overnight (12 h), and preweighed rodent chows were supplied for 1 h. Saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> were i.p. injected. Each group of mice was sacrificed 4 h after peptide injection. Stomach was isolated once pylorus and cardia were quickly ligated. The gastric contents were removed and dried using a VFD-1000B freeze dryer (Bilon, Shanghai, China). The rate of solid-phase gastric emptying was determined as [1 – (weight of stomach content/weight of food intake)] × 100%.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Kaolin Consumption Test</h3><div class="NLM_p last">Kaolin pellets were made according to the previously described method.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In brief, a thick paste was made by mixing kaolin with 1% gum arabic, and the rods with similar diameter to rodent chow were obtained by extruding the thick paste through a syringe. The rods were dried at room temperature and were cut into pellets with comparable length to standard food pellets. Male SD rats were individually housed and randomly divided into six groups (<i>n</i> = 6). Four days prior to the experiment, apart from the standard rodent chow, kaolin pellets were also provided in a separate food hopper. Kaolin and rodent chow were removed for 16 h before the experiment, and each group of mice was i.p. administered with saline (10% DMSO), cisplatin (3 mg·kg<sup>–1</sup>), ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>). Preweighted kaolin and rodent chow were immediately provided, and the consumption of kaolin and rodent chow was determined at 24 h. In another experiment, five groups of SD rats (<i>n</i> = 6) were housed and acclimatized using the same procedure as described above. On day 0, the consumption of rodent chow and kaolin in the last 24 h was determined, and each group of mice was s.c. administered three times a day with saline and ZP3022 (25 nmol·kg<sup>–1</sup>) or s.c. administered twice daily with liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) for 12 days. The consumption of kaolin and rodent chow was determined every 2 days.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Toxicity Assay</h3><div class="NLM_p last">The in vitro toxicity study of <b>6a</b> and <b>6b</b> was conducted on INS-1 cells using the previously described method.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In brief, cells (∼10,000 cells/well) were kept in RPMI 1640 medium with supplements and cultured in a polypropylene plate (96-well) for 24 h. Cells were then directly treated with ZP3022, liraglutide (100 nM), <b>6a</b>, and <b>6b</b> (10, 100, and 1000 nM) or treated with ZP3022, liraglutide (100 nM), <b>6a</b>, and <b>6b</b> (10, 100, and 1000 nM) combined with glucotoxicity media (30 mM glucose). After 24 h, 5 mg·mL<sup>–1</sup> MTT solution was added and incubated for another 5 h. DMSO was added to dissolve the formazan precipitate, and the absorbance at 570 nm was determined using a Thermo spectrophotometer (Waltham, MA, USA). The absorbance results in the saline, ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> groups were normalized to the control cells. For in vivo study, male ICR mice (20–25 g) were divided randomly into five groups (<i>n</i> = 6) and acclimatized for 1 week. Then, mice were s.c. treated twice daily with saline, 100 nmol·kg<sup>–1</sup> liraglutide and ZP3022, and 1000 nmol·kg<sup>–1</sup><b>6a</b> and <b>6b</b> for 14 days. Mice were sacrificed on day 15 to collect the whole blood followed by centrifugation to obtain serum. The values of AST, ALT, SCr, and BUN were measured using a Beckman AU5811 Coulter automatic analyzer.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Metabolic Benefits of <b>6a</b> and <b>6b</b> in DIO Mice</h3><div class="NLM_p last">Male C57BL/6 mice were randomly divided into five groups (<i>n</i> = 6) and individually housed. Mice were fed with high-fat diet for at least 18 weeks until the body weight reached a plateau.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Saline and 25 nmol·kg<sup>–1</sup> ZP3022 were s.c. injected three times a day, and 25 nmol·kg<sup>–1</sup> liraglutide, <b>6a</b>, and <b>6b</b> were s.c. injected twice daily for 21 days. Body weight changes and food intake were monitored daily and every 3 days, respectively. The fat mass was measured using NMR technology (MiniQMR) on days −1 and 22. Fasted blood glucose levels were determined on days −1 and 22 after mice were fasted for 6 h. Two OGTTs were conducted on days −2 and 23 in mice fasted for 12 h. Glucose (1.5 g·kg<sup>–1</sup>) was orally loaded at 0 min, and at 0, 15, 30, 60, and 120 min, blood glucose levels were determined. The mice were all sacrificed to collect the whole blood. The serum triglycerides and total cholesterol were measured using a Beckman AU5811 Coulter automatic analyzer.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Short-Term Effects of <b>6a</b> and <b>6b</b> on Pancreas Development</h3><div class="NLM_p last">Male db/db mice (9 weeks, <i>n</i> = 6) were randomly divided into five groups and acclimatized for 1 week before the study. Saline and 25 nmol·kg<sup>–1</sup> ZP3022 were s.c. injected three times a day, and 25 nmol·kg<sup>–1</sup> liraglutide, <b>6a</b>, and <b>6b</b> were s.c. injected twice daily for 21 days. The amount of food intake and body weight was measured daily. Fasted blood glucose levels were determined on days −1 and 22 after mice were fasted for 6 h. The HbA1c levels in each group of mice were determined using a DCA 2000 chemistry analyzer before and after the experiment. At the end of the study, mice were killed, and the pancreas was immediately removed and stored in 4% paraformaldehyde. The procedures for hematoxylin–eosin (HE) staining and immunohistochemistry study were the same as described previously.<a onclick="showRef(event, 'ref23 ref38'); return false;" href="javascript:void(0);" class="ref ref23 ref38">(23,38)</a> The percentage of α- and β-cell areas were determined by glucagon and insulin immunostaining, respectively. The insulin integrated optical density (IOD) levels were recorded by a Nikon DS-Ri2 fluorescence microscope using Image-Pro Plus 6.0 software (Media Cybernetics Inc., USA).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Long-Term Effects of <b>6a</b> and <b>6b</b> on Glycemic Control</h3><div class="NLM_p last">Male db/db mice (8 weeks) were fasted overnight (16 h) and subjected to an OGTT before the experiment.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Glucose (1.5 g·kg<sup>–1</sup>) was orally loaded at 0 min, and at −30, 0, 15, 30, 60, and 120 min, blood glucose levels were determined. Based on the OGTT results, mice with similar glucose tolerance profiles were divided into four groups (<i>n</i> = 6). Saline and 25 nmol·kg<sup>–1</sup> ZP3022 were s.c. injected three times a day, and 25 nmol·kg<sup>–1</sup> liraglutide, <b>6a</b>, and <b>6b</b> were s.c. injected twice daily for 42 days. In the following 42 days, each group of mice was s.c. injected twice daily with saline. OGTTs were performed on days 42, 56, 70, and 84, and on days 0, 35, 49, 63, and 77, mice were fasted for 6 h to determine the fasted blood glucose levels. The levels of HbA1c were measured on days −1, 43, and 85 using the same method as described above.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Data Analysis</h3><div class="NLM_p last">All statistical calculations were conducted using GraphPad Prism 5.0 software, and <i>P</i> values <0.05 were considered as statistically significant. The statistical evaluations of the data were performed by one-way analysis of variance (ANOVA) followed by Tukey post-hoc analysis. All results are expressed as means ± SD.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00736" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34623" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34623" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00736?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00736</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data and characterizations of <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, <b>4a</b>–<b>4x</b>, <b>5a</b>–<b>5d</b>, <b>6a</b>–<b>6d</b>, <b>7a</b>, and <b>7b</b>; dose–response curves of <b>1</b>, <b>2</b>, <b>3</b>, <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, and <b>4a</b>–<b>4x</b> on GLP-1R; albumin binding capacities of liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b>; general synthetic route of <b>5c</b> and <b>5d</b>; dose–response curves of <b>2</b>, Leu<sub>15</sub>-gastrin-17, ZP3022, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> on GLP-1R and CCK-2R; PK profiles of ZP3022, <b>6a</b>, and <b>6b</b> in ICR mice; PK profiles of <b>7a</b> and <b>7b</b> in SD rats; and docking studies of <b>6a′</b> and <b>6b′</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, <b>4a</b>–<b>4x</b>, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf">jm0c00736_si_001.pdf (5.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_002.csv">jm0c00736_si_002.csv (58.1 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00736" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neng Jiang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, Affiliated Tumor Hospital of
Guangxi Medical University, Nanning 530021, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b6d5c6c3dcd8def687808598d5d9db"><span class="__cf_email__" data-cfemail="d1b2a1a4bbbfb991e0e7e2ffb2bebc">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Yin</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of
Education, School of Biotechnology, Jiangnan
University, Wuxi 214122, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2284-1666" title="Orcid link">http://orcid.org/0000-0002-2284-1666</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#117b78707f68787f517b78707f767f707f3f7475643f727f"><span class="__cf_email__" data-cfemail="98f2f1f9f6e1f1f6d8f2f1f9f6fff6f9f6b6fdfcedb6fbf6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Han</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of
Education, School of Biotechnology, Jiangnan
University, Wuxi 214122, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5605-1868" title="Orcid link">http://orcid.org/0000-0001-5605-1868</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5f37356e6667696b6d6b1f352c312a713a3b2a713c31"><span class="__cf_email__" data-cfemail="97fffda6aeafa1a3a5a3d7fde4f9e2b9f2f3e2b9f4f9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinyu Chen</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junjie Fu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of
Education, School of Biotechnology, Jiangnan
University, Wuxi 214122, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2741-7469" title="Orcid link">http://orcid.org/0000-0002-2741-7469</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Zhou</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qimeng Yang</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jialing Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Feng</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen Jiang</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luofan Jin</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuelin Tang</span> - <span class="hlFld-Affiliation affiliation">School
of Chemistry & Materials Science, Jiangsu
Normal University, Xuzhou 221116, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.C., J.F., and F.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work is supported by the National Natural Science Foundation of China (nos. 81602964 and 81602960), the Fundamental Research Funds for the Central Universities (JUSRP51712B), National First-class Discipline Program of Light Industry Technology and Engineering (LITE2018-14), the Natural Science Foundation of Xuzhou (no. KC19154), Guangxi Medical University Training Program for Distinguished Young Scholars, the Open Project from the Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education (no. KLCCB-KF202003), and Postgraduate Research and Practice Innovation Program of Jiangsu Province (no. KYCX20_2259).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">T2DM</td><td class="NLM_def"><p class="first last">type 2 diabetes mellitus</p></td></tr><tr><td class="NLM_term">SGLT2</td><td class="NLM_def"><p class="first last">sodium-glucose cotransporter 2</p></td></tr><tr><td class="NLM_term">GIP</td><td class="NLM_def"><p class="first last">glucose-dependent insulinotropic polypeptide</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">DIO</td><td class="NLM_def"><p class="first last">diet-induced obesity</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reversed-phase high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">OGTT</td><td class="NLM_def"><p class="first last">oral glucose tolerance test</p></td></tr><tr><td class="NLM_term">HSA</td><td class="NLM_def"><p class="first last">human serum albumin</p></td></tr><tr><td class="NLM_term">OEG</td><td class="NLM_def"><p class="first last">8-amino-3,6-dioxa-octanoic acid</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">circular dichroism</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BUN</td><td class="NLM_def"><p class="first last">blood urea nitrogen</p></td></tr><tr><td class="NLM_term">SCr</td><td class="NLM_def"><p class="first last">serum creatinine</p></td></tr><tr><td class="NLM_term">TC</td><td class="NLM_def"><p class="first last">total cholesterol</p></td></tr><tr><td class="NLM_term">TG</td><td class="NLM_def"><p class="first last">serum triglycerides</p></td></tr><tr><td class="NLM_term">IOD</td><td class="NLM_def"><p class="first last">integrated optical density</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin–eosin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S. M.</span></span> <span> </span><span class="NLM_article-title">Emerging Hormonal-based Combination Pharmacotherapies for the Treatment of Metabolic Diseases</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1038/s41574-018-0118-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fs41574-018-0118-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30446744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=90-104&author=C.+Clemmensenauthor=B.+Finanauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6pauthor=S.+M.+Hofmann&title=Emerging+Hormonal-based+Combination+Pharmacotherapies+for+the+Treatment+of+Metabolic+Diseases&doi=10.1038%2Fs41574-018-0118-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases</span></div><div class="casAuthors">Clemmensen Christoffer; Clemmensen Christoffer; Muller Timo D; Tschop Matthias H; Finan Brian; DiMarchi Richard D; Tschop Matthias H; Hofmann Susanna M; Hofmann Susanna M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Obesity and its comorbidities, such as type 2 diabetes mellitus and cardiovascular disease, constitute growing challenges for public health and economies globally.  The available treatment options for these metabolic disorders cannot reverse the disease in most individuals and have not substantially reduced disease prevalence, which underscores the unmet need for more efficacious interventions.  Neurobiological resilience to energy homeostatic perturbations, combined with the heterogeneous pathophysiology of human metabolic disorders, has limited the sustainability and efficacy of current pharmacological options.  Emerging insights into the molecular origins of eating behaviour, energy expenditure, dyslipidaemia and insulin resistance suggest that coordinated targeting of multiple signalling pathways is probably necessary for sizeable improvements to reverse the progression of these diseases.  Accordingly, a broad set of combinatorial approaches targeting feeding circuits, energy expenditure and glucose metabolism in concert are currently being explored and developed.  Notably, several classes of peptide-based multi-agonists and peptide-small molecule conjugates with superior preclinical efficacy have emerged and are currently undergoing clinical evaluation.  Here, we summarize advances over the past decade in combination pharmacotherapy for the management of obesity and type 2 diabetes mellitus, exclusively focusing on large-molecule formats (notably enteroendocrine peptides and proteins) and discuss the associated therapeutic opportunities and challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBi3BP-gFLovSAs_PE1QvifW6udTcc2eYFwXMIliiOVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVeqtw%253D%253D&md5=ac6857dc287d02aa96c3d9376f5e8dbb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41574-018-0118-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41574-018-0118-x%26sid%3Dliteratum%253Aachs%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%2BM.%26atitle%3DEmerging%2520Hormonal-based%2520Combination%2520Pharmacotherapies%2520for%2520the%2520Treatment%2520of%2520Metabolic%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2019%26volume%3D15%26spage%3D90%26epage%3D104%26doi%3D10.1038%2Fs41574-018-0118-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scully, C. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=905-927&author=R.+Suzukiauthor=G.+A.+Brownauthor=J.+A.+Christopherauthor=C.+C.+G.+Scullyauthor=M.+Congreve&title=Recent+Developments+in+Therapeutic+Peptides+for+the+Glucagon-like+Peptide+1+and+2+Receptors&doi=10.1021%2Facs.jmedchem.9b00835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span></div><div class="casAuthors">Suzuki, Rie; Brown, Giles A.; Christopher, John A.; Scully, Conor C. G.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake.  These mols. are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents.  The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide mols. that hold promise as novel peptide therapeutics.  One emerging area is the discovery of multifunctional mols. that act at two or more pharmacol. systems to enhance therapeutic efficacy.  In addn., drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery.  These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdugqq7LLcprVg90H21EOLACvtfcHk0lhQsLYEoaRI_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I&md5=98554f261b9fd88ed7a12e806869be6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00835%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DScully%26aufirst%3DC.%2BC.%2BG.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DRecent%2520Developments%2520in%2520Therapeutic%2520Peptides%2520for%2520the%2520Glucagon-like%2520Peptide%25201%2520and%25202%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D905%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.9b00835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">728</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2012.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnrendo.2012.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=22945360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=728&author=J.+J.+Meier&title=GLP-1+Receptor+Agonists+for+Individualized+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.1038%2Fnrendo.2012.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Meier, Juris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">728-742</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and lowers glucose concns. by augmenting insulin secretion and suppressing glucagon release.  Addnl. effects of GLP-1 include retardation of gastric emptying, suppression of appetite and, potentially, inhibition of β-cell apoptosis.  Native GLP-1 is degraded within ∼2-3 min in the circulation; various GLP-1 receptor agonists have, therefore, been developed to provide prolonged in vivo actions.  These GLP-1 receptor agonists can be categorized as either short-acting compds., which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compds. (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose.  The pharmacokinetic differences between these drugs lead to important differences in their pharmacodynamic profiles.  The short-acting GLP-1 receptor agonists primarily lower postprandial blood glucose levels through inhibition of gastric emptying, whereas the long-acting compds. have a stronger effect on fasting glucose levels, which is mediated predominantly through their insulinotropic and glucagonostatic actions.  The adverse effect profiles of these compds. also differ.  The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GZovdW_ldbVg90H21EOLACvtfcHk0lgGsL8x3xz6BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP&md5=5dc374bda9f06bb96494f8ed7a61018f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.140%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DGLP-1%2520Receptor%2520Agonists%2520for%2520Individualized%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2012%26volume%3D8%26spage%3D728%26doi%3D10.1038%2Fnrendo.2012.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riboulet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebokova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Knape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfluger, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischerauthor=J.+E.+Campbellauthor=D.+Sandovalauthor=R.+J.+Seeleyauthor=K.+Bleicherauthor=S.+Uhlesauthor=W.+Ribouletauthor=J.+Funkauthor=C.+Hertelauthor=S.+Belliauthor=E.+Sebokovaauthor=K.+Conde-Knapeauthor=A.+Konkarauthor=D.+J.+Druckerauthor=V.+Gelfanovauthor=P.+T.+Pflugerauthor=T.+D.+M%C3%BCllerauthor=D.+Perez-Tilveauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=A+Rationally+Designed+Monomeric+Peptide+Triagonist+Corrects+Obesity+and+Diabetes+in+Rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0lgGsL8x3xz6BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DSandoval%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DUhles%26aufirst%3DS.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DSebokova%26aufirst%3DE.%26aulast%3DConde-Knape%26aufirst%3DK.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DA%2520Rationally%2520Designed%2520Monomeric%2520Peptide%2520Triagonist%2520Corrects%2520Obesity%2520and%2520Diabetes%2520in%2520Rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengelin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadereit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span> <span> </span><span class="NLM_article-title">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4303</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4293-4303&author=A.+Eversauthor=T.+Haackauthor=M.+Lorenzauthor=M.+Bossartauthor=R.+Elvertauthor=B.+Henkelauthor=S.+Stengelinauthor=M.+Kurzauthor=M.+Glienauthor=A.+Duddaauthor=K.+Lorenzauthor=D.+Kadereitauthor=M.+Wagner&title=Design+of+Novel+Exendin-Based+Dual+Glucagon-like+Peptide+1+%28GLP-1%29%2FGlucagon+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span></div><div class="casAuthors">Evers, Andreas; Haack, Torsten; Lorenz, Martin; Bossart, Martin; Elvert, Ralf; Henkel, Bernd; Stengelin, Siegfried; Kurz, Michael; Glien, Maike; Dudda, Angela; Lorenz, Katrin; Kadereit, Dieter; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4293-4303</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity.  Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design.  On the basis of sequence anal. and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity.  Detailed structure-activity relationship data are shown.  Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body wt. in diet-induced obese (DIO) mice.  Structural anal. by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chem. and phys. stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewDgurwTT4LVg90H21EOLACvtfcHk0liaYwqVm4dIaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D&md5=b59a7a25cdd56516b78c988860b39211</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DHaack%26aufirst%3DT.%26aulast%3DLorenz%26aufirst%3DM.%26aulast%3DBossart%26aufirst%3DM.%26aulast%3DElvert%26aufirst%3DR.%26aulast%3DHenkel%26aufirst%3DB.%26aulast%3DStengelin%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DGlien%26aufirst%3DM.%26aulast%3DDudda%26aufirst%3DA.%26aulast%3DLorenz%26aufirst%3DK.%26aulast%3DKadereit%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DM.%26atitle%3DDesign%2520of%2520Novel%2520Exendin-Based%2520Dual%2520Glucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%252FGlucagon%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4293%26epage%3D4303%26doi%3D10.1021%2Facs.jmedchem.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2eaAD8M-bbdJc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bech, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martos-Maldonado, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wismann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So̷rensen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Witteloostuijn, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelsing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. J.</span></span> <span> </span><span class="NLM_article-title">Peptide Half-life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7434</span>– <span class="NLM_lpage">7446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00787</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00787" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OmsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7434-7446&author=E.+M.+Bechauthor=M.+C.+Martos-Maldonadoauthor=P.+Wismannauthor=K.+K.+So%CC%B7rensenauthor=S.+B.+van+Witteloostuijnauthor=M.+B.+Thygesenauthor=N.+Vrangauthor=J.+Jelsingauthor=S.+L.+Pedersenauthor=K.+J.+Jensen&title=Peptide+Half-life+Extension%3A+Divalent%2C+Small-Molecule+Albumin+Interactions+Direct+the+Systemic+Properties+of+Glucagon-Like+Peptide+1+%28GLP-1%29+Analogues&doi=10.1021%2Facs.jmedchem.7b00787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues</span></div><div class="casAuthors">Bech, Esben M.; Maldonado, Manuel C.; Wismann, Pernille; Soerensen, Kasper K.; van Witteloostuijn, Soeren Blok; Thygesen, Mikkel B.; Vrang, Niels; Jelsing, Jacob; Pedersen, Soeren L.; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7434-7446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymic degrdn. and renal clearance.  Herein, we investigated the effect of mono- or divalent small-mol. albumin binders for half-life extension of peptides.  For proof-of-principle, the clin. relevant glucagon-like peptide 1 (GLP-1) was functionalized with diflunisal, indomethacin, or both.  In vitro, all GLP-1 analogs had subnanomolar GLP-1 receptor potency.  Surface plasmon resonance revealed that both small mols. were able to confer albumin affinity to GLP-1 and indicated that affinity is increased for divalent analogs.  In lean mice, the divalent GLP-1 analogs were superior to monovalent analogs with respect to control of glucose homeostasis and suppression of food intake.  Importantly, divalent GLP-1 analogs showed efficacy comparable to liraglutide, an antidiabetic GLP-1 analog that carries a long-chain fatty acid.  Finally, pharmacokinetic investigations of a divalent GLP-1 analog demonstrated a promising gain in circulatory half-life and absorption time compared to its monovalent equiv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDH8-idZnsPLVg90H21EOLACvtfcHk0liD635pmFuKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OmsLnO&md5=8ed415888afd85068ac6a4b98090b69c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00787%26sid%3Dliteratum%253Aachs%26aulast%3DBech%26aufirst%3DE.%2BM.%26aulast%3DMartos-Maldonado%26aufirst%3DM.%2BC.%26aulast%3DWismann%26aufirst%3DP.%26aulast%3DSo%25CC%25B7rensen%26aufirst%3DK.%2BK.%26aulast%3Dvan%2BWitteloostuijn%26aufirst%3DS.%2BB.%26aulast%3DThygesen%26aufirst%3DM.%2BB.%26aulast%3DVrang%26aufirst%3DN.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DPedersen%26aufirst%3DS.%2BL.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DPeptide%2520Half-life%2520Extension%253A%2520Divalent%252C%2520Small-Molecule%2520Albumin%2520Interactions%2520Direct%2520the%2520Systemic%2520Properties%2520of%2520Glucagon-Like%2520Peptide%25201%2520%2528GLP-1%2529%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7434%26epage%3D7446%26doi%3D10.1021%2Facs.jmedchem.7b00787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&author=D.+J.+Drucker&title=Mechanisms+of+Action+and+Therapeutic+Application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0liD635pmFuKWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520Action%2520and%2520Therapeutic%2520Application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habener, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nauck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang-Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">Glucagon-like Peptide 1 (GLP-1)</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2019.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.molmet.2019.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=31767182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKkurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=72-130&author=T.+D.+M%C3%BCllerauthor=B.+Finanauthor=S.+R.+Bloomauthor=D.+D%E2%80%99Alessioauthor=D.+J.+Druckerauthor=P.+R.+Flattauthor=A.+Fritscheauthor=F.+Gribbleauthor=H.+J.+Grillauthor=J.+F.+Habenerauthor=J.+J.+Holstauthor=W.+Langhansauthor=J.+J.+Meierauthor=M.+A.+Nauckauthor=D.+Perez-Tilveauthor=A.+Pocaiauthor=F.+Reimannauthor=D.+A.+Sandovalauthor=T.+W.+Schwartzauthor=R.+J.+Seeleyauthor=K.+Stemmerauthor=M.+Tang-Christensenauthor=S.+C.+Woodsauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=Glucagon-like+Peptide+1+%28GLP-1%29&doi=10.1016%2Fj.molmet.2019.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1 (GLP-1)</span></div><div class="casAuthors">Mueller, T. D.; Finan, B.; Bloom, S. R.; D'Alessio, D.; Drucker, D. J.; Flatt, P. R.; Fritsche, A.; Gribble, F.; Grill, H. J.; Habener, J. F.; Holst, J. J.; Langhans, W.; Meier, J. J.; Nauck, M. A.; Perez-Tilve, D.; Pocai, A.; Reimann, F.; Sandoval, D. A.; Schwartz, T. W.; Seeley, R. J.; Stemmer, K.; Tang-Christensen, M.; Woods, S. C.; Di Marchi, R. D.; Tschoep, M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-130</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacol. potential.  Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation.  GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability.  Biochem. modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clin. use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clin. evaluation for the treatment of obesity.In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacol. and discuss its therapeutic implications on various diseases.Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.  The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzuj3Nn8zhJrVg90H21EOLACvtfcHk0ljGzzZ5P993LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKkurfE&md5=ad8676e810b7b4abd72fbe9c790c0336</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2019.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2019.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DFritsche%26aufirst%3DA.%26aulast%3DGribble%26aufirst%3DF.%26aulast%3DGrill%26aufirst%3DH.%2BJ.%26aulast%3DHabener%26aufirst%3DJ.%2BF.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DLanghans%26aufirst%3DW.%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DSandoval%26aufirst%3DD.%2BA.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DTang-Christensen%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGlucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%26jtitle%3DMol.%2520Metab.%26date%3D2019%26volume%3D30%26spage%3D72%26epage%3D130%26doi%3D10.1016%2Fj.molmet.2019.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadry, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Combinatorial Hormone Therapies for the Treatment of Obesity and T2DM</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2013.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnrendo.2013.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=23478327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=425-433&author=S.+A.+Sadryauthor=D.+J.+Drucker&title=Emerging+Combinatorial+Hormone+Therapies+for+the+Treatment+of+Obesity+and+T2DM&doi=10.1038%2Fnrendo.2013.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging combinatorial hormone therapies for the treatment of obesity and T2DM</span></div><div class="casAuthors">Sadry, Sharon A.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">425-433</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Peptide hormones and proteins control body wt. and glucose homeostasis by engaging peripheral and central metabolic signalling pathways responsible for the maintenance of body wt. and euglycemia.  The development of obesity, often in assocn. with type 2 diabetes mellitus (T2DM), reflects a dysregulation of metabolic, anorectic and orexigenic pathways in multiple organs.  Notably, therapeutic attempts to normalize body wt. and glycemia with single agents alone have generally been disappointing.  The success of bariatric surgery, together with emerging data from preclin. studies, illustrates the rationale and feasibility of using two or more agonists, or single co-agonists, for the treatment of obesity and T2DM.  Here, we review advances in the science of co-agonist therapy, and highlight promising areas and challenges in co-agonist development.  We describe mechanisms of action for combinations of glucagon-like peptide 1, glucagon, gastric inhibitory polypeptide, gastrin, islet amyloid polypeptide and leptin, which enhance wt. loss while preserving glucoregulatory efficacy in exptl. models of obesity and T2DM.  Although substantial progress has been achieved in preclin. studies, the putative success and safety of co-agonist therapy for the treatment of patients with obesity and T2DM remains uncertain and requires extensive addnl. clin. validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgtf-WtnFhvrVg90H21EOLACvtfcHk0ljGzzZ5P993LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyhur0%253D&md5=5710f40e4fd9f27974ab0bae8954a08e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.47%26sid%3Dliteratum%253Aachs%26aulast%3DSadry%26aufirst%3DS.%2BA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DEmerging%2520Combinatorial%2520Hormone%2520Therapies%2520for%2520the%2520Treatment%2520of%2520Obesity%2520and%2520T2DM%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26spage%3D425%26epage%3D433%26doi%3D10.1038%2Fnrendo.2013.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">GLP-1/Glucagon Receptor Co-agonism for Treatment of Obesity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1851</span>– <span class="NLM_lpage">1861</span>, <span class="refDoi"> DOI: 10.1007/s00125-017-4354-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1007%2Fs00125-017-4354-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28733905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wru7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1851-1861&author=M.+A.+S%C3%A1nchez-Garridoauthor=S.+J.+Brandtauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=GLP-1%2FGlucagon+Receptor+Co-agonism+for+Treatment+of+Obesity&doi=10.1007%2Fs00125-017-4354-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1/glucagon receptor co-agonism for treatment of obesity</span></div><div class="casAuthors">Sanchez-Garrido, Miguel A.; Brandt, Sara J.; Clemmensen, Christoffer; Mueller, Timo D.; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1851-1861</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies.  The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications.  Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance.  Pharmacol. attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body wt.  Novel unimol., multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body wt.  In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacol. function at the receptors for glucagon and glucagon-like peptide-1.  Such peptides have advanced to clin. evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwna62NYSHj7Vg90H21EOLACvtfcHk0lj_baeVzb-kLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wru7%252FF&md5=ca76fc85634d91bcbdd5ffd239390f28</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4354-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4354-8%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Garrido%26aufirst%3DM.%2BA.%26aulast%3DBrandt%26aufirst%3DS.%2BJ.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGLP-1%252FGlucagon%2520Receptor%2520Co-agonism%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1851%26epage%3D1861%26doi%3D10.1007%2Fs00125-017-4354-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehfeld, J. F.</span></span> <span> </span><span class="NLM_article-title">Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy</span>.  <i>Clin. Med. Insights: Endocrinol. Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">12</span>, <span class="refDoi"> DOI: 10.1177/1179551419883608</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1177%2F1179551419883608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=31853211" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&author=J.+F.+Rehfeld&title=Premises+for+Cholecystokinin+and+Gastrin+Peptides+in+Diabetes+Therapy&doi=10.1177%2F1179551419883608"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1179551419883608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1179551419883608%26sid%3Dliteratum%253Aachs%26aulast%3DRehfeld%26aufirst%3DJ.%2BF.%26atitle%3DPremises%2520for%2520Cholecystokinin%2520and%2520Gastrin%2520Peptides%2520in%2520Diabetes%2520Therapy%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Endocrinol.%2520Diabetes%26date%3D2019%26volume%3D12%26doi%3D10.1177%2F1179551419883608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwens, L.</span></span> <span> </span><span class="NLM_article-title">Mitogenic Effect of Gastrin and Expression of Gastrin Receptors in Duct-like Cells of Rat Pancreas</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1053/gast.2001.27998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1053%2Fgast.2001.27998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=11606507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2001&pages=940-949&author=I.+Roomanauthor=J.+Lardonauthor=D.+Flamezauthor=F.+Schuitauthor=L.+Bouwens&title=Mitogenic+Effect+of+Gastrin+and+Expression+of+Gastrin+Receptors+in+Duct-like+Cells+of+Rat+Pancreas&doi=10.1053%2Fgast.2001.27998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas</span></div><div class="casAuthors">Rooman, Ilse; Lardon, Jessy; Flamez, Daisy; Schuit, Frans; Bouwens, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Ductular metaplastic cells are obsd. during pancreas injury.  Growth control by gastrin and expression of gastrin/cholecystokinin (CCK) B receptors were evaluated in these cells.  Acinoductal transdifferentiation was induced in vitro by culturing of acinar cells, and ductular metaplasia was obtained in vivo by ligation of the pancreatic ducts.  Mitogenic effects of gastrin I on ductal complexes in vivo and of tetragastrin, pentagastrin, and gastrin I and II, with or without the CCK-B receptor antagonist L-365,260, on duct-like cells in vitro were analyzed by 5-bromo-2'-deoxyuridine labeling.  Immunocytochem., Western blotting, and reverse-transcription polymerase chain reaction were applied for detection of the CCK-B receptor.  Gastrin analogs induced a mitogenic stimulus in the duct-like cells in vitro and in ductal complexes in duct-ligated rat pancreas.  Immunocytochem. showed expression of CCK-B receptors in these models and in fetal but not normal adult exocrine pancreas.  Addnl., up-regulation of CCK-B receptors during ductular metaplasia was shown by Western blotting and reverse-transcription polymerase chain reaction.  Duct-like pancreatic epithelial cells in vitro and ductal complexes in vivo express gastrin/CCK-B receptors and proliferate in response to gastrin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrW-bFlbBO7rVg90H21EOLACvtfcHk0lj_baeVzb-kLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVynu7w%253D&md5=c94d999957a6c37746f3fb73c26152d3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fgast.2001.27998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2001.27998%26sid%3Dliteratum%253Aachs%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DLardon%26aufirst%3DJ.%26aulast%3DFlamez%26aufirst%3DD.%26aulast%3DSchuit%26aufirst%3DF.%26aulast%3DBouwens%26aufirst%3DL.%26atitle%3DMitogenic%2520Effect%2520of%2520Gastrin%2520and%2520Expression%2520of%2520Gastrin%2520Receptors%2520in%2520Duct-like%2520Cells%2520of%2520Rat%2520Pancreas%26jtitle%3DGastroenterology%26date%3D2001%26volume%3D121%26spage%3D940%26epage%3D949%26doi%3D10.1053%2Fgast.2001.27998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwens, L.</span></span> <span> </span><span class="NLM_article-title">Gastrin Stimulates β-Cell Neogenesis and Increases Islet Mass from Transdifferentiated but not from Normal Exocrine Pancreas Tissue</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">686</span>, <span class="refDoi"> DOI: 10.2337/diabetes.51.3.686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdiabetes.51.3.686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=11872667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFSgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=686&author=I.+Roomanauthor=J.+Lardonauthor=L.+Bouwens&title=Gastrin+Stimulates+%CE%B2-Cell+Neogenesis+and+Increases+Islet+Mass+from+Transdifferentiated+but+not+from+Normal+Exocrine+Pancreas+Tissue&doi=10.2337%2Fdiabetes.51.3.686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue</span></div><div class="casAuthors">Rooman, Ilse; Lardon, Jessy; Bouwens, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">686-690</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">It is still unclear which factors regulate pancreatic regeneration and β-cell neogenesis and which precursor cells are involved.  We evaluated the role of i.v. infused gastrin in regenerating pancreas of duct-ligated rats.  The ligation of exocrine ducts draining the splenic half of the pancreas resulted in acinoductal transdifferentiation within the ligated part but not in the unligated part.  We found that infusion of gastrin from day 7 to 10 post ligation resulted in a doubling of the β-cell mass in the ligated part as measured by morphometry.  This increase in insulin-expressing cells was not assocd. with increased proliferation, hypertrophy, or reduced cell death of the β-cells.  Furthermore, we found an increased percentage of single, extra-insular β-cells and small β-cell clusters induced by gastrin infusion.  These changes occurred only in the ligated part of the pancreas, where transdifferentiation of the exocrine acinar cells to duct-like cells (metaplasia) had occurred, and was not found in the normal unaffected pancreatic tissue.  In conclusion, we demonstrate that administration of gastrin stimulates β-cell neogenesis and expansion of the β-cell mass from transdifferentiated exocrine pancreas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9YFF3rq5EhbVg90H21EOLACvtfcHk0lj_baeVzb-kLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFSgsLw%253D&md5=4ab83aac3c48405cec9272d8180f8076</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.51.3.686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.51.3.686%26sid%3Dliteratum%253Aachs%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DLardon%26aufirst%3DJ.%26aulast%3DBouwens%26aufirst%3DL.%26atitle%3DGastrin%2520Stimulates%2520%25CE%25B2-Cell%2520Neogenesis%2520and%2520Increases%2520Islet%2520Mass%2520from%2520Transdifferentiated%2520but%2520not%2520from%2520Normal%2520Exocrine%2520Pancreas%2520Tissue%26jtitle%3DDiabetes%26date%3D2002%26volume%3D51%26spage%3D686%26doi%3D10.2337%2Fdiabetes.51.3.686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, A.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Epidermal Growth Factor and Gastrin Increases β-Cell Mass and Reverses Hyperglycemia in Diabetic NOD Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2596</span>, <span class="refDoi"> DOI: 10.2337/diabetes.54.9.2596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdiabetes.54.9.2596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=16123347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVSjs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2596&author=W.+L.+Suarez-Pinzonauthor=Y.+Yanauthor=R.+Powerauthor=S.+J.+Brandauthor=A.+Rabinovitch&title=Combination+Therapy+with+Epidermal+Growth+Factor+and+Gastrin+Increases+%CE%B2-Cell+Mass+and+Reverses+Hyperglycemia+in+Diabetic+NOD+Mice&doi=10.2337%2Fdiabetes.54.9.2596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice</span></div><div class="casAuthors">Suarez-Pinzon, Wilma L.; Yan, Yanhua; Power, Robert; Brand, Stephen J.; Rabinovitch, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2596-2601</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Combination therapy with EGF and gastrin induces β-cell regeneration in rodents with chem. induced diabetes.  The authors investigated whether EGF plus gastrin could correct hyperglycemia in NOD mice with autoimmune diabetes.  Combined treatment with EGF (1 μg/kg) and gastrin (3 μg/kg) for 2 wk restored normoglycemia after diabetes onset in NOD mice, whereas EGF or gastrin alone did not.  Fasting blood glucose remained normal (3.5-6.5 mM) or mildly elevated (<11 mM) in five of six mice (83%) for 10 wk after EGF plus gastrin treatment was stopped, whereas all mice treated with vehicle or EGF or gastrin alone became severely hyperglycemic (12-35 mM).  Pancreatic β-cell mass was increased 3-fold and insulin content was increased 8-fold in mice treated with EGF plus gastrin compared with pretreatment values.  The correction of hyperglycemia correlated significantly with increases in pancreatic β-cell mass and insulin content.  In addn., splenic cells from mice treated with EGF plus gastrin delayed diabetes induction by adoptive transfer of diabetogenic cells into immunodeficient NOD-scid mice, suggesting the induction of immunoregulatory cells in NOD mice treated with EGF plus gastrin.  The authors conclude that a short course of combined EGF and gastrin therapy increases pancreatic β-cell mass and reverses hyperglycemia in acutely diabetic NOD mice; the impact of this combined therapy may result from the effects of EGF and gastrin on β-cells, immune cells, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSGbmXRCCLbVg90H21EOLACvtfcHk0lhvLC6zpJe09Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVSjs7rP&md5=2de90714d981beba91440c9d07a4f6c9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.9.2596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.9.2596%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPower%26aufirst%3DR.%26aulast%3DBrand%26aufirst%3DS.%2BJ.%26aulast%3DRabinovitch%26aufirst%3DA.%26atitle%3DCombination%2520Therapy%2520with%2520Epidermal%2520Growth%2520Factor%2520and%2520Gastrin%2520Increases%2520%25CE%25B2-Cell%2520Mass%2520and%2520Reverses%2520Hyperglycemia%2520in%2520Diabetic%2520NOD%2520Mice%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2596%26doi%3D10.2337%2Fdiabetes.54.9.2596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watada, H.</span></span> <span> </span><span class="NLM_article-title">Combination Treatment of db/db Mice with Exendin-4 and Gastrin Preserves β-cell Mass by Stimulating β-cell Growth and Differentiation</span>. <i>J. Diabetes Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1111/j.2040-1124.2010.00044.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fj.2040-1124.2010.00044.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=24843429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVantr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=172-183&author=M.+Tamakiauthor=Y.+Fujitaniauthor=T.+Uchidaauthor=T.+Hiroseauthor=R.+Kawamoriauthor=H.+Watada&title=Combination+Treatment+of+db%2Fdb+Mice+with+Exendin-4+and+Gastrin+Preserves+%CE%B2-cell+Mass+by+Stimulating+%CE%B2-cell+Growth+and+Differentiation&doi=10.1111%2Fj.2040-1124.2010.00044.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation</span></div><div class="casAuthors">Tamaki, Motoyuki; Fujitani, Yoshio; Uchida, Toyoyoshi; Hirose, Takahisa; Kawamori, Ryuzo; Watada, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JDIOAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-1124</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim/Introduction: Preservation of β-cell mass is crucial for maintaining long-term glucose homeostasis.  Therapies based on incretin and its mimetics are expected to achieve this goal through various biol. functions, particularly the restoration of β-cell mass.  Here we tested the effects of gastrin and exendin-4 in type 2 diabetic animals.  Materials and Methods: The effects of exendin-4 and gastrin on β-cell function and mass were examd. in 8-wk-old db/db mice.  INS-1 beta cells and AR42J cells were used to det. the mol. mechanism underlying the effects of the two agents.  Immunohistochem., western blotting and RT-PCR assays were used to assess the biol. effects of the two agents.  Results: Two weeks of combination administration of exendin-4 plus gastrin resulted in a significant improvement of glucose tolerance assocd. with a marked preservation of β-cell mass in db/db mice.  Immunohistochem. anal. showed that such treatment resulted in the appearance of numerous irregularly-shaped small islets and single insulin-pos. cells.  While gastrin had little biol. effect on INS-1 β-cells consistent with low expression of its intrinsic receptor on these cells, it caused differentiation of AR42J cells into insulin-producing cells.  Co-stimulation with exendin-4 significantly enhanced gastrin-induced endocrine differentiation of AR42J precursor cells.  These findings were further supported by enhanced expression of key genes involved in β-cell differentiation and maturation, such as neurogenin3 (Ngn3) and MafA.  Conclusions: These results suggest that combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAF4Lr3lVYILVg90H21EOLACvtfcHk0lhvLC6zpJe09Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVantr%252FE&md5=452d0539c83187c02cac84ea6af326bd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.2040-1124.2010.00044.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2040-1124.2010.00044.x%26sid%3Dliteratum%253Aachs%26aulast%3DTamaki%26aufirst%3DM.%26aulast%3DFujitani%26aufirst%3DY.%26aulast%3DUchida%26aufirst%3DT.%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DKawamori%26aufirst%3DR.%26aulast%3DWatada%26aufirst%3DH.%26atitle%3DCombination%2520Treatment%2520of%2520db%252Fdb%2520Mice%2520with%2520Exendin-4%2520and%2520Gastrin%2520Preserves%2520%25CE%25B2-cell%2520Mass%2520by%2520Stimulating%2520%25CE%25B2-cell%2520Growth%2520and%2520Differentiation%26jtitle%3DJ.%2520Diabetes%2520Invest.%26date%3D2010%26volume%3D1%26spage%3D172%26epage%3D183%26doi%3D10.1111%2Fj.2040-1124.2010.00044.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserfall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, A.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3281</span>, <span class="refDoi"> DOI: 10.2337/db08-0688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdb08-0688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=18835930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsleitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=3281&author=W.+L.+Suarez-Pinzonauthor=R.+F.+Powerauthor=Y.+Yanauthor=C.+Wasserfallauthor=M.+Atkinsonauthor=A.+Rabinovitch&title=Combination+Therapy+with+Glucagon-Like+Peptide-1+and+Gastrin+Restores+Normoglycemia+in+Diabetic+NOD+Mice&doi=10.2337%2Fdb08-0688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice</span></div><div class="casAuthors">Suarez-Pinzon, Wilma L.; Power, Robert F.; Yan, Yanhua; Wasserfall, Clive; Atkinson, Mark; Rabinovitch, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3281-3288</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Glucagon-like peptide-1 (GLP-1) and gastrin promote pancreatic β-cell function, survival, and growth.  Here, we investigated whether GLP-1 and gastrin can restore the β-cell mass and reverse hyperglycemia in NOD mice with autoimmune diabetes.  Research Design and Methods-Acutely diabetic NOD mice were treated with GLP-1 and gastrin, sep. or together, twice daily for 3 wk.  Blood glucose was measured weekly and for a further 5 wk after treatments, after which pancreatic insulin content and β-cell mass, proliferation, neogenesis, and apoptosis were measured.  Insulin autoantibodies were measured, and adoptive transfer of diabetes and syngeneic islet transplant studies were done to evaluate the effects of GLP-1 and gastrin treatment on autoimmunity.  Results-Combination therapy with GLP-1 and gastrin, but not with GLP-1 or gastrin alone, restored normoglycemia in diabetic NOD mice.  The GLP-1 and gastrin combination increased pancreatic insulin content, β-cell mass, and insulin-pos. cells in pancreatic ducts, and β-cell apoptosis was decreased.  Insulin autoantibodies were reduced in GLP-1- and gastrin-treated NOD mice, and splenocytes from these mice delayed adoptive transfer of diabetes in NOD-scid mice.  Syngeneic islet grafts in GLP-1- and gastrin-treated NOD mice were infiltrated by leukocytes with a shift in cytokine expression from interferon-γ to transforming growth factor-β1, and β-cells were protected from apoptosis.  Conclusions-Combination therapy with GLP-1 and gastrin restores normoglycemia in diabetic NOD mice by increasing the pancreatic β-cell mass and downregulating the autoimmune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8SaURFivKh7Vg90H21EOLACvtfcHk0ljQfKJK9IdYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsleitr0%253D&md5=98167648a694082055f9abf8f2836b3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2337%2Fdb08-0688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb08-0688%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DPower%26aufirst%3DR.%2BF.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWasserfall%26aufirst%3DC.%26aulast%3DAtkinson%26aufirst%3DM.%26aulast%3DRabinovitch%26aufirst%3DA.%26atitle%3DCombination%2520Therapy%2520with%2520Glucagon-Like%2520Peptide-1%2520and%2520Gastrin%2520Restores%2520Normoglycemia%2520in%2520Diabetic%2520NOD%2520Mice%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26spage%3D3281%26doi%3D10.2337%2Fdb08-0688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolborg, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O̷sterlund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolsted, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brorson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelsing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neerup, T. S. R.</span></span> <span> </span><span class="NLM_article-title">The Novel GLP-1-gastrin Dual Agonist, ZP3022, Increases β-cell Mass and Prevents Diabetes in db/db Mice</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1111/j.1463-1326.2012.01676.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fj.1463-1326.2012.01676.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=22862961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=62-71&author=K.+Fosgerauauthor=L.+Jessenauthor=J.+L.+Tolborgauthor=T.+O%CC%B7sterlundauthor=K.+S.+Larsenauthor=K.+Rolstedauthor=M.+Brorsonauthor=J.+Jelsingauthor=T.+S.+R.+Neerup&title=The+Novel+GLP-1-gastrin+Dual+Agonist%2C+ZP3022%2C+Increases+%CE%B2-cell+Mass+and+Prevents+Diabetes+in+db%2Fdb+Mice&doi=10.1111%2Fj.1463-1326.2012.01676.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span></div><div class="casAuthors">Fosgerau, K.; Jessen, L.; Lind Tolborg, J.; Osterlund, T.; Schaeffer Larsen, K.; Rolsted, K.; Brorson, M.; Jelsing, J.; Skovlund Ryge Neerup, T.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Diabetes is characterized by β-cell deficiency, and therefore restoration of β-cell function has been suggested as a potential therapy.  We hypothesized that a novel glucagon-like peptide-1 (GLP-1)-gastrin dual agonist, ZP3022, improves glycemic control via improvement of β-cell status in db/db mice..  Methods : Diabetic mice were studied following short- or long-term treatment with either the GLP-1-gastrin dual agonist or the com. available GLP-1 agonists (exendin-4 and liraglutide).  The effects on glycemic control were addressed by repeated glucose tolerance tests and/or measurements of HbA1c levels, and pancreatic islet and β-cell masses were detd. by stereol.Results : ZP3022 and the pure GLP-1 agonists improved glycemic control after both short- and long-term treatment compared with vehicle.  Interestingly, the effect was sustainable only in mice treated with ZP3022.  Stereol. data displayed a dose-dependent increase of β-cell mass (p < 0.05) following treatment with ZP3022, whereas no significant effect of liraglutide was obsd. (β-cell mass: vehicle 3.7 ± 0.2 mg; liraglutide (30 nmol/kg) 3.4 ± 0.5 mg; ZP3022 (30 nmol/kg) 4.3 ± 0.4 mg and ZP3022 (100 nmol/kg) 5.2 ± 0.4 mg).Conclusion : The novel GLP-1-gastrin dual agonist, ZP3022, improved glycemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ta9zMqxjlbVg90H21EOLACvtfcHk0ljQfKJK9IdYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE&md5=cc432fa85f778937f2c2113f189b8aa4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01676.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01676.x%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DL.%26aulast%3DTolborg%26aufirst%3DJ.%2BL.%26aulast%3DO%25CC%25B7sterlund%26aufirst%3DT.%26aulast%3DLarsen%26aufirst%3DK.%2BS.%26aulast%3DRolsted%26aufirst%3DK.%26aulast%3DBrorson%26aufirst%3DM.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DNeerup%26aufirst%3DT.%2BS.%2BR.%26atitle%3DThe%2520Novel%2520GLP-1-gastrin%2520Dual%2520Agonist%252C%2520ZP3022%252C%2520Increases%2520%25CE%25B2-cell%2520Mass%2520and%2520Prevents%2520Diabetes%2520in%2520db%252Fdb%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D62%26epage%3D71%26doi%3D10.1111%2Fj.1463-1326.2012.01676.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Xenopus GLP-1-inspired Discovery of Novel GLP-1 Receptor Agonists as Long-acting Hypoglycemic and Insulinotropic Agents with Significant Therapeutic Potential</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.06.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.bcp.2017.06.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28668697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=155-167&author=J.+Hanauthor=X.+Chenauthor=Y.+Wangauthor=Y.+Feiauthor=F.+Zhouauthor=Y.+Zhangauthor=L.+Liuauthor=P.+Siauthor=J.+Fu&title=Xenopus+GLP-1-inspired+Discovery+of+Novel+GLP-1+Receptor+Agonists+as+Long-acting+Hypoglycemic+and+Insulinotropic+Agents+with+Significant+Therapeutic+Potential&doi=10.1016%2Fj.bcp.2017.06.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential</span></div><div class="casAuthors">Han, Jing; Chen, Xinyu; Wang, Yiyun; Fei, Yingying; Zhou, Feng; Zhang, Ying; Liu, Lin; Si, Pengbin; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-167</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We here report the discovery and therapeutic efficacy of a novel series of glucagon-like peptide-1 (GLP-1) receptor agonists derived from Xenopus GLP-1.  First, five amino acid-mutated Xenopus GLP-1s were synthesized, and xGLP-3 with the best acute and long-acting hypoglycemic activity was selected for further modification.  Next, PEGylation of xGLP-3 was performed at specific sites, which were detd. using cysteine mutagenesis scanning.  Twelve PEGylated conjugates tethered with Mal-PEGs of 1, 2, and 5 kDa were synthesized.  Conjugates 7b and 7c, which exhibited comparable hypoglycemic and insulinotropic effects to Gly8-GLP-1, were selected for in-depth evaluation.  It was found that 7b and 7c exhibited prolonged in vivo half-life and improved pharmacokinetic behaviors.  The long-term hypoglycemic effects of 7b and 7c were further confirmed by pre-OGTT and multiple OGTT.  Importantly, long-term administration of 7b or 7c in db/db mice achieved beneficial effects on body wt. loss, food intake and HbA1c redn., and glucose tolerance normalization.  These preclin. studies indicate the promising role of 7b and 7c as long-acting type 2 diabetes therapeutics.  In addn., our research demonstrated the feasibility of developing novel antidiabetic agents based on Xenopus GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocX8k-np5op7Vg90H21EOLACvtfcHk0ljojO5c4ZVtxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt73N&md5=2ec89287e59d29972ad43e30ab3c6c0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.06.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.06.132%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSi%26aufirst%3DP.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DXenopus%2520GLP-1-inspired%2520Discovery%2520of%2520Novel%2520GLP-1%2520Receptor%2520Agonists%2520as%2520Long-acting%2520Hypoglycemic%2520and%2520Insulinotropic%2520Agents%2520with%2520Significant%2520Therapeutic%2520Potential%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D142%26spage%3D155%26epage%3D167%26doi%3D10.1016%2Fj.bcp.2017.06.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Xenopus-derived Glucagon-like Peptide-1 and Polyethylene-glycosylated Glucagon-like Peptide-1 Receptor Agonists: Long-acting Hypoglycaemic and Insulinotropic Activities with Potential Therapeutic Utilities</span>. <i>Brit. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1111/bph.14107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fbph.14107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29171021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=544-557&author=J.+Hanauthor=Y.+Feiauthor=F.+Zhouauthor=X.+Chenauthor=Y.+Zhangauthor=L.+Liuauthor=J.+Fu&title=Xenopus-derived+Glucagon-like+Peptide-1+and+Polyethylene-glycosylated+Glucagon-like+Peptide-1+Receptor+Agonists%3A+Long-acting+Hypoglycaemic+and+Insulinotropic+Activities+with+Potential+Therapeutic+Utilities&doi=10.1111%2Fbph.14107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities</span></div><div class="casAuthors">Han, Jing; Fei, Yingying; Zhou, Feng; Chen, Xinyu; Zhang, Ying; Liu, Lin; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Incretin-based therapies based on glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments of type 2 diabetes.  Abundant research has focused on the development of long-acting GLP-1 receptor agonists.  However, all GLP-1 receptor agonists in clin. use or development are based on human or Gila GLP-1.  We have identified a potent GLP-1 receptor agonist, xGLP-1B, based on Xenopus GLP-1.  Exptl. Approach : To further modify the structure of xGLP-1B, alanine scanning was performed to study the structure -activity relationship of xGLP-1B.  Two strategies were then employed to improve bioactivity.  First, the C-terminal tail of lixisenatide was appended to cysteine-altered xGLP-1B analogs.  Second, polyethylene glycol (PEG) chains with different mol. wts. were conjugated with the peptides, giving a series of PEGylated conjugates.  Comprehensive bioactivity studies of these conjugates were performed in vitro and in vivo.  Results : From the in vitro receptor activation potency and in vivo acute hypoglycemic activities of conjugates 25 -36, 33 was identified as the best candidate for further biol. assessments.  Conjugate 33 exhibited prominent hypoglycemic and insulinotropic activities, as well as improved pharmacokinetic profiles in vivo.  The prolonged antidiabetic duration of 33 was further confirmed by pre-oral glucose tolerance tests (OGTT) and multiple OGTT.  Furthermore, chronic treatment of db/db mice with 33 ameliorated non-fasting blood glucose and insulin levels, reduced HbA1c values and normalized their impaired glucose tolerance.  Importantly, no in vivo toxicity was obsd. in mice treated with 33.  Conclusions and Implications : Peptide 33 is a promising long-acting type 2 diabetes therapeutic deserving further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoendOb7bXB37Vg90H21EOLACvtfcHk0lhETpt72tN6rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFyrsw%253D%253D&md5=71a3d53e9b008b866e938db15871485a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fbph.14107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14107%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DXenopus-derived%2520Glucagon-like%2520Peptide-1%2520and%2520Polyethylene-glycosylated%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Agonists%253A%2520Long-acting%2520Hypoglycaemic%2520and%2520Insulinotropic%2520Activities%2520with%2520Potential%2520Therapeutic%2520Utilities%26jtitle%3DBrit.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D544%26epage%3D557%26doi%3D10.1111%2Fbph.14107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">The Chronic Administration of Two Novel Long-acting Xenopus Glucagon-like Peptide-1 Analogs xGLP159 and xGLP296 Potently Improved Systemic Metabolism and Glycemic Control in Rodent Models</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">7113</span>– <span class="NLM_lpage">7125</span>, <span class="refDoi"> DOI: 10.1096/fj.201801479R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1096%2Ffj.201801479R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30860869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2jsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=7113-7125&author=J.+Hanauthor=T.+Mengauthor=X.+Chenauthor=Y.+Hanauthor=J.+Fuauthor=F.+Zhouauthor=Y.+Feiauthor=C.+Li&title=The+Chronic+Administration+of+Two+Novel+Long-acting+Xenopus+Glucagon-like+Peptide-1+Analogs+xGLP159+and+xGLP296+Potently+Improved+Systemic+Metabolism+and+Glycemic+Control+in+Rodent+Models&doi=10.1096%2Ffj.201801479R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models</span></div><div class="casAuthors">Han, Jing; Meng, Tingting; Chen, Xinyu; Han, Yue; Fu, Junjie; Zhou, Feng; Fei, Yingying; Li, Chenglin</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">7113-7125</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">We here reported 2 novel Xenopus glucagon-like peptide-1 (xGLP-1) analogs, xGLP159 and xGLP296, whose therapeutic effects on metabolic efficacy and glycemic control were evaluated in rodents.  The in vitro potency of xGLP159 and xGLP296 were investigated on human embryonic kidney 293 cells.  The acute glucose-lowering and insulinotropic effects of xGLP159 and xGLP296 were assessed in the Institute of Cancer Research, Kunming, and diabetic (db/db) mice.  The pharmacokinetic profiles of xGLP159 and xGLP296 were confirmed on Sprague-Dawley (SD) rats and their long-acting hypoglycemic and anorectic effects were evaluated in db/db mice.  Chronic treatment effects of xGLP159 and xGLP296 were evaluated in diet-induced obese (DIO) mice and db/db mice.  The results showed that xGLP159 and xGLP296 exhibited comparable receptor activation potency, hypoglycemic effect, and insulinotropic activity to liraglutide.  The enhanced half-lives of xGLP159 and xGLP296 in SD rats (5.1 and 5.8 h, resp.) resulted in prolonged anti-db/db durations in db/db mice.  Three weeks' administration of xGLP159 and xGLP296 normalized glucose tolerance and adiposity in DIO mice.  Furthermore, 11-wk treatment of xGLP159 and xGLP296 cor. hyperglycemia and improved pancreatic function in db/db mice.  These preclin. studies supported xGLP159 and xGLP296 as promising candidates for the treatment of metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp30OyVXfjNrVg90H21EOLACvtfcHk0lhETpt72tN6rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2jsLnO&md5=283c620e07ddf5b913a6916dbefd6fa4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801479R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801479R%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DThe%2520Chronic%2520Administration%2520of%2520Two%2520Novel%2520Long-acting%2520Xenopus%2520Glucagon-like%2520Peptide-1%2520Analogs%2520xGLP159%2520and%2520xGLP296%2520Potently%2520Improved%2520Systemic%2520Metabolism%2520and%2520Glycemic%2520Control%2520in%2520Rodent%2520Models%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D7113%26epage%3D7125%26doi%3D10.1096%2Ffj.201801479R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3954</span>– <span class="NLM_lpage">3967</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFCltr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3954-3967&author=J.+Hanauthor=Y.+Feiauthor=F.+Zhouauthor=X.+Chenauthor=W.+Zhengauthor=J.+Fu&title=Micellar+Nanomedicine+of+Novel+Fatty+Acid+Modified+Xenopus+Glucagon-like+Peptide-1%3A+Improved+Physicochemical+Characteristics+and+Therapeutic+Utilities+for+Type+2+Diabetes&doi=10.1021%2Facs.molpharmaceut.7b00632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes</span></div><div class="casAuthors">Han, Jing; Fei, Yingying; Zhou, Feng; Chen, Xinyu; Zheng, Weiwei; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3954-3967</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop novel long-acting antidiabetics with improved therapeutic efficacy, two glucagon-like peptide-1 (GLP-1) analogs were constructed through the hybridization of key sequences of GLP-1, xenGLP-1B, exendin-4, and lixisenatide.  Hybrids 1 and 2 demonstrated enhanced in vitro and in vivo biol. activities and were further site-specifically lipidized at lysine residues to achieve prolonged duration of action and less frequent administration.  Compared with their native peptides, compds. 3-6 showed similar in vitro activities but impaired in vivo acute hypoglycemic potencies due to decreased aq. soly. and retarded absorption in vivo.  To circumvent these issues, compd. 3 (xenoglutide) was selected to be self-assocd. with sterically stabilized micelles (SSM).  The α-helix and soly. of xenoglutide were significantly improved after self-assocd. with SSM.  Notably, the improved physicochem. characteristics of xenoglutide-SSM led to revival of acute hypoglycemic ability without affecting its long-term glucose-lowering activity.  Most importantly, preclin. studies demonstrated improved therapeutic effects and safety of xenoglutide-SSM in diabetic db/db mice.  Our work suggests the SSM incorporation as an effective approach to improve the pharmacokinetic and biol. properties of hydrophobicity peptide drugs.  Furthermore, our data clearly indicate xenoglutide-SSM as a novel nanomedicine for the treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0a7z0NNT_NbVg90H21EOLACvtfcHk0lgViZwvhGQ1hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFCltr%252FF&md5=3e968d16939bdeee1437b9e75cb9ee89</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00632%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DMicellar%2520Nanomedicine%2520of%2520Novel%2520Fatty%2520Acid%2520Modified%2520Xenopus%2520Glucagon-like%2520Peptide-1%253A%2520Improved%2520Physicochemical%2520Characteristics%2520and%2520Therapeutic%2520Utilities%2520for%2520Type%25202%2520Diabetes%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26spage%3D3954%26epage%3D3967%26doi%3D10.1021%2Facs.molpharmaceut.7b00632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of PEGylated Xenopus Glucagon-like Peptide-1 Derivatives as Long-acting Hypoglycemic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejmech.2017.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28342399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2017&pages=81-89&author=J.+Hanauthor=Y.+Wangauthor=Q.+Mengauthor=G.+Liauthor=F.+Huangauthor=S.+Wuauthor=Y.+Feiauthor=F.+Zhouauthor=J.+Fu&title=Design%2C+Synthesis+and+Biological+Evaluation+of+PEGylated+Xenopus+Glucagon-like+Peptide-1+Derivatives+as+Long-acting+Hypoglycemic+Agents&doi=10.1016%2Fj.ejmech.2017.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents</span></div><div class="casAuthors">Han, Jing; Wang, Yiyun; Meng, Qinghua; Li, Guangchao; Huang, Fangmin; Wu, Su; Fei, Yingying; Zhou, Feng; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To develop novel long-acting GLP-1 derivs., a peptide hybrid (1a, xGLP-1B) from human GLP-1 and Xenopus GLP-1 discovered in the authors' previous research was selected as the lead compd.  Exendin-4 inspired modification resulted in peptide 1b (ExGLP) with enhanced glucose-lowering activity.  Cysteine mutated 1b derivs. with reserved bioactivity were further site-specifically connected with mPEG2000-MAL to provide conjugates 3a-h, among which 3d (mPEG20Q0-MAL-Cys-ExG LP-04) and 3e (mPEG2000-MAL-Cys-ExGLP-07) were found to have significantly improved hypoglycemic activity and insulinotropic ability than GLP-1.  The hypoglycemic durations of 3d and 3e were remarkably prolonged to ∼20 h in type 2 diabetic db/db mice, compared with the 5.3 h of exendin-4 in the same test.  Finally, chronic in vivo studies revealed that a once-daily treatment of 3d or 3e for five weeks resulted in recovered glucose-controlling ability of type 2 diabetic db/db mice, along with other benefits, such as reduced body wt. gains, food intake amts. and HbA1c values.  Collectively, the authors' results suggest 3d and 3e as potential long-acting glucose-lowering agents for treating type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-GCoodrxBLVg90H21EOLACvtfcHk0lgViZwvhGQ1hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWksbk%253D&md5=7e8b746274596b99d49fe87a6233abc2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520PEGylated%2520Xenopus%2520Glucagon-like%2520Peptide-1%2520Derivatives%2520as%2520Long-acting%2520Hypoglycemic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D132%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.ejmech.2017.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Proteolytically Stable Oxyntomodulin Analogs</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00787</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00787" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=324-328&author=A.+Muppidiauthor=H.+Zouauthor=P.+Y.+Yangauthor=E.+Chaoauthor=L.+Sherwoodauthor=V.+Nunezauthor=A.+K.+Woodsauthor=P.+G.+Schultzauthor=Q.+Linauthor=W.+Shen&title=Design+of+Potent+and+Proteolytically+Stable+Oxyntomodulin+Analogs&doi=10.1021%2Facschembio.5b00787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Proteolytically Stable Oxyntomodulin Analogs</span></div><div class="casAuthors">Muppidi, Avinash; Zou, Huafei; Yang, Peng Yu; Chao, Elizabeth; Sherwood, Lance; Nunez, Vanessa; Woods, Ashley K.; Schultz, Peter G.; Lin, Qing; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-328</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incretin-based peptides are effective therapeutics for treating type 2 diabetes mellitus (T2DM).  Oxyntomodulin (OXM), a dual agonist of GLP-1R and GCGR, has shown superior wt. loss and glucose lowering effects, compared to single GLP-1R agonists.  To overcome the short half-life and rapid renal clearance of OXM, which limit its therapeutic potential, both lipid and PEG modified OXM analogs have been reported.  However, these approaches often result in reduced potency or PEG-assocd. toxicity.  Herein, we report a new class of cross-linked OXM analogs that show increased plasma stability and higher potency in activating both GLP-1R and GCGR.  Moreover, the extended in vivo half-life results in superior antihyperglycemic activity in mice compared to the wild-type OXM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2WYza_-0k2bVg90H21EOLACvtfcHk0lgViZwvhGQ1hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsro%253D&md5=8911f988a9db36935cda2a2bd93f19ed</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00787%26sid%3Dliteratum%253Aachs%26aulast%3DMuppidi%26aufirst%3DA.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%2BY.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DNunez%26aufirst%3DV.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Proteolytically%2520Stable%2520Oxyntomodulin%2520Analogs%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D324%26epage%3D328%26doi%3D10.1021%2Facschembio.5b00787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghartey-Tagoe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Engineering a Long-acting, Potent GLP-1 Analog for Microstructure-based Transdermal Delivery</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4145</span>, <span class="refDoi"> DOI: 10.1073/pnas.1601653113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1073%2Fpnas.1601653113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=27035989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4140-4145&author=P.-Y.+Yangauthor=H.+Zouauthor=E.+Chaoauthor=L.+Sherwoodauthor=V.+Nunezauthor=M.+Keeneyauthor=E.+Ghartey-Tagoeauthor=Z.+Dingauthor=H.+Quirinoauthor=X.+Luoauthor=G.+Welzelauthor=G.+Chenauthor=P.+Singhauthor=A.+K.+Woodsauthor=P.+G.+Schultzauthor=W.+Shen&title=Engineering+a+Long-acting%2C+Potent+GLP-1+Analog+for+Microstructure-based+Transdermal+Delivery&doi=10.1073%2Fpnas.1601653113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery</span></div><div class="casAuthors">Yang, Peng-Yu; Zou, Huafei; Chao, Elizabeth; Sherwood, Lance; Nunez, Vanessa; Keeney, Michael; Ghartey-Tagoe, Esi; Ding, Zhongli; Quirino, Herlinda; Luo, Xiaozhou; Welzel, Gus; Chen, Guohua; Singh, Parminder; Woods, Ashley K.; Schultz, Peter G.; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4140-4145</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Antidiabetic treatments aiming to reduce body wt. are currently gaining increased interest.  Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice daily via s.c. injection, improves glycemic control, often with assocd. wt. redn.  To further improve the therapeutic efficacy of exendin-4, the authors have developed a novel peptide engineering strategy that incorporates a serum protein binding motif onto a covalent side-chain staple and applied to the peptide to enhance its helicity and, as a consequence, its potency and serum half-life.  The authors demonstrated that one of the resulting peptides, E6 (comprising exendin-4 derived sequence HGEGTFTSDLSKQMEECAVRLFICWLKNGGPSSGAPPPS with PEG-based linker), has significantly improved half-life and glucose tolerance in an oral glucose tolerance test in rodents.  Chronic treatment of E6 significantly decreased body wt. and fasting blood glucose, improved lipid metab., and also reduced hepatic steatosis in diet-induced obese mice.  Moreover, the high potency of E6 allowed the authors to administer this peptide using a dissolvable microstructure-based transdermal delivery system.  Pharmacokinetic and pharmacodynamic studies in guinea pigs showed that a single 5-min application of a microstructure system contg. E6 significantly improved glucose tolerance for 96 h.  This delivery strategy may offer an effective and patient-friendly alternative to currently marketed GLP-1 injectables and can likely be extended to other peptide hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom26i7k0QKvbVg90H21EOLACvtfcHk0lhQCdKAJx9u5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisro%253D&md5=2e0bba2aa9238f4407199593063a2aa9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1601653113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1601653113%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.-Y.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DNunez%26aufirst%3DV.%26aulast%3DKeeney%26aufirst%3DM.%26aulast%3DGhartey-Tagoe%26aufirst%3DE.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DQuirino%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWelzel%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DEngineering%2520a%2520Long-acting%252C%2520Potent%2520GLP-1%2520Analog%2520for%2520Microstructure-based%2520Transdermal%2520Delivery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D4140%26epage%3D4145%26doi%3D10.1073%2Fpnas.1601653113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Stapled, Long-acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3218</span>– <span class="NLM_lpage">3223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3218-3223&author=P.-Y.+Yangauthor=H.+Zouauthor=C.+Leeauthor=A.+Muppidiauthor=E.+Chaoauthor=Q.+Fuauthor=X.+Luoauthor=D.+Wangauthor=P.+G.+Schultzauthor=W.+Shen&title=Stapled%2C+Long-acting+Glucagon-like+Peptide+2+Analog+with+Efficacy+in+Dextran+Sodium+Sulfate+Induced+Mouse+Colitis+Models&doi=10.1021%2Facs.jmedchem.7b00768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models</span></div><div class="casAuthors">Yang, Peng-Yu; Zou, Huafei; Lee, Candy; Muppidi, Avinash; Chao, Elizabeth; Fu, Qiangwei; Luo, Xiaozhou; Wang, Danling; Schultz, Peter G.; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3218-3223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) is a hormone that has been shown to stimulate intestinal growth and attenuate intestinal inflammation.  Despite being efficacious in a variety of animal models of disease, its therapeutic potential is hampered by the short half-life in vivo.  We now describe a highly potent, stapled long-acting GLP-2 analog, Peptide 10, that has a more than 10-fold longer half-life than teduglutide and improved intestinotrophic and anti-inflammatory effects in mouse models of DSS-induced colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTlIM94DlXbVg90H21EOLACvtfcHk0lhTyFm6UjKkgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhsrw%253D&md5=a6252986057ddfb933d13b4db8ac822b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00768%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.-Y.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMuppidi%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DStapled%252C%2520Long-acting%2520Glucagon-like%2520Peptide%25202%2520Analog%2520with%2520Efficacy%2520in%2520Dextran%2520Sodium%2520Sulfate%2520Induced%2520Mouse%2520Colitis%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3218%26epage%3D3223%26doi%3D10.1021%2Facs.jmedchem.7b00768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiberg, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl Peptidase IV Resistant Analogues of Glucagon-like Peptide-1 which Have Extended Metabolic Stability and Improved Biological Activity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1007/s001250050903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1007%2Fs001250050903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=9541166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlelu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=271-278&author=C.+F.+Deaconauthor=L.+B.+Knudsenauthor=K.+Madsenauthor=F.+C.+Wibergauthor=O.+Jacobsenauthor=J.+J.+Holst&title=Dipeptidyl+Peptidase+IV+Resistant+Analogues+of+Glucagon-like+Peptide-1+which+Have+Extended+Metabolic+Stability+and+Improved+Biological+Activity&doi=10.1007%2Fs001250050903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV resistant analogs of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity</span></div><div class="casAuthors">Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-278</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) has great potential in diabetes therapy due to its glucose-dependent stimulation of insulin secretion, but this is limited by its rapid degrdn., primarily by dipeptidyl peptidase IV.  Four analogs, N-terminally substituted with Thr, Gly, Ser, or α-aminoisobutyric acid (Aib), were synthesized and tested for metabolic stability.  All were more resistant to dipeptidyl peptidase IV in porcine blood plasma in vitro, ranging from a t1/2 of 159 min (Gly8 analog) to undetectable degrdn. after 6 h (Aib8 analog; t1/2 for GLP-1 (7-36) amide, 28 min).  During i. v. infusion in anesthetized swine, <50% of each analog remained undegraded compared to 22.7% for GLP-1 (7- 36) amide.  In vivo, analogs had longer N-terminal t1/2 (intact peptides: means, 3.3-3.9 min) than GLP-1 (7-36) amide (0.9 min), but these did not exceed the C-terminal t1/2 (intact plus metabolite: analogs, 3.5-4.4 min; GLP-1 (7-36) amide, 4.1 min).  Analogs were assessed for receptor binding using a cell line expressing the cloned receptor, and for ability to stimulate insulin or inhibit glucagon secretion from the isolated perfused porcine pancreas.  All bound to the receptor, but only the Aib8 and Gly8 analogs had similar affinities to GLP-1 (7-36) amide (IC50; Aib8=0.45, Gly8=2.8, GLP-1 (7-36) amide=0.78 nmol/L).  All analogs were active in the isolated pancreas, with the potency order reflecting receptor affinities (Aib8>Gly8>Ser8>Thr8).  N-terminal modification of GLP-1 confers resistance to dipeptidyl peptidase IV degrdn.  Such analogs are biol. active and have prolonged metabolic stability in vivo, which, if assocd. with greater potency and duration of action, may help to realize the potential of GLP-1 in diabetes therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTIpMWFcmVLVg90H21EOLACvtfcHk0lhTyFm6UjKkgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlelu7Y%253D&md5=11e697a17ec4b916589606323e52edc4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs001250050903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001250050903%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DWiberg%26aufirst%3DF.%2BC.%26aulast%3DJacobsen%26aufirst%3DO.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DDipeptidyl%2520Peptidase%2520IV%2520Resistant%2520Analogues%2520of%2520Glucagon-like%2520Peptide-1%2520which%2520Have%2520Extended%2520Metabolic%2520Stability%2520and%2520Improved%2520Biological%2520Activity%26jtitle%3DDiabetologia%26date%3D1998%26volume%3D41%26spage%3D271%26epage%3D278%26doi%3D10.1007%2Fs001250050903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Once-weekly Glucagon-like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Grammauthor=S.+M.+Knudsenauthor=N.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+Once-weekly+Glucagon-like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0lhaYK20sbGRVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGramm%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DNielsen%26aufirst%3DN.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Once-weekly%2520Glucagon-like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span> <span> </span><span class="NLM_article-title">Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=390-402&author=J.+Hanauthor=F.+Zhouauthor=Y.+Feiauthor=X.+Chenauthor=J.+Fuauthor=H.+Qian&title=Preparation+and+Pharmaceutical+Characterizations+of+Lipidated+Dimeric+Xenopus+Glucagon-Like+Peptide-1+Conjugates&doi=10.1021%2Facs.bioconjchem.7b00712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates</span></div><div class="casAuthors">Han, Jing; Zhou, Feng; Fei, Yingying; Chen, Xinyu; Fu, Junjie; Qian, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">390-402</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pair of glucagon-like peptide-1 (GLP-1) analogs (1 and 2) were synthesized by hybridizing the key sequences of GLP-1, exendin-4, lixisenatide, and xenGLP-1B (Xenopus GLP-1 analog).  To achieve long-acting hypoglycemic effects and to further improve their anti-diabetic potencies, lipidization and dimerization strategies were used to afford two lipidated dimeric conjugates (9 and 11).  Conjugates 9 and 11 showed stronger receptor activation potency than GLP-1 and exendin-4 in vitro.  Moreover, 9 and 11 exhibited superior hypoglycemic and insulinotropic activities to liraglutide in type 2 diabetic C57BL/6J-m+/+ Leprdb (db/db) mice.  Pharmacokinetic studies revealed that the circulating half-lives (t1/2) of 9 and 11 were 2.3- and 1.7-fold longer than that of liraglutide.  The improved pharmacokinetic profiles led to significantly protracted in vivo anti-diabetic effects as confirmed by multiple oral glucose tolerance tests and hypoglycemic duration tests.  Most importantly, chronic treatment studies found that once daily administration of 9 or 11 in db/db mice achieved more beneficial effects on HbA1c redn. and glucose tolerance normalization than liraglutide.  Our research demonstrated lipidization and dimerization as useful tools for the development of novel GLP-1 receptor agonists.  The preclin. studies suggested the potential of 9 and 11 to be developed as novel anti-diabetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdDcZ6PsWCbVg90H21EOLACvtfcHk0lhaYK20sbGRVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgt7nK&md5=da3d8f26e47d8fc635ebc8436f4e76b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00712%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DH.%26atitle%3DPreparation%2520and%2520Pharmaceutical%2520Characterizations%2520of%2520Lipidated%2520Dimeric%2520Xenopus%2520Glucagon-Like%2520Peptide-1%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D390%26epage%3D402%26doi%3D10.1021%2Facs.bioconjchem.7b00712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span> <span> </span><span class="NLM_article-title">Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-acting Conjugates for Type 2 Anti-diabetes Therapeutics</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1021/bc100404x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100404x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2mu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=625-632&author=T.+H.+Kimauthor=H.+H.+Jiangauthor=S.+Leeauthor=Y.+S.+Younauthor=C.+W.+Parkauthor=Y.+Byunauthor=X.+Chenauthor=K.+C.+Lee&title=Mono-PEGylated+Dimeric+Exendin-4+as+High+Receptor+Binding+and+Long-acting+Conjugates+for+Type+2+Anti-diabetes+Therapeutics&doi=10.1021%2Fbc100404x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics</span></div><div class="casAuthors">Kim, Tae Hyung; Jiang, Hai Hua; Lee, Seulki; Youn, Yu Seok; Park, Chan Woong; Byun, Youngro; Chen, Xiaoyuan; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-632</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dimerization is viewed as the most effective means of increasing receptor binding affinity, and both dimerization and PEGylation effectively prolong the life spans of short-lived peptides and proteins in vivo by delaying excretion via the renal route.  Here, we describe the high binding affinities of two long-acting exendin-4 (Ex4) conjugates, dimerized Ex4 (Di-Ex4) and PEGylated Di-Ex-4 (PEG-Di-Ex4).  Di-Ex4 and PEG-Di-Ex4 were prepd. using cysteine and amine residue specific coupling reactions using Ex4-Cys, bisMal-NH2, and activated PEG.  The Ex4 conjugates produced were of high purity (>98.5%), as detd. by size-exclusion chromatog. and MALDI-TOF mass spectrometry.  The receptor binding affinity of Di-Ex4 on RIN-m5F cells was 3.5-fold higher than that of Ex4, and the in vivo antihyperglycemic efficacy of Di-Ex4 was also greater than that of native Ex4 in type 2 diabetic db/db mice.  Furthermore, Di-Ex4 and PEG-Di-Ex4 were found to have greater blood circulating t1/2 and AUCinf values than native Ex4 by 2.7- and 13.7-fold, and by 4.0- and 17.3-fold, resp.  Accordingly, hypoglycemic durations were greatly increased to 15.0 and 40.1 h, resp., at a dose of 25 nmol/kg (native Ex4 7.3 h).  The results of this study show that combined dimerization and PEGylation are effective when applied to Ex4, and suggest that PEG-Di-Ex4 has considerable potential as a type 2 anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWGsCV-iYfBLVg90H21EOLACvtfcHk0lhaYK20sbGRVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2mu74%253D&md5=5bb66fffeb0ad1ddb42547053adb80c7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbc100404x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100404x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BH.%26aulast%3DJiang%26aufirst%3DH.%2BH.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYoun%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BW.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DMono-PEGylated%2520Dimeric%2520Exendin-4%2520as%2520High%2520Receptor%2520Binding%2520and%2520Long-acting%2520Conjugates%2520for%2520Type%25202%2520Anti-diabetes%2520Therapeutics%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D625%26epage%3D632%26doi%3D10.1021%2Fbc100404x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfeld, J. F.</span></span> <span> </span><span class="NLM_article-title">Does Sulfation of Gastrin Influence Gastric Acid Secretion in Man</span>. <i>Scand. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.3109/00365529008997601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.3109%2F00365529008997601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=2396089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVGnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1990&pages=739-745&author=P.+Cantorauthor=M.+B.+Petersenauthor=J.+Christiansenauthor=J.+F.+Rehfeld&title=Does+Sulfation+of+Gastrin+Influence+Gastric+Acid+Secretion+in+Man&doi=10.3109%2F00365529008997601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Does sulfation of gastrin influence gastric acid secretion in man?</span></div><div class="casAuthors">Cantor, Per; Petersen, M. Boye; Christiansen, J.; Rehfeld, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">739-45</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    </div><div class="casAbstract">To assess the physiol. significance of tyrosine O-sulfation of gastrin in humans, the gastric acid stimulatory potencies of sulfated and non-sulfated human gastrin-17 were compared in normal young subjects.  Sulfated and non-sulfated forms of synthetic human gastrin-17 were infused i.v. in doses of 12.7-478 pmol/kg/h.  Similar acid secretory responses were obsd.  The calcd. maximal acid response for sulfated gastrin-17 was 35.7 mmol/h, and that for non-sulfated gastrin-17 was 39.8 mmol/h.  The 50% ED of sulfated gastrin-17 was 22.2 pmol/kg/h, whereas it was 29.3 pmol/kg/h for non-sulfated gastrin-17.  Finally, the 50% effective concn. of gastrin in serum was 34.7 pmol sulfated gastrin-17/L and 4.25 pmol non-sulfated gastrin-17/L.  Thus, tyrosine O-sulfation is without influence on the gastric acid secretory potency of gastrin-17 in man.  Moreover, sulfated and non-sulfated gastrin-17 have similar rates of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplezO5aq8fobVg90H21EOLACvtfcHk0lh_21tM7yl3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVGnsbk%253D&md5=40d7e5f0e5ce93d074eea82a5d88f7aa</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3109%2F00365529008997601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00365529008997601%26sid%3Dliteratum%253Aachs%26aulast%3DCantor%26aufirst%3DP.%26aulast%3DPetersen%26aufirst%3DM.%2BB.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DRehfeld%26aufirst%3DJ.%2BF.%26atitle%3DDoes%2520Sulfation%2520of%2520Gastrin%2520Influence%2520Gastric%2520Acid%2520Secretion%2520in%2520Man%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D1990%26volume%3D25%26spage%3D739%26epage%3D745%26doi%3D10.3109%2F00365529008997601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Dimeric Lipidated Xenopus Glucagon-like Peptide 1 Analogues as Long-acting Antihyperglycaemic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejmech.2018.07.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30096651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=177-187&author=J.+Hanauthor=Y.+Huangauthor=X.+Chenauthor=F.+Zhouauthor=Y.+Feiauthor=J.+Fu&title=Rational+Design+of+Dimeric+Lipidated+Xenopus+Glucagon-like+Peptide+1+Analogues+as+Long-acting+Antihyperglycaemic+Agents&doi=10.1016%2Fj.ejmech.2018.07.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycemic agents</span></div><div class="casAuthors">Han, Jing; Huang, Yue; Chen, Xinyu; Zhou, Feng; Fei, Yingying; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dimerization is viewed as an effective means to enhance the binding affinity and therapeutic potency of peptides.  Both dimerization and lipidation effectively prolong the half-life of peptides in vivo by increasing hydrodynamic size and facilitating phys. interactions with serum albumin.  Here, we report a novel method to discover long-acting glucagon-like peptide 1 (GLP-1) analogs by rational design based on Xenopus GLP-1 through a combined dimerization and lipidization strategy.  On the basis of our previous structure anal. of Xenopus GLP-1, palmitic acid and a C-terminal Cys were firstly introduced into two Xenopus GLP-1 analogs (1 and 2), and the afforded 3 and 4 were further reacted with bis-maleimide amine to afford two dimeric lipidated Xenopus GLP-1 analogs (5 and 6).  The in vitro and in vivo biol. activities of 5 and 6 were significantly improved as compared with their monomers.  Moreover, the selected compd. 6 showed greater hypoglycemic and insulinotropic activities than liraglutide even when the dose of 6 was reduced to half in db/db mice.  Pharmacokinetic test revealed that 6 had a ∼ 3-fold longer half-life than liraglutide in Kunming mice and SD rats, and the longer half-life of 6 led to excellent long-acting hypoglycemic effects as confirmed by two different pharmacol. methods conducted on db/db mice.  Finally, a 7 wk chronic study conducted on db/db mice demonstrated the better therapeutic efficacies of 6 on glucose tolerance normalization, HbA1c redn. and pancreas islets protection than liraglutide.  The present research showed that combined dimerization and lipidization is effective when applied to Xenopus GLP-1 analog to develop novel GLP-1 analog for the treatment of type 2 diabetes.  In addn., the promising preclin. data of 6 suggested the therapeutic potential of 6 as a novel anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu69hLGs6cPLVg90H21EOLACvtfcHk0lh_21tM7yl3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO&md5=ae25a20f5222a840602f9bece420e690</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.072%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DRational%2520Design%2520of%2520Dimeric%2520Lipidated%2520Xenopus%2520Glucagon-like%2520Peptide%25201%2520Analogues%2520as%2520Long-acting%2520Antihyperglycaemic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.ejmech.2018.07.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skarbaliene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigbolt, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billestrup, N.</span></span> <span> </span><span class="NLM_article-title">In-vitro and In-vivo Studies Supporting the Therapeutic Potential of ZP3022 in Diabetes</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>815</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejphar.2017.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28928089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFems73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=815&publication_year=2017&pages=181-189&author=J.+Skarbalieneauthor=K.+T.+Rigboltauthor=K.+Fosgerauauthor=N.+Billestrup&title=In-vitro+and+In-vivo+Studies+Supporting+the+Therapeutic+Potential+of+ZP3022+in+Diabetes&doi=10.1016%2Fj.ejphar.2017.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro and in-vivo studies supporting the therapeutic potential of zp3022 in diabetes</span></div><div class="casAuthors">Skarbaliene, Jolanta; Rigbolt, Kristoffer T.; Fosgerau, Keld; Billestrup, Nils</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">815</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GLP-1-gastrin dual agonist ZP3022 has been shown to increase β-cell mass with a concomitant improvement of glycemic control in diabetic mice and rats.  Here we tested the in-vitro effects of ZP3022 on β-cell proliferation, islet apoptosis and glucose-stimulated insulin secretion (GSIS) in rat islets of Langerhans.  Moreover, gene expression profiling in whole pancreas from Zucker Diabetic Fatty (ZDF) rats was performed to characterize genes differently regulated by short-term treatment with ZP3022.  Treatments with exendin-4, gastrin-17 alone or in combination were included in the studies.  ZP3022 promoted β-cell proliferation, protected from palmitate-, but not from cytokine-induced apoptosis, and induced an increase in GSIS, demonstrating a glucose dependent insulinotropic action of ZP3022 on β-cells.  The combination treatment with exendin-4 and gastrin-17 showed comparable effects on proliferation, apoptosis, and GSIS as did ZP3022.  Microarray anal. revealed that ZP3022 exerted specific effects on pancreatic gene expression not obsd. when treating ZDF rats with either exendin-4 alone or in combination with gastrin-17.  In particular MAPK signaling pathway was obsd. among the highest affected pathways; while also pathways related to insulin signaling and secretion were regulated by ZP3022.  Moreover, rats treated with ZP3022 had a higher expression of genes encoding for the specific β-cell/endocrine cell markers, such as islet amyloid polypeptide (IAPP), protein convertase 1/3 and -2 (PC 1/3 and-2), as well as transmembrane protein 27(TMEM27) compared to vehicle treated rats.  We conclude that ZP3022 may have therapeutic potential in the prevention/delay of β cell dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY1L8Xu974X7Vg90H21EOLACvtfcHk0li9Fz_M5mKpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFems73M&md5=17d4cd2612edc6ef3e6275b4f1c92bbc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DSkarbaliene%26aufirst%3DJ.%26aulast%3DRigbolt%26aufirst%3DK.%2BT.%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DBillestrup%26aufirst%3DN.%26atitle%3DIn-vitro%2520and%2520In-vivo%2520Studies%2520Supporting%2520the%2520Therapeutic%2520Potential%2520of%2520ZP3022%2520in%2520Diabetes%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D815%26spage%3D181%26epage%3D189%26doi%3D10.1016%2Fj.ejphar.2017.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span> <span> </span><span class="NLM_article-title">Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-modified Long-acting Exendin-4 Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6889</span>– <span class="NLM_lpage">6896</span>, <span class="refDoi"> DOI: 10.1021/jm901153x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901153x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kjtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6889-6896&author=S.+Sonauthor=S.+Y.+Chaeauthor=C.+W.+Kimauthor=Y.+G.+Choiauthor=S.+Y.+Jungauthor=S.+Leeauthor=K.+C.+Lee&title=Preparation+and+Structural%2C+Biochemical%2C+and+Pharmaceutical+Characterizations+of+Bile+Acid-modified+Long-acting+Exendin-4+Derivatives&doi=10.1021%2Fjm901153x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-Modified Long-Acting Exendin-4 Derivatives</span></div><div class="casAuthors">Son, Sohee; Chae, Su Young; Kim, Chang Wan; Choi, Yang Gyu; Jung, Sung Youb; Lee, Seulki; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6889-6896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop an effective long-acting antidiabetic, the GLP-1 analog of exendin-4 was modified with three different bile acids (BAs; cholic, deoxycholic, or lithocholic acid), at its two lysine residues.  The biol., pharmaceutical, and physicochem. characteristics of these exendin-4 analogs were carefully investigated.  Biol. activity tests demonstrated that the monobile acid substitutions of exendin-4 showed well preserved receptor binding efficacy without noticeable insulinotropic or antidiabetic activity loss.  However, physicochem. and pharmacokinetic studies revealed that the albumin-binding properties and in vivo elimination half-lives of BAM1-Ex4s (Lys27-BA-Ex4s) were significantly enhanced by increasing the hydrophobicities of the conjugated BAs.  Furthermore, the protracted antidiabetic effects of the BAM1-Ex4s were also verified by the prolonged restoration of normoglycemia in type 2 diabetic mice.  Accordingly, the present study suggests that the derivatization of exendin-4 with BAs offers a means of producing long-acting GLP-1 receptor agonists for type 2 diabetic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8cucxupDebLVg90H21EOLACvtfcHk0li9Fz_M5mKpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kjtb7M&md5=f3309b520be1159081e59aac471f7edc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm901153x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901153x%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%26aulast%3DChae%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DChoi%26aufirst%3DY.%2BG.%26aulast%3DJung%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DPreparation%2520and%2520Structural%252C%2520Biochemical%252C%2520and%2520Pharmaceutical%2520Characterizations%2520of%2520Bile%2520Acid-modified%2520Long-acting%2520Exendin-4%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6889%26epage%3D6896%26doi%3D10.1021%2Fjm901153x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trevaskis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athanacio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samant, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatarkiewicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkers, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. D.</span></span> <span> </span><span class="NLM_article-title">Synergistic Metabolic Benefits of an Exenatide Analogue and Cholecystokinin in Diet-induced Obese and Leptin-deficient Rodents</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/dom.12390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fdom.12390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=25204356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVylurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=61-73&author=J.+L.+Trevaskisauthor=C.+Sunauthor=J.+Athanacioauthor=L.+J.+D%E2%80%99Souzaauthor=M.+P.+Samantauthor=K.+Tatarkiewiczauthor=P.+S.+Griffinauthor=C.+Wittmerauthor=Y.+Wangauthor=C.-H.+Tengauthor=B.+Foroodauthor=D.+G.+Parkersauthor=J.+D.+Roth&title=Synergistic+Metabolic+Benefits+of+an+Exenatide+Analogue+and+Cholecystokinin+in+Diet-induced+Obese+and+Leptin-deficient+Rodents&doi=10.1111%2Fdom.12390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents</span></div><div class="casAuthors">Trevaskis, J. L.; Sun, C.; Athanacio, J.; D'Souza, L.; Samant, M.; Tatarkiewicz, K.; Griffin, P. S.; Wittmer, C.; Wang, Y.; Teng, C.-H.; Forood, B.; Parkes, D. G.; Roth, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-73</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To test the impact of cholecystokinin (CCK) plus either amylin or a glucagon-like peptide-1 receptor (GLP-1R) agonist on metabolic variables in diet-induced obese (DIO) rodents.  Methods : A stabilized acetylated version of CCK-8 (Ac-Y*-CCK-8), selective CCK1 receptor (CCK1R) or CCK2 receptor (CCK2R) agonists, amylin or the GLP-1R agonist and exenatide analog AC3174 were administered in select combinations via continuous s.c. infusion to DIO rats for 14 days, or Lepob/Lepob mice for 28 days, and metabolic variables were assessed.  Results : Combined administration of Ac-Y*-CCK-8 with either amylin or AC3174 induced greater than additive wt. loss in DIO rats, with the overall magnitude of effect being greater with AC3174 + Ac-Y*-CCK-8 treatment.  Co-infusion of AC3174 with a specific CCK1R agonist, but not a CCK2R agonist, recapitulated the wt. loss mediated by AC3174 + Ac-Y*-CCK-8 in DIO rats, suggesting that synergy is mediated by CCK1R activation.  In a 4 × 4 full-factorial response surface methodol. study in DIO rats, a synergistic interaction between AC3174 and the CCK1R-selective agonist on body wt. and food intake was noted.  Co-administration of AC3174 and the CCK1R-selective agonist to obese diabetic Lepob/Lepob mice elicited a significantly greater redn. in percentage of glycated Hb and food intake relative to the sum effects of monotherapy groups.  Conclusions : The anti-obesity and antidiabetic potential of combined GLP-1R and CCK1R agonism is an approach that warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ymduZxipoLVg90H21EOLACvtfcHk0li9Fz_M5mKpWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVylurvI&md5=c5b8717cd0f03a6eceb8c23a16a770e6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fdom.12390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12390%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAthanacio%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DL.%2BJ.%26aulast%3DSamant%26aufirst%3DM.%2BP.%26aulast%3DTatarkiewicz%26aufirst%3DK.%26aulast%3DGriffin%26aufirst%3DP.%2BS.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTeng%26aufirst%3DC.-H.%26aulast%3DForood%26aufirst%3DB.%26aulast%3DParkers%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DSynergistic%2520Metabolic%2520Benefits%2520of%2520an%2520Exenatide%2520Analogue%2520and%2520Cholecystokinin%2520in%2520Diet-induced%2520Obese%2520and%2520Leptin-deficient%2520Rodents%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2015%26volume%3D17%26spage%3D61%26epage%3D73%26doi%3D10.1111%2Fdom.12390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Long-lasting GLP-1/anti-GLP-1R Antibody Fusion Protein, Exerts Anti-diabetic Effects Through Targeting Dual Receptor Binding Sites</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.bcp.2018.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29355505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVentr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=46-53&author=C.+Liauthor=M.+Yangauthor=X.+Wangauthor=H.+Zhangauthor=C.+Yaoauthor=S.+Sunauthor=Q.+Liuauthor=H.+Panauthor=S.+Liuauthor=Y.+Huanauthor=S.+Liauthor=J.+Caoauthor=X.+Wangauthor=Y.+Guoauthor=N.+Guoauthor=S.+Jingauthor=C.+Zhangauthor=S.+Shen&title=A+Novel+Long-lasting+GLP-1%2Fanti-GLP-1R+Antibody+Fusion+Protein%2C+Exerts+Anti-diabetic+Effects+Through+Targeting+Dual+Receptor+Binding+Sites&doi=10.1016%2Fj.bcp.2018.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites</span></div><div class="casAuthors">Li, Caina; Yang, Miaomiao; Wang, Xiaofeng; Zhang, Hua; Yao, Chenjiang; Sun, Sujuan; Liu, Quan; Pan, Hao; Liu, Shuainan; Huan, Yi; Li, Shengnan; Cao, Jun; Wang, Xing; Guo, Yong; Guo, Nan; Jing, Shuqian; Zhang, Cheng; Shen, Zhufang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-53</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glucagon like-peptide-1 (GLP-1)-based drugs have been proposed as mono- or combined therapy for type 2 diabetes mellitus.  Thus we characterized a novel antibody fusion protein engineered by linking the human GLP-1 deriv. to a humanized GLP-1 receptor (GLP-1R) antibody via a peptide linker.  Glutazumab was characterized by receptor binding and reporter activation assays, and its specificity was investigated with the aid of the cognate receptor antagonist exendin (9-39) and antibody Ab1.  Pharmacokinetics was evaluated in Sprague-Dawley (SD) rats and cynomolgus monkeys, and pharmacodynamics was assessed in normal ICR and spontaneous type 2 diabetic KKAy mice.  Hypoglycemic effects were evaluated after acute administration and glucose metab. and β-cell function were assessed with repeated administrations.  Dulaglutide was a pos. control in all expts.  Glutazumab significantly bound and activated GLP-1R, but the receptor antagonist exendin (9-39) did not inhibit the activation except when combined with Ab1.  Single injection of glutazumab reduced the blood glucose in ICR mice and KKAy mice, and the half-lives in SD rats and cynomolgus monkeys were 18 h and 33.6 h.  Repeated injections of glutazumab controlled glycemic fluctuations and improved β-cell function in KKAy mice.  As a novel GLP-1R agonist, glutazumab may be a potential treatment for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpJTySrEuQLVg90H21EOLACvtfcHk0livbNx9XsE_KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVentr0%253D&md5=539f06ff9f27edc190fb2c7981b16675</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DJing%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Long-lasting%2520GLP-1%252Fanti-GLP-1R%2520Antibody%2520Fusion%2520Protein%252C%2520Exerts%2520Anti-diabetic%2520Effects%2520Through%2520Targeting%2520Dual%2520Receptor%2520Binding%2520Sites%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D150%26spage%3D46%26epage%3D53%26doi%3D10.1016%2Fj.bcp.2018.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">An Albumin-exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2008.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1053%2Fj.gastro.2008.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=18313669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=1137-1147&author=L.+L.+Baggioauthor=Q.+Huangauthor=X.+Caoauthor=D.+J.+Drucker&title=An+Albumin-exendin-4+Conjugate+Engages+Central+and+Peripheral+Circuits+Regulating+Murine+Energy+and+Glucose+Homeostasis&doi=10.1053%2Fj.gastro.2008.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis</span></div><div class="casAuthors">Baggio, Laurie L.; Huang, Qingling; Cao, Xiemin; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1137-1147</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis through multiple mechanisms including direct actions on the endocrine pancreas and indirect activation of central nervous system circuits regulating gastric emptying, satiety, and body wt.  Because native GLP-1 is rapidly degraded, there is considerable interest in development of more potent GLP-1 receptor (GLP-1R) agonists with sustained activity; however, the extent to which much larger GLP-1R agonists will mimic some or all of the actions of smaller peptides remains uncertain.  Methods: We studied the actions of CJC-1134-PC, a recombinant human serum albumin-exendin-4 conjugated protein, at the GLP-1 R using heterologous cells expressing the GLP-1R in vitro and both wild-type and Glp1r-/- mice in vivo.  Results: CJC-1134-PC activated GLP-1R-dependent signaling in baby hamster kidney-GLP-1R cells and acutely lowered blood glucose in wild-type but not in Glp1r-/- mice.  Moreover, acute administration of CJC-1134-PC rapidly activated c-Fos expression in multiple regions of the central nervous system, acutely inhibited gastric emptying, and produced sustained inhibition of food intake in a GLP-1R-dependent manner.  Furthermore, chronic daily treatment of high-fat diet-fed wild-type mice with CJC-1134-PC for 4 wk led to improved glucose tolerance, increased levels of glucose-stimulated insulin, decreased HbA1c, and wt. loss assocd. with decreased hepatic triglyceride content.  Conclusions: These findings illustrate that a high-mol.-wt. exendin-4-albumin conjugate retains the ability to mimic a full spectrum of GLP-1R-dependent actions, including activation of central nervous system circuits regulating gastric emptying, food intake, and body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxypVQ2EIAS7Vg90H21EOLACvtfcHk0livbNx9XsE_KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1Gls7s%253D&md5=2fb7202fa81db14fe2e83a7baca618e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DBaggio%26aufirst%3DL.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DAn%2520Albumin-exendin-4%2520Conjugate%2520Engages%2520Central%2520and%2520Peripheral%2520Circuits%2520Regulating%2520Murine%2520Energy%2520and%2520Glucose%2520Homeostasis%26jtitle%3DGastroenterology%26date%3D2008%26volume%3D134%26spage%3D1137%26epage%3D1147%26doi%3D10.1053%2Fj.gastro.2008.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span> <span> </span><span class="NLM_article-title">Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2840</span>– <span class="NLM_lpage">2856</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSktb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=2840-2856&author=J.+Hanauthor=X.+Chenauthor=L.+Zhaoauthor=J.+Fuauthor=L.+Sunauthor=Y.+Zhangauthor=F.+Zhouauthor=Y.+Fei&title=Lithocholic+Acid-Based+Peptide+Delivery+System+for+an+Enhanced+Pharmacological+and+Pharmacokinetic+Profile+of+Xenopus+GLP-1+Analogs&doi=10.1021%2Facs.molpharmaceut.8b00336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs</span></div><div class="casAuthors">Han, Jing; Chen, Xinyu; Zhao, Liming; Fu, Junjie; Sun, Lidan; Zhang, Ying; Zhou, Feng; Fei, Yingying</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2840-2856</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GLP-1 analogs suffer from the main disadvantage of a short in vivo half-life.  Lithocholic acid (LCA), one of the four main bile acids in the human body, possesses a high albumin binding rate.  We therefore envisioned that a LCA-based peptide delivery system could extend the half-life of GLP-1 analogs by facilitating the noncovalent binding of peptides to human serum albumin.  On the basis of our previously identified Xenopus GLP-1 analogs (1-3), a series of LCA-modified Xenopus GLP-1 conjugates were designed (4a-4r), and the bioactivity studies of these conjugates were performed to identify compds. with balanced in vitro receptor activation potency and plasma stability.  4C, 4i, and 4r were selected, and their LCA side chains were optimized to further increase their stability, affording 5a-5c.  Compd. 5b showed a more increased albumin affinity and prolonged in vitro stability than that of 4i and liraglutide.  In db/db mice, 5b exhibited comparable hypoglycemic and insulinotropic activity to liraglutide and semaglutide.  Importantly, the enhanced albumin affinity of 5b resulted in a prolonged in vivo antidiabetic duration.  Finally, chronic treatment investigations of 5b demonstrated the therapeutic effects of 5b on HbA1c, body wt., blood glucose, and pancreatic endocrine deficiencies on db/db mice.  Our studies revealed 5b as a promising antidiabetic candidate.  Furthermore, our study suggests the derivatization of Xenopus GLP-1 analogs with LCA represents an effective strategy to develop potent long-acting GLP-1 receptor agonists for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg7cAD-Es-7Vg90H21EOLACvtfcHk0lgGZBaK2iFouQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSktb3F&md5=668ebb515707233f7fcc67ca1aee47aa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00336%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26atitle%3DLithocholic%2520Acid-Based%2520Peptide%2520Delivery%2520System%2520for%2520an%2520Enhanced%2520Pharmacological%2520and%2520Pharmacokinetic%2520Profile%2520of%2520Xenopus%2520GLP-1%2520Analogs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D2840%26epage%3D2856%26doi%3D10.1021%2Facs.molpharmaceut.8b00336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chun Han, Yuqing Sun, Qimeng Yang, Feng Zhou, Xinyu Chen, Lintao Wu, Lidan Sun, <span class="NLM_string-name hlFld-ContribAuthor">Jing Han</span>. </span><span class="cited-content_cbyCitation_article-title">Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2021,</strong> <em>18 </em>
                                    (8)
                                     , 2906-2923. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00995" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00995%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DStapled%25252C%252BLong-Acting%252BXenopus%252BGLP-1-Based%252BDual%252BGLP-1%25252FGlucagon%252BReceptor%252BAgonists%252Bwith%252BPotent%252BTherapeutic%252BEfficacy%252Bfor%252BMetabolic%252BDisease%26aulast%3DHan%26aufirst%3DChun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D05102020%26date%3D29062021%26date%3D24062021%26date%3D09072021%26volume%3D18%26issue%3D8%26spage%3D2906%26epage%3D2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of liraglutide, semaglutide, ZP3022, <b>1</b>, <b>2</b>, <b>3</b>, and their dual cysteine mutants.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Acute hypoglycemic activity of GLP-1, <b>1</b>, <b>2</b>, <b>3</b>, <b>1d</b>, <b>1k</b>, <b>2d</b>, <b>2k</b>, <b>3d</b>, and <b>3k</b> in ICR mice as assessed by the OGTT. Test peptides (each at 25 nmol·kg<sup>–1</sup>) were i.p. administered at −15 min, and glucose (3 g·kg<sup>–1</sup>) was orally loaded at 0 min. (A, C, E) Curves of blood glucose during the OGTT. (B, D, F) Corresponding glucose AUC<sub>0–120min</sub> values. Means ± SD, <i>n</i> = 6. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> GLP-1; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> GLP-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of stapled <i>Xenopus</i> GLP-1 derivatives <b>4a</b>–<b>4x</b>. (A) Sequence of selected dual Cys mutants. (B) Structures of fatty acid-modified BisMAL cross-linkers (L1–L4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route of Stapled Peptides <b>4a</b>–<b>4x</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>PG: acid labile protecting group.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Alpha-helicity and in vivo pharmacodynamics of stapled peptides. (A) CD spectra of <b>1</b>, <b>2</b>, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> in phosphate buffer containing 20% TFE. (B, C) Hypoglycemic effects of liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> in nonfasted male db/db mice after s.c. dosing of 25 nmol·kg<sup>–1</sup>. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A–F) Effects of 1 week s.c. treatment of 25 nmol·kg<sup>–1</sup> liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b> on body weight change (A, B), food intake (C, D), and fasted blood glucose (E, F) of male DIO mice. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> semaglutide; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> semaglutide; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> semaglutide. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of <b>5a</b>–<b>5d</b> and <b>6a</b>–<b>6d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo glucose-lowering, insulinotropic, and anorectic effects and PK profiles of <b>6a</b> and <b>6b</b>. The hypoglycemic and insulinotropic effects of ZP3022, <b>6a</b>, and <b>6b</b> were measured by the OGTT in male db/db mice. Saline, ZP3022, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were i.p. injected 30 min prior to oral administration of glucose (1.5 g·kg<sup>–1</sup>). (A–D) Time–blood glucose levels, time–plasma insulin levels, and the corresponding AUC values for blood glucose and plasma insulin. Means ± SD, <i>n</i> = 6. (E) PK profiles of ZP3022, <b>6a</b>, and <b>6b</b> in male ICR mice by s.c. injection at a dose of 50 nmol·kg<sup>–1</sup>. Means ± SD, <i>n</i> = 3. (F–I) Antihyperglycemic duration and anorectic effects of ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in nonfasted male db/db mice at doses of 25 (F, G) and 100 nmol·kg<sup>–1</sup> (H, I). Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Gastric emptying, kaolin consumption, and toxicity assays of <b>6a</b> and <b>6b</b>. (A) Time–response curves of plasma acetaminophen and the corresponding AUC values measured by the acetaminophen absorption assay in 6 h fasted male ICR mice that received i.p. injection of saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> at −30 min followed by orally administered acetaminophen (100 mg·kg<sup>–1</sup>) at 0 min. (B) Solid gastric emptying rates in male ICR mice 4 h after i.p. injection of saline and 25 nmol·kg<sup>–1</sup> ZP3022, liraglutide, <b>6a</b>, and <b>6b</b>. (C, D) Kaolin and food intake during 24 h in male SD rats following i.p. injection of saline (containing 10% DMSO), cisplatin (3 mg·kg<sup>–1</sup>), ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>). (E, F) Daily kaolin and food consumption in male SD rats for 12 days. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day. Liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were s.c. injected twice daily. Means ± SD, <i>n</i> = 6. (G, H) Effects of liraglutide, ZP3022, and <b>6a</b> on the viability of INS-1 cells under normal (G) or glucotoxicity (H) condition. (I, J) Effects of liraglutide, ZP3022, and <b>6b</b> on the viability of INS-1 cells under normal (I) or glucotoxicity (J) condition. Means ± SD, <i>n</i> = 3. (K, L) Values of hepatotoxicity and renal toxicity indicators in male ICR mice after a 2 week s.c. dosing of ZP3022, liraglutide (100 nmol·kg<sup>–1</sup>), <b>6a</b>, and <b>6b</b> (1000 nmol·kg<sup>–1</sup>). Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Three week treatment effects of <b>6a</b> and <b>6b</b> in male DIO mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. administered three times a day. Liraglutide, <b>6a</b>, and <b>6b</b> were s.c. administered (25 nmol·kg<sup>–1</sup>) twice daily in DIO mice for 3 weeks. (A–L) Effects on body weight change (A, B), fat mass change (C), food intake (D), fasted blood glucose levels (E, F), glucose tolerance before (G, H) and after (I, J) treatment, serum TC (K), and TG (L) were measured. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> ZP3022; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Glycemic, body weight, and islet benefits following a 21 day treatment with ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in male db/db mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day, and liraglutide, <b>6a</b>, and <b>6b</b> (25 nmol·kg<sup>–1</sup>) were s.c. injected twice daily for 21 days. (A–K) Effects on food intake (A), body weight (B), fasted blood glucose (C, D), HbA1c (E, F), percent β-cell (G) and α-cell (H) area per islet, islet area (I), islet number (J), and IOD values of insulin staining (K) were measured. (L–P) Representative H&E and insulin staining images in saline (L), liraglutide (M), ZP3022 (N), <b>6a</b> (O), and <b>6b</b> (P) groups are shown. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>a</sup><i>P</i> < 0.05 <i>vs</i> liraglutide; <sup>b</sup><i>P</i> < 0.01 <i>vs</i> liraglutide; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>a′</sup><i>P</i> < 0.05 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/medium/jm0c00736_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chronic treatment effects of ZP3022, liraglutide, <b>6a</b>, and <b>6b</b> in male db/db mice. Saline and ZP3022 (25 nmol·kg<sup>–1</sup>) were s.c. injected three times a day, and 25 nmol·kg<sup>–1</sup> liraglutide, <b>6a</b>, and <b>6b</b> were s.c. injected twice daily for 42 days. In the following 42 days, each group of mice was s.c. injected twice daily with saline. (A–E) Effects on glucose tolerance on days 0 (A), 42 (B), 56 (C), 70 (D), and 84 (E) during the treatment were determined by OGTTs, and (F) corresponding glucose AUC values were summarized. (G, H) Effects on fasted blood glucose levels (G) and HbA1c (H) values were also determined. ***<i>P</i> < 0.001 <i>vs</i> saline; <sup>c</sup><i>P</i> < 0.001 <i>vs</i> liraglutide; <sup>b′</sup><i>P</i> < 0.01 <i>vs</i> ZP3022; <sup>c′</sup><i>P</i> < 0.001 <i>vs</i> ZP3022. Means ± SD, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00736/20201105/images/large/jm0c00736_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00736&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, S. M.</span></span> <span> </span><span class="NLM_article-title">Emerging Hormonal-based Combination Pharmacotherapies for the Treatment of Metabolic Diseases</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1038/s41574-018-0118-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fs41574-018-0118-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30446744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVeqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=90-104&author=C.+Clemmensenauthor=B.+Finanauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6pauthor=S.+M.+Hofmann&title=Emerging+Hormonal-based+Combination+Pharmacotherapies+for+the+Treatment+of+Metabolic+Diseases&doi=10.1038%2Fs41574-018-0118-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases</span></div><div class="casAuthors">Clemmensen Christoffer; Clemmensen Christoffer; Muller Timo D; Tschop Matthias H; Finan Brian; DiMarchi Richard D; Tschop Matthias H; Hofmann Susanna M; Hofmann Susanna M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Obesity and its comorbidities, such as type 2 diabetes mellitus and cardiovascular disease, constitute growing challenges for public health and economies globally.  The available treatment options for these metabolic disorders cannot reverse the disease in most individuals and have not substantially reduced disease prevalence, which underscores the unmet need for more efficacious interventions.  Neurobiological resilience to energy homeostatic perturbations, combined with the heterogeneous pathophysiology of human metabolic disorders, has limited the sustainability and efficacy of current pharmacological options.  Emerging insights into the molecular origins of eating behaviour, energy expenditure, dyslipidaemia and insulin resistance suggest that coordinated targeting of multiple signalling pathways is probably necessary for sizeable improvements to reverse the progression of these diseases.  Accordingly, a broad set of combinatorial approaches targeting feeding circuits, energy expenditure and glucose metabolism in concert are currently being explored and developed.  Notably, several classes of peptide-based multi-agonists and peptide-small molecule conjugates with superior preclinical efficacy have emerged and are currently undergoing clinical evaluation.  Here, we summarize advances over the past decade in combination pharmacotherapy for the management of obesity and type 2 diabetes mellitus, exclusively focusing on large-molecule formats (notably enteroendocrine peptides and proteins) and discuss the associated therapeutic opportunities and challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBi3BP-gFLovSAs_PE1QvifW6udTcc2eak8dZP8rAycbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVeqtw%253D%253D&md5=ac6857dc287d02aa96c3d9376f5e8dbb</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41574-018-0118-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41574-018-0118-x%26sid%3Dliteratum%253Aachs%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DHofmann%26aufirst%3DS.%2BM.%26atitle%3DEmerging%2520Hormonal-based%2520Combination%2520Pharmacotherapies%2520for%2520the%2520Treatment%2520of%2520Metabolic%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2019%26volume%3D15%26spage%3D90%26epage%3D104%26doi%3D10.1038%2Fs41574-018-0118-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scully, C. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=905-927&author=R.+Suzukiauthor=G.+A.+Brownauthor=J.+A.+Christopherauthor=C.+C.+G.+Scullyauthor=M.+Congreve&title=Recent+Developments+in+Therapeutic+Peptides+for+the+Glucagon-like+Peptide+1+and+2+Receptors&doi=10.1021%2Facs.jmedchem.9b00835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span></div><div class="casAuthors">Suzuki, Rie; Brown, Giles A.; Christopher, John A.; Scully, Conor C. G.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake.  These mols. are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents.  The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide mols. that hold promise as novel peptide therapeutics.  One emerging area is the discovery of multifunctional mols. that act at two or more pharmacol. systems to enhance therapeutic efficacy.  In addn., drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery.  These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdugqq7LLcprVg90H21EOLACvtfcHk0lgHP9Ak45o6DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I&md5=98554f261b9fd88ed7a12e806869be6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00835%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DScully%26aufirst%3DC.%2BC.%2BG.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DRecent%2520Developments%2520in%2520Therapeutic%2520Peptides%2520for%2520the%2520Glucagon-like%2520Peptide%25201%2520and%25202%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D905%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.9b00835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">728</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2012.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnrendo.2012.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=22945360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=728&author=J.+J.+Meier&title=GLP-1+Receptor+Agonists+for+Individualized+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.1038%2Fnrendo.2012.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Meier, Juris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">728-742</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and lowers glucose concns. by augmenting insulin secretion and suppressing glucagon release.  Addnl. effects of GLP-1 include retardation of gastric emptying, suppression of appetite and, potentially, inhibition of β-cell apoptosis.  Native GLP-1 is degraded within ∼2-3 min in the circulation; various GLP-1 receptor agonists have, therefore, been developed to provide prolonged in vivo actions.  These GLP-1 receptor agonists can be categorized as either short-acting compds., which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compds. (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose.  The pharmacokinetic differences between these drugs lead to important differences in their pharmacodynamic profiles.  The short-acting GLP-1 receptor agonists primarily lower postprandial blood glucose levels through inhibition of gastric emptying, whereas the long-acting compds. have a stronger effect on fasting glucose levels, which is mediated predominantly through their insulinotropic and glucagonostatic actions.  The adverse effect profiles of these compds. also differ.  The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GZovdW_ldbVg90H21EOLACvtfcHk0lgHP9Ak45o6DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP&md5=5dc374bda9f06bb96494f8ed7a61018f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.140%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DGLP-1%2520Receptor%2520Agonists%2520for%2520Individualized%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2012%26volume%3D8%26spage%3D728%26doi%3D10.1038%2Fnrendo.2012.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riboulet, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebokova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Knape, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfluger, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nm.3761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnm.3761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=25485909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=27-36&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=D.+L.+Smileyauthor=T.+Maauthor=C.+Clemmensenauthor=J.+Chabenneauthor=L.+Zhangauthor=K.+M.+Habeggerauthor=K.+Fischerauthor=J.+E.+Campbellauthor=D.+Sandovalauthor=R.+J.+Seeleyauthor=K.+Bleicherauthor=S.+Uhlesauthor=W.+Ribouletauthor=J.+Funkauthor=C.+Hertelauthor=S.+Belliauthor=E.+Sebokovaauthor=K.+Conde-Knapeauthor=A.+Konkarauthor=D.+J.+Druckerauthor=V.+Gelfanovauthor=P.+T.+Pflugerauthor=T.+D.+M%C3%BCllerauthor=D.+Perez-Tilveauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=A+Rationally+Designed+Monomeric+Peptide+Triagonist+Corrects+Obesity+and+Diabetes+in+Rodents&doi=10.1038%2Fnm.3761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Smiley, David L.; Ma, Tao; Clemmensen, Christoffer; Chabenne, Joe; Zhang, Lianshan; Habegger, Kirk M.; Fischer, Katrin; Campbell, Jonathan E.; Sandoval, Darleen; Seeley, Randy J.; Bleicher, Konrad; Uhles, Sabine; Riboulet, William; Funk, Juergen; Hertel, Cornelia; Belli, Sara; Sebokova, Elena; Conde-Knape, Karin; Konkar, Anish; Drucker, Daniel J.; Gelfanov, Vasily; Pfluger, Paul T.; Mueller, Timo D.; Perez-Tilve, Diego; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the discovery of a new monomeric peptide that reduces body wt. and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.  This triple agonist demonstrates supraphysiol. potency and equally aligned constituent activities at each receptor, all without cross-reactivity at other related receptors.  Such balanced unimol. triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body wt., enhance glycemic control and reverse hepatic steatosis in relevant rodent models.  Various loss-of-function models, including genetic knockout, pharmacol. blockade and selective chem. knockout, confirmed contributions of each constituent activity in vivo.  We demonstrate that these individual constituent activities harmonize to govern the overall metabolic efficacy, which predominantly results from synergistic glucagon action to increase energy expenditure, GLP-1 action to reduce caloric intake and improve glucose control, and GIP action to potentiate the incretin effect and buffer against the diabetogenic effect of inherent glucagon activity.  These preclin. studies suggest that, so far, this unimol., polypharmaceutical strategy has potential to be the most effective pharmacol. approach to reversing obesity and related metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHrGvoJsN6LVg90H21EOLACvtfcHk0ljvsytZM-racQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCks73J&md5=9024ca9e43d498db95332d64e9e16039</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.3761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3761%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DSmiley%26aufirst%3DD.%2BL.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DChabenne%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHabegger%26aufirst%3DK.%2BM.%26aulast%3DFischer%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DJ.%2BE.%26aulast%3DSandoval%26aufirst%3DD.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DBleicher%26aufirst%3DK.%26aulast%3DUhles%26aufirst%3DS.%26aulast%3DRiboulet%26aufirst%3DW.%26aulast%3DFunk%26aufirst%3DJ.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DBelli%26aufirst%3DS.%26aulast%3DSebokova%26aufirst%3DE.%26aulast%3DConde-Knape%26aufirst%3DK.%26aulast%3DKonkar%26aufirst%3DA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPfluger%26aufirst%3DP.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DA%2520Rationally%2520Designed%2520Monomeric%2520Peptide%2520Triagonist%2520Corrects%2520Obesity%2520and%2520Diabetes%2520in%2520Rodents%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnm.3761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haack, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stengelin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadereit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, M.</span></span> <span> </span><span class="NLM_article-title">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4303</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4293-4303&author=A.+Eversauthor=T.+Haackauthor=M.+Lorenzauthor=M.+Bossartauthor=R.+Elvertauthor=B.+Henkelauthor=S.+Stengelinauthor=M.+Kurzauthor=M.+Glienauthor=A.+Duddaauthor=K.+Lorenzauthor=D.+Kadereitauthor=M.+Wagner&title=Design+of+Novel+Exendin-Based+Dual+Glucagon-like+Peptide+1+%28GLP-1%29%2FGlucagon+Receptor+Agonists&doi=10.1021%2Facs.jmedchem.7b00174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists</span></div><div class="casAuthors">Evers, Andreas; Haack, Torsten; Lorenz, Martin; Bossart, Martin; Elvert, Ralf; Henkel, Bernd; Stengelin, Siegfried; Kurz, Michael; Glien, Maike; Dudda, Angela; Lorenz, Katrin; Kadereit, Dieter; Wagner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4293-4303</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity.  Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design.  On the basis of sequence anal. and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity.  Detailed structure-activity relationship data are shown.  Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body wt. in diet-induced obese (DIO) mice.  Structural anal. by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chem. and phys. stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrewDgurwTT4LVg90H21EOLACvtfcHk0ljvsytZM-racQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslKrsr8%253D&md5=b59a7a25cdd56516b78c988860b39211</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00174%26sid%3Dliteratum%253Aachs%26aulast%3DEvers%26aufirst%3DA.%26aulast%3DHaack%26aufirst%3DT.%26aulast%3DLorenz%26aufirst%3DM.%26aulast%3DBossart%26aufirst%3DM.%26aulast%3DElvert%26aufirst%3DR.%26aulast%3DHenkel%26aufirst%3DB.%26aulast%3DStengelin%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DM.%26aulast%3DGlien%26aufirst%3DM.%26aulast%3DDudda%26aufirst%3DA.%26aulast%3DLorenz%26aufirst%3DK.%26aulast%3DKadereit%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DM.%26atitle%3DDesign%2520of%2520Novel%2520Exendin-Based%2520Dual%2520Glucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%252FGlucagon%2520Receptor%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4293%26epage%3D4303%26doi%3D10.1021%2Facs.jmedchem.7b00174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.cmet.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=27411008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=51-62&author=M.+H.+Tsch%C3%B6pauthor=B.+Finanauthor=C.+Clemmensenauthor=V.+Gelfanovauthor=D.+Perez-Tilveauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchi&title=Unimolecular+Polypharmacy+for+Treatment+of+Diabetes+and+Obesity&doi=10.1016%2Fj.cmet.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Unimolecular Polypharmacy for Treatment of Diabetes and Obesity</span></div><div class="casAuthors">Tschop Matthias H; Finan Brian; Clemmensen Christoffer; Muller Timo D; Gelfanov Vasily; Perez-Tilve Diego; DiMarchi Richard D</div><div class="citationInfo"><span class="NLM_cas:title">Cell metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches.  Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis.  Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines.  Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity.  On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules.  More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes.  Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSD_iD9oiDSziEJCPKhJPuqfW6udTcc2eYXuzmdpEfax7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3gtleisQ%253D%253D&md5=36cbafe2232e829ccc52d5c83895f6a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DUnimolecular%2520Polypharmacy%2520for%2520Treatment%2520of%2520Diabetes%2520and%2520Obesity%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D24%26spage%3D51%26epage%3D62%26doi%3D10.1016%2Fj.cmet.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bech, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martos-Maldonado, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wismann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So̷rensen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Witteloostuijn, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelsing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. J.</span></span> <span> </span><span class="NLM_article-title">Peptide Half-life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7434</span>– <span class="NLM_lpage">7446</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00787</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00787" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OmsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7434-7446&author=E.+M.+Bechauthor=M.+C.+Martos-Maldonadoauthor=P.+Wismannauthor=K.+K.+So%CC%B7rensenauthor=S.+B.+van+Witteloostuijnauthor=M.+B.+Thygesenauthor=N.+Vrangauthor=J.+Jelsingauthor=S.+L.+Pedersenauthor=K.+J.+Jensen&title=Peptide+Half-life+Extension%3A+Divalent%2C+Small-Molecule+Albumin+Interactions+Direct+the+Systemic+Properties+of+Glucagon-Like+Peptide+1+%28GLP-1%29+Analogues&doi=10.1021%2Facs.jmedchem.7b00787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues</span></div><div class="casAuthors">Bech, Esben M.; Maldonado, Manuel C.; Wismann, Pernille; Soerensen, Kasper K.; van Witteloostuijn, Soeren Blok; Thygesen, Mikkel B.; Vrang, Niels; Jelsing, Jacob; Pedersen, Soeren L.; Jensen, Knud J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7434-7446</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymic degrdn. and renal clearance.  Herein, we investigated the effect of mono- or divalent small-mol. albumin binders for half-life extension of peptides.  For proof-of-principle, the clin. relevant glucagon-like peptide 1 (GLP-1) was functionalized with diflunisal, indomethacin, or both.  In vitro, all GLP-1 analogs had subnanomolar GLP-1 receptor potency.  Surface plasmon resonance revealed that both small mols. were able to confer albumin affinity to GLP-1 and indicated that affinity is increased for divalent analogs.  In lean mice, the divalent GLP-1 analogs were superior to monovalent analogs with respect to control of glucose homeostasis and suppression of food intake.  Importantly, divalent GLP-1 analogs showed efficacy comparable to liraglutide, an antidiabetic GLP-1 analog that carries a long-chain fatty acid.  Finally, pharmacokinetic investigations of a divalent GLP-1 analog demonstrated a promising gain in circulatory half-life and absorption time compared to its monovalent equiv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDH8-idZnsPLVg90H21EOLACvtfcHk0ljmy4pSw9TGvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OmsLnO&md5=8ed415888afd85068ac6a4b98090b69c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00787%26sid%3Dliteratum%253Aachs%26aulast%3DBech%26aufirst%3DE.%2BM.%26aulast%3DMartos-Maldonado%26aufirst%3DM.%2BC.%26aulast%3DWismann%26aufirst%3DP.%26aulast%3DSo%25CC%25B7rensen%26aufirst%3DK.%2BK.%26aulast%3Dvan%2BWitteloostuijn%26aufirst%3DS.%2BB.%26aulast%3DThygesen%26aufirst%3DM.%2BB.%26aulast%3DVrang%26aufirst%3DN.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DPedersen%26aufirst%3DS.%2BL.%26aulast%3DJensen%26aufirst%3DK.%2BJ.%26atitle%3DPeptide%2520Half-life%2520Extension%253A%2520Divalent%252C%2520Small-Molecule%2520Albumin%2520Interactions%2520Direct%2520the%2520Systemic%2520Properties%2520of%2520Glucagon-Like%2520Peptide%25201%2520%2528GLP-1%2529%2520Analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7434%26epage%3D7446%26doi%3D10.1021%2Facs.jmedchem.7b00787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&author=D.+J.+Drucker&title=Mechanisms+of+Action+and+Therapeutic+Application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0ljmy4pSw9TGvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520Action%2520and%2520Therapeutic%2520Application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flatt, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habener, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nauck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang-Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">Glucagon-like Peptide 1 (GLP-1)</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2019.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.molmet.2019.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=31767182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKkurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=72-130&author=T.+D.+M%C3%BCllerauthor=B.+Finanauthor=S.+R.+Bloomauthor=D.+D%E2%80%99Alessioauthor=D.+J.+Druckerauthor=P.+R.+Flattauthor=A.+Fritscheauthor=F.+Gribbleauthor=H.+J.+Grillauthor=J.+F.+Habenerauthor=J.+J.+Holstauthor=W.+Langhansauthor=J.+J.+Meierauthor=M.+A.+Nauckauthor=D.+Perez-Tilveauthor=A.+Pocaiauthor=F.+Reimannauthor=D.+A.+Sandovalauthor=T.+W.+Schwartzauthor=R.+J.+Seeleyauthor=K.+Stemmerauthor=M.+Tang-Christensenauthor=S.+C.+Woodsauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=Glucagon-like+Peptide+1+%28GLP-1%29&doi=10.1016%2Fj.molmet.2019.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Glucagon-like peptide 1 (GLP-1)</span></div><div class="casAuthors">Mueller, T. D.; Finan, B.; Bloom, S. R.; D'Alessio, D.; Drucker, D. J.; Flatt, P. R.; Fritsche, A.; Gribble, F.; Grill, H. J.; Habener, J. F.; Holst, J. J.; Langhans, W.; Meier, J. J.; Nauck, M. A.; Perez-Tilve, D.; Pocai, A.; Reimann, F.; Sandoval, D. A.; Schwartz, T. W.; Seeley, R. J.; Stemmer, K.; Tang-Christensen, M.; Woods, S. C.; Di Marchi, R. D.; Tschoep, M. H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-130</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacol. potential.  Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation.  GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability.  Biochem. modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clin. use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clin. evaluation for the treatment of obesity.In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacol. and discuss its therapeutic implications on various diseases.Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.  The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzuj3Nn8zhJrVg90H21EOLACvtfcHk0lhgPK0IS5bDuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKkurfE&md5=ad8676e810b7b4abd72fbe9c790c0336</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2019.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2019.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26aulast%3DFlatt%26aufirst%3DP.%2BR.%26aulast%3DFritsche%26aufirst%3DA.%26aulast%3DGribble%26aufirst%3DF.%26aulast%3DGrill%26aufirst%3DH.%2BJ.%26aulast%3DHabener%26aufirst%3DJ.%2BF.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26aulast%3DLanghans%26aufirst%3DW.%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DNauck%26aufirst%3DM.%2BA.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DReimann%26aufirst%3DF.%26aulast%3DSandoval%26aufirst%3DD.%2BA.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DTang-Christensen%26aufirst%3DM.%26aulast%3DWoods%26aufirst%3DS.%2BC.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGlucagon-like%2520Peptide%25201%2520%2528GLP-1%2529%26jtitle%3DMol.%2520Metab.%26date%3D2019%26volume%3D30%26spage%3D72%26epage%3D130%26doi%3D10.1016%2Fj.molmet.2019.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadry, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Emerging Combinatorial Hormone Therapies for the Treatment of Obesity and T2DM</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2013.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1038%2Fnrendo.2013.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=23478327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVyhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=425-433&author=S.+A.+Sadryauthor=D.+J.+Drucker&title=Emerging+Combinatorial+Hormone+Therapies+for+the+Treatment+of+Obesity+and+T2DM&doi=10.1038%2Fnrendo.2013.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging combinatorial hormone therapies for the treatment of obesity and T2DM</span></div><div class="casAuthors">Sadry, Sharon A.; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">425-433</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Peptide hormones and proteins control body wt. and glucose homeostasis by engaging peripheral and central metabolic signalling pathways responsible for the maintenance of body wt. and euglycemia.  The development of obesity, often in assocn. with type 2 diabetes mellitus (T2DM), reflects a dysregulation of metabolic, anorectic and orexigenic pathways in multiple organs.  Notably, therapeutic attempts to normalize body wt. and glycemia with single agents alone have generally been disappointing.  The success of bariatric surgery, together with emerging data from preclin. studies, illustrates the rationale and feasibility of using two or more agonists, or single co-agonists, for the treatment of obesity and T2DM.  Here, we review advances in the science of co-agonist therapy, and highlight promising areas and challenges in co-agonist development.  We describe mechanisms of action for combinations of glucagon-like peptide 1, glucagon, gastric inhibitory polypeptide, gastrin, islet amyloid polypeptide and leptin, which enhance wt. loss while preserving glucoregulatory efficacy in exptl. models of obesity and T2DM.  Although substantial progress has been achieved in preclin. studies, the putative success and safety of co-agonist therapy for the treatment of patients with obesity and T2DM remains uncertain and requires extensive addnl. clin. validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgtf-WtnFhvrVg90H21EOLACvtfcHk0lhgPK0IS5bDuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVyhur0%253D&md5=5710f40e4fd9f27974ab0bae8954a08e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.47%26sid%3Dliteratum%253Aachs%26aulast%3DSadry%26aufirst%3DS.%2BA.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DEmerging%2520Combinatorial%2520Hormone%2520Therapies%2520for%2520the%2520Treatment%2520of%2520Obesity%2520and%2520T2DM%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26spage%3D425%26epage%3D433%26doi%3D10.1038%2Fnrendo.2013.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemmensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschöp, M. H.</span></span> <span> </span><span class="NLM_article-title">GLP-1/Glucagon Receptor Co-agonism for Treatment of Obesity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1851</span>– <span class="NLM_lpage">1861</span>, <span class="refDoi"> DOI: 10.1007/s00125-017-4354-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1007%2Fs00125-017-4354-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28733905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wru7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1851-1861&author=M.+A.+S%C3%A1nchez-Garridoauthor=S.+J.+Brandtauthor=C.+Clemmensenauthor=T.+D.+M%C3%BCllerauthor=R.+D.+DiMarchiauthor=M.+H.+Tsch%C3%B6p&title=GLP-1%2FGlucagon+Receptor+Co-agonism+for+Treatment+of+Obesity&doi=10.1007%2Fs00125-017-4354-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1/glucagon receptor co-agonism for treatment of obesity</span></div><div class="casAuthors">Sanchez-Garrido, Miguel A.; Brandt, Sara J.; Clemmensen, Christoffer; Mueller, Timo D.; Di Marchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1851-1861</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies.  The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications.  Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance.  Pharmacol. attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body wt.  Novel unimol., multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body wt.  In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacol. function at the receptors for glucagon and glucagon-like peptide-1.  Such peptides have advanced to clin. evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwna62NYSHj7Vg90H21EOLACvtfcHk0ljWIxJYYpdCKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wru7%252FF&md5=ca76fc85634d91bcbdd5ffd239390f28</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00125-017-4354-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-017-4354-8%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Garrido%26aufirst%3DM.%2BA.%26aulast%3DBrandt%26aufirst%3DS.%2BJ.%26aulast%3DClemmensen%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DT.%2BD.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTsch%25C3%25B6p%26aufirst%3DM.%2BH.%26atitle%3DGLP-1%252FGlucagon%2520Receptor%2520Co-agonism%2520for%2520Treatment%2520of%2520Obesity%26jtitle%3DDiabetologia%26date%3D2017%26volume%3D60%26spage%3D1851%26epage%3D1861%26doi%3D10.1007%2Fs00125-017-4354-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehfeld, J. F.</span></span> <span> </span><span class="NLM_article-title">Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy</span>.  <i>Clin. Med. Insights: Endocrinol. Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">12</span>, <span class="refDoi"> DOI: 10.1177/1179551419883608</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1177%2F1179551419883608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=31853211" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&author=J.+F.+Rehfeld&title=Premises+for+Cholecystokinin+and+Gastrin+Peptides+in+Diabetes+Therapy&doi=10.1177%2F1179551419883608"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1179551419883608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1179551419883608%26sid%3Dliteratum%253Aachs%26aulast%3DRehfeld%26aufirst%3DJ.%2BF.%26atitle%3DPremises%2520for%2520Cholecystokinin%2520and%2520Gastrin%2520Peptides%2520in%2520Diabetes%2520Therapy%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Endocrinol.%2520Diabetes%26date%3D2019%26volume%3D12%26doi%3D10.1177%2F1179551419883608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwens, L.</span></span> <span> </span><span class="NLM_article-title">Mitogenic Effect of Gastrin and Expression of Gastrin Receptors in Duct-like Cells of Rat Pancreas</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1053/gast.2001.27998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1053%2Fgast.2001.27998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=11606507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2001&pages=940-949&author=I.+Roomanauthor=J.+Lardonauthor=D.+Flamezauthor=F.+Schuitauthor=L.+Bouwens&title=Mitogenic+Effect+of+Gastrin+and+Expression+of+Gastrin+Receptors+in+Duct-like+Cells+of+Rat+Pancreas&doi=10.1053%2Fgast.2001.27998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas</span></div><div class="casAuthors">Rooman, Ilse; Lardon, Jessy; Flamez, Daisy; Schuit, Frans; Bouwens, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">940-949</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">Ductular metaplastic cells are obsd. during pancreas injury.  Growth control by gastrin and expression of gastrin/cholecystokinin (CCK) B receptors were evaluated in these cells.  Acinoductal transdifferentiation was induced in vitro by culturing of acinar cells, and ductular metaplasia was obtained in vivo by ligation of the pancreatic ducts.  Mitogenic effects of gastrin I on ductal complexes in vivo and of tetragastrin, pentagastrin, and gastrin I and II, with or without the CCK-B receptor antagonist L-365,260, on duct-like cells in vitro were analyzed by 5-bromo-2'-deoxyuridine labeling.  Immunocytochem., Western blotting, and reverse-transcription polymerase chain reaction were applied for detection of the CCK-B receptor.  Gastrin analogs induced a mitogenic stimulus in the duct-like cells in vitro and in ductal complexes in duct-ligated rat pancreas.  Immunocytochem. showed expression of CCK-B receptors in these models and in fetal but not normal adult exocrine pancreas.  Addnl., up-regulation of CCK-B receptors during ductular metaplasia was shown by Western blotting and reverse-transcription polymerase chain reaction.  Duct-like pancreatic epithelial cells in vitro and ductal complexes in vivo express gastrin/CCK-B receptors and proliferate in response to gastrin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrW-bFlbBO7rVg90H21EOLACvtfcHk0ljWIxJYYpdCKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVynu7w%253D&md5=c94d999957a6c37746f3fb73c26152d3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1053%2Fgast.2001.27998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fgast.2001.27998%26sid%3Dliteratum%253Aachs%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DLardon%26aufirst%3DJ.%26aulast%3DFlamez%26aufirst%3DD.%26aulast%3DSchuit%26aufirst%3DF.%26aulast%3DBouwens%26aufirst%3DL.%26atitle%3DMitogenic%2520Effect%2520of%2520Gastrin%2520and%2520Expression%2520of%2520Gastrin%2520Receptors%2520in%2520Duct-like%2520Cells%2520of%2520Rat%2520Pancreas%26jtitle%3DGastroenterology%26date%3D2001%26volume%3D121%26spage%3D940%26epage%3D949%26doi%3D10.1053%2Fgast.2001.27998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rooman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwens, L.</span></span> <span> </span><span class="NLM_article-title">Gastrin Stimulates β-Cell Neogenesis and Increases Islet Mass from Transdifferentiated but not from Normal Exocrine Pancreas Tissue</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">686</span>, <span class="refDoi"> DOI: 10.2337/diabetes.51.3.686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdiabetes.51.3.686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=11872667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFSgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=686&author=I.+Roomanauthor=J.+Lardonauthor=L.+Bouwens&title=Gastrin+Stimulates+%CE%B2-Cell+Neogenesis+and+Increases+Islet+Mass+from+Transdifferentiated+but+not+from+Normal+Exocrine+Pancreas+Tissue&doi=10.2337%2Fdiabetes.51.3.686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue</span></div><div class="casAuthors">Rooman, Ilse; Lardon, Jessy; Bouwens, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">686-690</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">It is still unclear which factors regulate pancreatic regeneration and β-cell neogenesis and which precursor cells are involved.  We evaluated the role of i.v. infused gastrin in regenerating pancreas of duct-ligated rats.  The ligation of exocrine ducts draining the splenic half of the pancreas resulted in acinoductal transdifferentiation within the ligated part but not in the unligated part.  We found that infusion of gastrin from day 7 to 10 post ligation resulted in a doubling of the β-cell mass in the ligated part as measured by morphometry.  This increase in insulin-expressing cells was not assocd. with increased proliferation, hypertrophy, or reduced cell death of the β-cells.  Furthermore, we found an increased percentage of single, extra-insular β-cells and small β-cell clusters induced by gastrin infusion.  These changes occurred only in the ligated part of the pancreas, where transdifferentiation of the exocrine acinar cells to duct-like cells (metaplasia) had occurred, and was not found in the normal unaffected pancreatic tissue.  In conclusion, we demonstrate that administration of gastrin stimulates β-cell neogenesis and expansion of the β-cell mass from transdifferentiated exocrine pancreas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9YFF3rq5EhbVg90H21EOLACvtfcHk0lhOmh3Txk7GBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFSgsLw%253D&md5=4ab83aac3c48405cec9272d8180f8076</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.51.3.686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.51.3.686%26sid%3Dliteratum%253Aachs%26aulast%3DRooman%26aufirst%3DI.%26aulast%3DLardon%26aufirst%3DJ.%26aulast%3DBouwens%26aufirst%3DL.%26atitle%3DGastrin%2520Stimulates%2520%25CE%25B2-Cell%2520Neogenesis%2520and%2520Increases%2520Islet%2520Mass%2520from%2520Transdifferentiated%2520but%2520not%2520from%2520Normal%2520Exocrine%2520Pancreas%2520Tissue%26jtitle%3DDiabetes%26date%3D2002%26volume%3D51%26spage%3D686%26doi%3D10.2337%2Fdiabetes.51.3.686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, A.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Epidermal Growth Factor and Gastrin Increases β-Cell Mass and Reverses Hyperglycemia in Diabetic NOD Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2596</span>, <span class="refDoi"> DOI: 10.2337/diabetes.54.9.2596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdiabetes.54.9.2596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=16123347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVSjs7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2596&author=W.+L.+Suarez-Pinzonauthor=Y.+Yanauthor=R.+Powerauthor=S.+J.+Brandauthor=A.+Rabinovitch&title=Combination+Therapy+with+Epidermal+Growth+Factor+and+Gastrin+Increases+%CE%B2-Cell+Mass+and+Reverses+Hyperglycemia+in+Diabetic+NOD+Mice&doi=10.2337%2Fdiabetes.54.9.2596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice</span></div><div class="casAuthors">Suarez-Pinzon, Wilma L.; Yan, Yanhua; Power, Robert; Brand, Stephen J.; Rabinovitch, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2596-2601</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Combination therapy with EGF and gastrin induces β-cell regeneration in rodents with chem. induced diabetes.  The authors investigated whether EGF plus gastrin could correct hyperglycemia in NOD mice with autoimmune diabetes.  Combined treatment with EGF (1 μg/kg) and gastrin (3 μg/kg) for 2 wk restored normoglycemia after diabetes onset in NOD mice, whereas EGF or gastrin alone did not.  Fasting blood glucose remained normal (3.5-6.5 mM) or mildly elevated (<11 mM) in five of six mice (83%) for 10 wk after EGF plus gastrin treatment was stopped, whereas all mice treated with vehicle or EGF or gastrin alone became severely hyperglycemic (12-35 mM).  Pancreatic β-cell mass was increased 3-fold and insulin content was increased 8-fold in mice treated with EGF plus gastrin compared with pretreatment values.  The correction of hyperglycemia correlated significantly with increases in pancreatic β-cell mass and insulin content.  In addn., splenic cells from mice treated with EGF plus gastrin delayed diabetes induction by adoptive transfer of diabetogenic cells into immunodeficient NOD-scid mice, suggesting the induction of immunoregulatory cells in NOD mice treated with EGF plus gastrin.  The authors conclude that a short course of combined EGF and gastrin therapy increases pancreatic β-cell mass and reverses hyperglycemia in acutely diabetic NOD mice; the impact of this combined therapy may result from the effects of EGF and gastrin on β-cells, immune cells, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSGbmXRCCLbVg90H21EOLACvtfcHk0lhOmh3Txk7GBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVSjs7rP&md5=2de90714d981beba91440c9d07a4f6c9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.9.2596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.9.2596%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPower%26aufirst%3DR.%26aulast%3DBrand%26aufirst%3DS.%2BJ.%26aulast%3DRabinovitch%26aufirst%3DA.%26atitle%3DCombination%2520Therapy%2520with%2520Epidermal%2520Growth%2520Factor%2520and%2520Gastrin%2520Increases%2520%25CE%25B2-Cell%2520Mass%2520and%2520Reverses%2520Hyperglycemia%2520in%2520Diabetic%2520NOD%2520Mice%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2596%26doi%3D10.2337%2Fdiabetes.54.9.2596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tamaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamori, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watada, H.</span></span> <span> </span><span class="NLM_article-title">Combination Treatment of db/db Mice with Exendin-4 and Gastrin Preserves β-cell Mass by Stimulating β-cell Growth and Differentiation</span>. <i>J. Diabetes Invest.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1111/j.2040-1124.2010.00044.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fj.2040-1124.2010.00044.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=24843429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVantr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=172-183&author=M.+Tamakiauthor=Y.+Fujitaniauthor=T.+Uchidaauthor=T.+Hiroseauthor=R.+Kawamoriauthor=H.+Watada&title=Combination+Treatment+of+db%2Fdb+Mice+with+Exendin-4+and+Gastrin+Preserves+%CE%B2-cell+Mass+by+Stimulating+%CE%B2-cell+Growth+and+Differentiation&doi=10.1111%2Fj.2040-1124.2010.00044.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation</span></div><div class="casAuthors">Tamaki, Motoyuki; Fujitani, Yoshio; Uchida, Toyoyoshi; Hirose, Takahisa; Kawamori, Ryuzo; Watada, Hirotaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes Investigation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">172-183</span>CODEN:
                <span class="NLM_cas:coden">JDIOAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-1124</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim/Introduction: Preservation of β-cell mass is crucial for maintaining long-term glucose homeostasis.  Therapies based on incretin and its mimetics are expected to achieve this goal through various biol. functions, particularly the restoration of β-cell mass.  Here we tested the effects of gastrin and exendin-4 in type 2 diabetic animals.  Materials and Methods: The effects of exendin-4 and gastrin on β-cell function and mass were examd. in 8-wk-old db/db mice.  INS-1 beta cells and AR42J cells were used to det. the mol. mechanism underlying the effects of the two agents.  Immunohistochem., western blotting and RT-PCR assays were used to assess the biol. effects of the two agents.  Results: Two weeks of combination administration of exendin-4 plus gastrin resulted in a significant improvement of glucose tolerance assocd. with a marked preservation of β-cell mass in db/db mice.  Immunohistochem. anal. showed that such treatment resulted in the appearance of numerous irregularly-shaped small islets and single insulin-pos. cells.  While gastrin had little biol. effect on INS-1 β-cells consistent with low expression of its intrinsic receptor on these cells, it caused differentiation of AR42J cells into insulin-producing cells.  Co-stimulation with exendin-4 significantly enhanced gastrin-induced endocrine differentiation of AR42J precursor cells.  These findings were further supported by enhanced expression of key genes involved in β-cell differentiation and maturation, such as neurogenin3 (Ngn3) and MafA.  Conclusions: These results suggest that combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAF4Lr3lVYILVg90H21EOLACvtfcHk0lhOmh3Txk7GBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVantr%252FE&md5=452d0539c83187c02cac84ea6af326bd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.2040-1124.2010.00044.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2040-1124.2010.00044.x%26sid%3Dliteratum%253Aachs%26aulast%3DTamaki%26aufirst%3DM.%26aulast%3DFujitani%26aufirst%3DY.%26aulast%3DUchida%26aufirst%3DT.%26aulast%3DHirose%26aufirst%3DT.%26aulast%3DKawamori%26aufirst%3DR.%26aulast%3DWatada%26aufirst%3DH.%26atitle%3DCombination%2520Treatment%2520of%2520db%252Fdb%2520Mice%2520with%2520Exendin-4%2520and%2520Gastrin%2520Preserves%2520%25CE%25B2-cell%2520Mass%2520by%2520Stimulating%2520%25CE%25B2-cell%2520Growth%2520and%2520Differentiation%26jtitle%3DJ.%2520Diabetes%2520Invest.%26date%3D2010%26volume%3D1%26spage%3D172%26epage%3D183%26doi%3D10.1111%2Fj.2040-1124.2010.00044.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Power, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserfall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, A.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3281</span>, <span class="refDoi"> DOI: 10.2337/db08-0688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.2337%2Fdb08-0688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=18835930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsleitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=3281&author=W.+L.+Suarez-Pinzonauthor=R.+F.+Powerauthor=Y.+Yanauthor=C.+Wasserfallauthor=M.+Atkinsonauthor=A.+Rabinovitch&title=Combination+Therapy+with+Glucagon-Like+Peptide-1+and+Gastrin+Restores+Normoglycemia+in+Diabetic+NOD+Mice&doi=10.2337%2Fdb08-0688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice</span></div><div class="casAuthors">Suarez-Pinzon, Wilma L.; Power, Robert F.; Yan, Yanhua; Wasserfall, Clive; Atkinson, Mark; Rabinovitch, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3281-3288</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Objective-Glucagon-like peptide-1 (GLP-1) and gastrin promote pancreatic β-cell function, survival, and growth.  Here, we investigated whether GLP-1 and gastrin can restore the β-cell mass and reverse hyperglycemia in NOD mice with autoimmune diabetes.  Research Design and Methods-Acutely diabetic NOD mice were treated with GLP-1 and gastrin, sep. or together, twice daily for 3 wk.  Blood glucose was measured weekly and for a further 5 wk after treatments, after which pancreatic insulin content and β-cell mass, proliferation, neogenesis, and apoptosis were measured.  Insulin autoantibodies were measured, and adoptive transfer of diabetes and syngeneic islet transplant studies were done to evaluate the effects of GLP-1 and gastrin treatment on autoimmunity.  Results-Combination therapy with GLP-1 and gastrin, but not with GLP-1 or gastrin alone, restored normoglycemia in diabetic NOD mice.  The GLP-1 and gastrin combination increased pancreatic insulin content, β-cell mass, and insulin-pos. cells in pancreatic ducts, and β-cell apoptosis was decreased.  Insulin autoantibodies were reduced in GLP-1- and gastrin-treated NOD mice, and splenocytes from these mice delayed adoptive transfer of diabetes in NOD-scid mice.  Syngeneic islet grafts in GLP-1- and gastrin-treated NOD mice were infiltrated by leukocytes with a shift in cytokine expression from interferon-γ to transforming growth factor-β1, and β-cells were protected from apoptosis.  Conclusions-Combination therapy with GLP-1 and gastrin restores normoglycemia in diabetic NOD mice by increasing the pancreatic β-cell mass and downregulating the autoimmune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8SaURFivKh7Vg90H21EOLACvtfcHk0ljikVPzIdZC7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsleitr0%253D&md5=98167648a694082055f9abf8f2836b3c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2337%2Fdb08-0688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb08-0688%26sid%3Dliteratum%253Aachs%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DPower%26aufirst%3DR.%2BF.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DWasserfall%26aufirst%3DC.%26aulast%3DAtkinson%26aufirst%3DM.%26aulast%3DRabinovitch%26aufirst%3DA.%26atitle%3DCombination%2520Therapy%2520with%2520Glucagon-Like%2520Peptide-1%2520and%2520Gastrin%2520Restores%2520Normoglycemia%2520in%2520Diabetic%2520NOD%2520Mice%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26spage%3D3281%26doi%3D10.2337%2Fdb08-0688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolborg, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O̷sterlund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolsted, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brorson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelsing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neerup, T. S. R.</span></span> <span> </span><span class="NLM_article-title">The Novel GLP-1-gastrin Dual Agonist, ZP3022, Increases β-cell Mass and Prevents Diabetes in db/db Mice</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1111/j.1463-1326.2012.01676.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fj.1463-1326.2012.01676.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=22862961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=62-71&author=K.+Fosgerauauthor=L.+Jessenauthor=J.+L.+Tolborgauthor=T.+O%CC%B7sterlundauthor=K.+S.+Larsenauthor=K.+Rolstedauthor=M.+Brorsonauthor=J.+Jelsingauthor=T.+S.+R.+Neerup&title=The+Novel+GLP-1-gastrin+Dual+Agonist%2C+ZP3022%2C+Increases+%CE%B2-cell+Mass+and+Prevents+Diabetes+in+db%2Fdb+Mice&doi=10.1111%2Fj.1463-1326.2012.01676.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice</span></div><div class="casAuthors">Fosgerau, K.; Jessen, L.; Lind Tolborg, J.; Osterlund, T.; Schaeffer Larsen, K.; Rolsted, K.; Brorson, M.; Jelsing, J.; Skovlund Ryge Neerup, T.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-71</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : Diabetes is characterized by β-cell deficiency, and therefore restoration of β-cell function has been suggested as a potential therapy.  We hypothesized that a novel glucagon-like peptide-1 (GLP-1)-gastrin dual agonist, ZP3022, improves glycemic control via improvement of β-cell status in db/db mice..  Methods : Diabetic mice were studied following short- or long-term treatment with either the GLP-1-gastrin dual agonist or the com. available GLP-1 agonists (exendin-4 and liraglutide).  The effects on glycemic control were addressed by repeated glucose tolerance tests and/or measurements of HbA1c levels, and pancreatic islet and β-cell masses were detd. by stereol.Results : ZP3022 and the pure GLP-1 agonists improved glycemic control after both short- and long-term treatment compared with vehicle.  Interestingly, the effect was sustainable only in mice treated with ZP3022.  Stereol. data displayed a dose-dependent increase of β-cell mass (p < 0.05) following treatment with ZP3022, whereas no significant effect of liraglutide was obsd. (β-cell mass: vehicle 3.7 ± 0.2 mg; liraglutide (30 nmol/kg) 3.4 ± 0.5 mg; ZP3022 (30 nmol/kg) 4.3 ± 0.4 mg and ZP3022 (100 nmol/kg) 5.2 ± 0.4 mg).Conclusion : The novel GLP-1-gastrin dual agonist, ZP3022, improved glycemic control in db/db mice, and pancreatic islet and β-cell mass increased significantly following treatment with ZP3022 compared with vehicle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8ta9zMqxjlbVg90H21EOLACvtfcHk0ljikVPzIdZC7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCksLrE&md5=cc432fa85f778937f2c2113f189b8aa4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1463-1326.2012.01676.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1463-1326.2012.01676.x%26sid%3Dliteratum%253Aachs%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DL.%26aulast%3DTolborg%26aufirst%3DJ.%2BL.%26aulast%3DO%25CC%25B7sterlund%26aufirst%3DT.%26aulast%3DLarsen%26aufirst%3DK.%2BS.%26aulast%3DRolsted%26aufirst%3DK.%26aulast%3DBrorson%26aufirst%3DM.%26aulast%3DJelsing%26aufirst%3DJ.%26aulast%3DNeerup%26aufirst%3DT.%2BS.%2BR.%26atitle%3DThe%2520Novel%2520GLP-1-gastrin%2520Dual%2520Agonist%252C%2520ZP3022%252C%2520Increases%2520%25CE%25B2-cell%2520Mass%2520and%2520Prevents%2520Diabetes%2520in%2520db%252Fdb%2520Mice%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2013%26volume%3D15%26spage%3D62%26epage%3D71%26doi%3D10.1111%2Fj.1463-1326.2012.01676.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Xenopus GLP-1-inspired Discovery of Novel GLP-1 Receptor Agonists as Long-acting Hypoglycemic and Insulinotropic Agents with Significant Therapeutic Potential</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.06.132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.bcp.2017.06.132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28668697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=155-167&author=J.+Hanauthor=X.+Chenauthor=Y.+Wangauthor=Y.+Feiauthor=F.+Zhouauthor=Y.+Zhangauthor=L.+Liuauthor=P.+Siauthor=J.+Fu&title=Xenopus+GLP-1-inspired+Discovery+of+Novel+GLP-1+Receptor+Agonists+as+Long-acting+Hypoglycemic+and+Insulinotropic+Agents+with+Significant+Therapeutic+Potential&doi=10.1016%2Fj.bcp.2017.06.132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential</span></div><div class="casAuthors">Han, Jing; Chen, Xinyu; Wang, Yiyun; Fei, Yingying; Zhou, Feng; Zhang, Ying; Liu, Lin; Si, Pengbin; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-167</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We here report the discovery and therapeutic efficacy of a novel series of glucagon-like peptide-1 (GLP-1) receptor agonists derived from Xenopus GLP-1.  First, five amino acid-mutated Xenopus GLP-1s were synthesized, and xGLP-3 with the best acute and long-acting hypoglycemic activity was selected for further modification.  Next, PEGylation of xGLP-3 was performed at specific sites, which were detd. using cysteine mutagenesis scanning.  Twelve PEGylated conjugates tethered with Mal-PEGs of 1, 2, and 5 kDa were synthesized.  Conjugates 7b and 7c, which exhibited comparable hypoglycemic and insulinotropic effects to Gly8-GLP-1, were selected for in-depth evaluation.  It was found that 7b and 7c exhibited prolonged in vivo half-life and improved pharmacokinetic behaviors.  The long-term hypoglycemic effects of 7b and 7c were further confirmed by pre-OGTT and multiple OGTT.  Importantly, long-term administration of 7b or 7c in db/db mice achieved beneficial effects on body wt. loss, food intake and HbA1c redn., and glucose tolerance normalization.  These preclin. studies indicate the promising role of 7b and 7c as long-acting type 2 diabetes therapeutics.  In addn., our research demonstrated the feasibility of developing novel antidiabetic agents based on Xenopus GLP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocX8k-np5op7Vg90H21EOLACvtfcHk0ljSsyqbMBUCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSmt73N&md5=2ec89287e59d29972ad43e30ab3c6c0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.06.132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.06.132%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSi%26aufirst%3DP.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DXenopus%2520GLP-1-inspired%2520Discovery%2520of%2520Novel%2520GLP-1%2520Receptor%2520Agonists%2520as%2520Long-acting%2520Hypoglycemic%2520and%2520Insulinotropic%2520Agents%2520with%2520Significant%2520Therapeutic%2520Potential%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D142%26spage%3D155%26epage%3D167%26doi%3D10.1016%2Fj.bcp.2017.06.132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Xenopus-derived Glucagon-like Peptide-1 and Polyethylene-glycosylated Glucagon-like Peptide-1 Receptor Agonists: Long-acting Hypoglycaemic and Insulinotropic Activities with Potential Therapeutic Utilities</span>. <i>Brit. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1111/bph.14107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fbph.14107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29171021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=544-557&author=J.+Hanauthor=Y.+Feiauthor=F.+Zhouauthor=X.+Chenauthor=Y.+Zhangauthor=L.+Liuauthor=J.+Fu&title=Xenopus-derived+Glucagon-like+Peptide-1+and+Polyethylene-glycosylated+Glucagon-like+Peptide-1+Receptor+Agonists%3A+Long-acting+Hypoglycaemic+and+Insulinotropic+Activities+with+Potential+Therapeutic+Utilities&doi=10.1111%2Fbph.14107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities</span></div><div class="casAuthors">Han, Jing; Fei, Yingying; Zhou, Feng; Chen, Xinyu; Zhang, Ying; Liu, Lin; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Incretin-based therapies based on glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments of type 2 diabetes.  Abundant research has focused on the development of long-acting GLP-1 receptor agonists.  However, all GLP-1 receptor agonists in clin. use or development are based on human or Gila GLP-1.  We have identified a potent GLP-1 receptor agonist, xGLP-1B, based on Xenopus GLP-1.  Exptl. Approach : To further modify the structure of xGLP-1B, alanine scanning was performed to study the structure -activity relationship of xGLP-1B.  Two strategies were then employed to improve bioactivity.  First, the C-terminal tail of lixisenatide was appended to cysteine-altered xGLP-1B analogs.  Second, polyethylene glycol (PEG) chains with different mol. wts. were conjugated with the peptides, giving a series of PEGylated conjugates.  Comprehensive bioactivity studies of these conjugates were performed in vitro and in vivo.  Results : From the in vitro receptor activation potency and in vivo acute hypoglycemic activities of conjugates 25 -36, 33 was identified as the best candidate for further biol. assessments.  Conjugate 33 exhibited prominent hypoglycemic and insulinotropic activities, as well as improved pharmacokinetic profiles in vivo.  The prolonged antidiabetic duration of 33 was further confirmed by pre-oral glucose tolerance tests (OGTT) and multiple OGTT.  Furthermore, chronic treatment of db/db mice with 33 ameliorated non-fasting blood glucose and insulin levels, reduced HbA1c values and normalized their impaired glucose tolerance.  Importantly, no in vivo toxicity was obsd. in mice treated with 33.  Conclusions and Implications : Peptide 33 is a promising long-acting type 2 diabetes therapeutic deserving further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoendOb7bXB37Vg90H21EOLACvtfcHk0ljSsyqbMBUCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFyrsw%253D%253D&md5=71a3d53e9b008b866e938db15871485a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fbph.14107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14107%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DXenopus-derived%2520Glucagon-like%2520Peptide-1%2520and%2520Polyethylene-glycosylated%2520Glucagon-like%2520Peptide-1%2520Receptor%2520Agonists%253A%2520Long-acting%2520Hypoglycaemic%2520and%2520Insulinotropic%2520Activities%2520with%2520Potential%2520Therapeutic%2520Utilities%26jtitle%3DBrit.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D544%26epage%3D557%26doi%3D10.1111%2Fbph.14107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">The Chronic Administration of Two Novel Long-acting Xenopus Glucagon-like Peptide-1 Analogs xGLP159 and xGLP296 Potently Improved Systemic Metabolism and Glycemic Control in Rodent Models</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">7113</span>– <span class="NLM_lpage">7125</span>, <span class="refDoi"> DOI: 10.1096/fj.201801479R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1096%2Ffj.201801479R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30860869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2jsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=7113-7125&author=J.+Hanauthor=T.+Mengauthor=X.+Chenauthor=Y.+Hanauthor=J.+Fuauthor=F.+Zhouauthor=Y.+Feiauthor=C.+Li&title=The+Chronic+Administration+of+Two+Novel+Long-acting+Xenopus+Glucagon-like+Peptide-1+Analogs+xGLP159+and+xGLP296+Potently+Improved+Systemic+Metabolism+and+Glycemic+Control+in+Rodent+Models&doi=10.1096%2Ffj.201801479R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models</span></div><div class="casAuthors">Han, Jing; Meng, Tingting; Chen, Xinyu; Han, Yue; Fu, Junjie; Zhou, Feng; Fei, Yingying; Li, Chenglin</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">7113-7125</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">We here reported 2 novel Xenopus glucagon-like peptide-1 (xGLP-1) analogs, xGLP159 and xGLP296, whose therapeutic effects on metabolic efficacy and glycemic control were evaluated in rodents.  The in vitro potency of xGLP159 and xGLP296 were investigated on human embryonic kidney 293 cells.  The acute glucose-lowering and insulinotropic effects of xGLP159 and xGLP296 were assessed in the Institute of Cancer Research, Kunming, and diabetic (db/db) mice.  The pharmacokinetic profiles of xGLP159 and xGLP296 were confirmed on Sprague-Dawley (SD) rats and their long-acting hypoglycemic and anorectic effects were evaluated in db/db mice.  Chronic treatment effects of xGLP159 and xGLP296 were evaluated in diet-induced obese (DIO) mice and db/db mice.  The results showed that xGLP159 and xGLP296 exhibited comparable receptor activation potency, hypoglycemic effect, and insulinotropic activity to liraglutide.  The enhanced half-lives of xGLP159 and xGLP296 in SD rats (5.1 and 5.8 h, resp.) resulted in prolonged anti-db/db durations in db/db mice.  Three weeks' administration of xGLP159 and xGLP296 normalized glucose tolerance and adiposity in DIO mice.  Furthermore, 11-wk treatment of xGLP159 and xGLP296 cor. hyperglycemia and improved pancreatic function in db/db mice.  These preclin. studies supported xGLP159 and xGLP296 as promising candidates for the treatment of metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp30OyVXfjNrVg90H21EOLACvtfcHk0ljSsyqbMBUCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2jsLnO&md5=283c620e07ddf5b913a6916dbefd6fa4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801479R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801479R%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DThe%2520Chronic%2520Administration%2520of%2520Two%2520Novel%2520Long-acting%2520Xenopus%2520Glucagon-like%2520Peptide-1%2520Analogs%2520xGLP159%2520and%2520xGLP296%2520Potently%2520Improved%2520Systemic%2520Metabolism%2520and%2520Glycemic%2520Control%2520in%2520Rodent%2520Models%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D7113%26epage%3D7125%26doi%3D10.1096%2Ffj.201801479R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3954</span>– <span class="NLM_lpage">3967</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00632</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00632" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFCltr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3954-3967&author=J.+Hanauthor=Y.+Feiauthor=F.+Zhouauthor=X.+Chenauthor=W.+Zhengauthor=J.+Fu&title=Micellar+Nanomedicine+of+Novel+Fatty+Acid+Modified+Xenopus+Glucagon-like+Peptide-1%3A+Improved+Physicochemical+Characteristics+and+Therapeutic+Utilities+for+Type+2+Diabetes&doi=10.1021%2Facs.molpharmaceut.7b00632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes</span></div><div class="casAuthors">Han, Jing; Fei, Yingying; Zhou, Feng; Chen, Xinyu; Zheng, Weiwei; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3954-3967</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop novel long-acting antidiabetics with improved therapeutic efficacy, two glucagon-like peptide-1 (GLP-1) analogs were constructed through the hybridization of key sequences of GLP-1, xenGLP-1B, exendin-4, and lixisenatide.  Hybrids 1 and 2 demonstrated enhanced in vitro and in vivo biol. activities and were further site-specifically lipidized at lysine residues to achieve prolonged duration of action and less frequent administration.  Compared with their native peptides, compds. 3-6 showed similar in vitro activities but impaired in vivo acute hypoglycemic potencies due to decreased aq. soly. and retarded absorption in vivo.  To circumvent these issues, compd. 3 (xenoglutide) was selected to be self-assocd. with sterically stabilized micelles (SSM).  The α-helix and soly. of xenoglutide were significantly improved after self-assocd. with SSM.  Notably, the improved physicochem. characteristics of xenoglutide-SSM led to revival of acute hypoglycemic ability without affecting its long-term glucose-lowering activity.  Most importantly, preclin. studies demonstrated improved therapeutic effects and safety of xenoglutide-SSM in diabetic db/db mice.  Our work suggests the SSM incorporation as an effective approach to improve the pharmacokinetic and biol. properties of hydrophobicity peptide drugs.  Furthermore, our data clearly indicate xenoglutide-SSM as a novel nanomedicine for the treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0a7z0NNT_NbVg90H21EOLACvtfcHk0lglHrq_zNs-fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFCltr%252FF&md5=3e968d16939bdeee1437b9e75cb9ee89</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00632%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DMicellar%2520Nanomedicine%2520of%2520Novel%2520Fatty%2520Acid%2520Modified%2520Xenopus%2520Glucagon-like%2520Peptide-1%253A%2520Improved%2520Physicochemical%2520Characteristics%2520and%2520Therapeutic%2520Utilities%2520for%2520Type%25202%2520Diabetes%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26spage%3D3954%26epage%3D3967%26doi%3D10.1021%2Facs.molpharmaceut.7b00632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of PEGylated Xenopus Glucagon-like Peptide-1 Derivatives as Long-acting Hypoglycemic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejmech.2017.03.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28342399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2017&pages=81-89&author=J.+Hanauthor=Y.+Wangauthor=Q.+Mengauthor=G.+Liauthor=F.+Huangauthor=S.+Wuauthor=Y.+Feiauthor=F.+Zhouauthor=J.+Fu&title=Design%2C+Synthesis+and+Biological+Evaluation+of+PEGylated+Xenopus+Glucagon-like+Peptide-1+Derivatives+as+Long-acting+Hypoglycemic+Agents&doi=10.1016%2Fj.ejmech.2017.03.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents</span></div><div class="casAuthors">Han, Jing; Wang, Yiyun; Meng, Qinghua; Li, Guangchao; Huang, Fangmin; Wu, Su; Fei, Yingying; Zhou, Feng; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">81-89</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To develop novel long-acting GLP-1 derivs., a peptide hybrid (1a, xGLP-1B) from human GLP-1 and Xenopus GLP-1 discovered in the authors' previous research was selected as the lead compd.  Exendin-4 inspired modification resulted in peptide 1b (ExGLP) with enhanced glucose-lowering activity.  Cysteine mutated 1b derivs. with reserved bioactivity were further site-specifically connected with mPEG2000-MAL to provide conjugates 3a-h, among which 3d (mPEG20Q0-MAL-Cys-ExG LP-04) and 3e (mPEG2000-MAL-Cys-ExGLP-07) were found to have significantly improved hypoglycemic activity and insulinotropic ability than GLP-1.  The hypoglycemic durations of 3d and 3e were remarkably prolonged to ∼20 h in type 2 diabetic db/db mice, compared with the 5.3 h of exendin-4 in the same test.  Finally, chronic in vivo studies revealed that a once-daily treatment of 3d or 3e for five weeks resulted in recovered glucose-controlling ability of type 2 diabetic db/db mice, along with other benefits, such as reduced body wt. gains, food intake amts. and HbA1c values.  Collectively, the authors' results suggest 3d and 3e as potential long-acting glucose-lowering agents for treating type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-GCoodrxBLVg90H21EOLACvtfcHk0lhQpqaWsvEYtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWksbk%253D&md5=7e8b746274596b99d49fe87a6233abc2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520PEGylated%2520Xenopus%2520Glucagon-like%2520Peptide-1%2520Derivatives%2520as%2520Long-acting%2520Hypoglycemic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D132%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.ejmech.2017.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Design of Potent and Proteolytically Stable Oxyntomodulin Analogs</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00787</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00787" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVGmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=324-328&author=A.+Muppidiauthor=H.+Zouauthor=P.+Y.+Yangauthor=E.+Chaoauthor=L.+Sherwoodauthor=V.+Nunezauthor=A.+K.+Woodsauthor=P.+G.+Schultzauthor=Q.+Linauthor=W.+Shen&title=Design+of+Potent+and+Proteolytically+Stable+Oxyntomodulin+Analogs&doi=10.1021%2Facschembio.5b00787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Potent and Proteolytically Stable Oxyntomodulin Analogs</span></div><div class="casAuthors">Muppidi, Avinash; Zou, Huafei; Yang, Peng Yu; Chao, Elizabeth; Sherwood, Lance; Nunez, Vanessa; Woods, Ashley K.; Schultz, Peter G.; Lin, Qing; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-328</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incretin-based peptides are effective therapeutics for treating type 2 diabetes mellitus (T2DM).  Oxyntomodulin (OXM), a dual agonist of GLP-1R and GCGR, has shown superior wt. loss and glucose lowering effects, compared to single GLP-1R agonists.  To overcome the short half-life and rapid renal clearance of OXM, which limit its therapeutic potential, both lipid and PEG modified OXM analogs have been reported.  However, these approaches often result in reduced potency or PEG-assocd. toxicity.  Herein, we report a new class of cross-linked OXM analogs that show increased plasma stability and higher potency in activating both GLP-1R and GCGR.  Moreover, the extended in vivo half-life results in superior antihyperglycemic activity in mice compared to the wild-type OXM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2WYza_-0k2bVg90H21EOLACvtfcHk0lhQpqaWsvEYtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVGmsro%253D&md5=8911f988a9db36935cda2a2bd93f19ed</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00787%26sid%3Dliteratum%253Aachs%26aulast%3DMuppidi%26aufirst%3DA.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%2BY.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DNunez%26aufirst%3DV.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DDesign%2520of%2520Potent%2520and%2520Proteolytically%2520Stable%2520Oxyntomodulin%2520Analogs%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D324%26epage%3D328%26doi%3D10.1021%2Facschembio.5b00787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghartey-Tagoe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welzel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Engineering a Long-acting, Potent GLP-1 Analog for Microstructure-based Transdermal Delivery</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4140</span>– <span class="NLM_lpage">4145</span>, <span class="refDoi"> DOI: 10.1073/pnas.1601653113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1073%2Fpnas.1601653113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=27035989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4140-4145&author=P.-Y.+Yangauthor=H.+Zouauthor=E.+Chaoauthor=L.+Sherwoodauthor=V.+Nunezauthor=M.+Keeneyauthor=E.+Ghartey-Tagoeauthor=Z.+Dingauthor=H.+Quirinoauthor=X.+Luoauthor=G.+Welzelauthor=G.+Chenauthor=P.+Singhauthor=A.+K.+Woodsauthor=P.+G.+Schultzauthor=W.+Shen&title=Engineering+a+Long-acting%2C+Potent+GLP-1+Analog+for+Microstructure-based+Transdermal+Delivery&doi=10.1073%2Fpnas.1601653113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery</span></div><div class="casAuthors">Yang, Peng-Yu; Zou, Huafei; Chao, Elizabeth; Sherwood, Lance; Nunez, Vanessa; Keeney, Michael; Ghartey-Tagoe, Esi; Ding, Zhongli; Quirino, Herlinda; Luo, Xiaozhou; Welzel, Gus; Chen, Guohua; Singh, Parminder; Woods, Ashley K.; Schultz, Peter G.; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4140-4145</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Antidiabetic treatments aiming to reduce body wt. are currently gaining increased interest.  Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice daily via s.c. injection, improves glycemic control, often with assocd. wt. redn.  To further improve the therapeutic efficacy of exendin-4, the authors have developed a novel peptide engineering strategy that incorporates a serum protein binding motif onto a covalent side-chain staple and applied to the peptide to enhance its helicity and, as a consequence, its potency and serum half-life.  The authors demonstrated that one of the resulting peptides, E6 (comprising exendin-4 derived sequence HGEGTFTSDLSKQMEECAVRLFICWLKNGGPSSGAPPPS with PEG-based linker), has significantly improved half-life and glucose tolerance in an oral glucose tolerance test in rodents.  Chronic treatment of E6 significantly decreased body wt. and fasting blood glucose, improved lipid metab., and also reduced hepatic steatosis in diet-induced obese mice.  Moreover, the high potency of E6 allowed the authors to administer this peptide using a dissolvable microstructure-based transdermal delivery system.  Pharmacokinetic and pharmacodynamic studies in guinea pigs showed that a single 5-min application of a microstructure system contg. E6 significantly improved glucose tolerance for 96 h.  This delivery strategy may offer an effective and patient-friendly alternative to currently marketed GLP-1 injectables and can likely be extended to other peptide hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom26i7k0QKvbVg90H21EOLACvtfcHk0ljDClH4z2jXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisro%253D&md5=2e0bba2aa9238f4407199593063a2aa9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1601653113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1601653113%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.-Y.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DSherwood%26aufirst%3DL.%26aulast%3DNunez%26aufirst%3DV.%26aulast%3DKeeney%26aufirst%3DM.%26aulast%3DGhartey-Tagoe%26aufirst%3DE.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DQuirino%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWelzel%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DEngineering%2520a%2520Long-acting%252C%2520Potent%2520GLP-1%2520Analog%2520for%2520Microstructure-based%2520Transdermal%2520Delivery%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D4140%26epage%3D4145%26doi%3D10.1073%2Fpnas.1601653113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muppidi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span> <span> </span><span class="NLM_article-title">Stapled, Long-acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3218</span>– <span class="NLM_lpage">3223</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3218-3223&author=P.-Y.+Yangauthor=H.+Zouauthor=C.+Leeauthor=A.+Muppidiauthor=E.+Chaoauthor=Q.+Fuauthor=X.+Luoauthor=D.+Wangauthor=P.+G.+Schultzauthor=W.+Shen&title=Stapled%2C+Long-acting+Glucagon-like+Peptide+2+Analog+with+Efficacy+in+Dextran+Sodium+Sulfate+Induced+Mouse+Colitis+Models&doi=10.1021%2Facs.jmedchem.7b00768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models</span></div><div class="casAuthors">Yang, Peng-Yu; Zou, Huafei; Lee, Candy; Muppidi, Avinash; Chao, Elizabeth; Fu, Qiangwei; Luo, Xiaozhou; Wang, Danling; Schultz, Peter G.; Shen, Weijun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3218-3223</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucagon-like peptide 2 (GLP-2) is a hormone that has been shown to stimulate intestinal growth and attenuate intestinal inflammation.  Despite being efficacious in a variety of animal models of disease, its therapeutic potential is hampered by the short half-life in vivo.  We now describe a highly potent, stapled long-acting GLP-2 analog, Peptide 10, that has a more than 10-fold longer half-life than teduglutide and improved intestinotrophic and anti-inflammatory effects in mouse models of DSS-induced colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQTlIM94DlXbVg90H21EOLACvtfcHk0ljDClH4z2jXmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhsrw%253D&md5=a6252986057ddfb933d13b4db8ac822b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00768%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DP.-Y.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMuppidi%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DE.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DShen%26aufirst%3DW.%26atitle%3DStapled%252C%2520Long-acting%2520Glucagon-like%2520Peptide%25202%2520Analog%2520with%2520Efficacy%2520in%2520Dextran%2520Sodium%2520Sulfate%2520Induced%2520Mouse%2520Colitis%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3218%26epage%3D3223%26doi%3D10.1021%2Facs.jmedchem.7b00768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiberg, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J. J.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl Peptidase IV Resistant Analogues of Glucagon-like Peptide-1 which Have Extended Metabolic Stability and Improved Biological Activity</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1007/s001250050903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1007%2Fs001250050903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=9541166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADyaK1cXhtlelu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=271-278&author=C.+F.+Deaconauthor=L.+B.+Knudsenauthor=K.+Madsenauthor=F.+C.+Wibergauthor=O.+Jacobsenauthor=J.+J.+Holst&title=Dipeptidyl+Peptidase+IV+Resistant+Analogues+of+Glucagon-like+Peptide-1+which+Have+Extended+Metabolic+Stability+and+Improved+Biological+Activity&doi=10.1007%2Fs001250050903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl peptidase IV resistant analogs of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity</span></div><div class="casAuthors">Deacon, C. F.; Knudsen, L. B.; Madsen, K.; Wiberg, F. C.; Jacobsen, O.; Holst, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-278</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Glucagon-like peptide 1 (GLP-1) has great potential in diabetes therapy due to its glucose-dependent stimulation of insulin secretion, but this is limited by its rapid degrdn., primarily by dipeptidyl peptidase IV.  Four analogs, N-terminally substituted with Thr, Gly, Ser, or α-aminoisobutyric acid (Aib), were synthesized and tested for metabolic stability.  All were more resistant to dipeptidyl peptidase IV in porcine blood plasma in vitro, ranging from a t1/2 of 159 min (Gly8 analog) to undetectable degrdn. after 6 h (Aib8 analog; t1/2 for GLP-1 (7-36) amide, 28 min).  During i. v. infusion in anesthetized swine, <50% of each analog remained undegraded compared to 22.7% for GLP-1 (7- 36) amide.  In vivo, analogs had longer N-terminal t1/2 (intact peptides: means, 3.3-3.9 min) than GLP-1 (7-36) amide (0.9 min), but these did not exceed the C-terminal t1/2 (intact plus metabolite: analogs, 3.5-4.4 min; GLP-1 (7-36) amide, 4.1 min).  Analogs were assessed for receptor binding using a cell line expressing the cloned receptor, and for ability to stimulate insulin or inhibit glucagon secretion from the isolated perfused porcine pancreas.  All bound to the receptor, but only the Aib8 and Gly8 analogs had similar affinities to GLP-1 (7-36) amide (IC50; Aib8=0.45, Gly8=2.8, GLP-1 (7-36) amide=0.78 nmol/L).  All analogs were active in the isolated pancreas, with the potency order reflecting receptor affinities (Aib8>Gly8>Ser8>Thr8).  N-terminal modification of GLP-1 confers resistance to dipeptidyl peptidase IV degrdn.  Such analogs are biol. active and have prolonged metabolic stability in vivo, which, if assocd. with greater potency and duration of action, may help to realize the potential of GLP-1 in diabetes therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTIpMWFcmVLVg90H21EOLACvtfcHk0limzPpkN4Kc7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtlelu7Y%253D&md5=11e697a17ec4b916589606323e52edc4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs001250050903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001250050903%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DWiberg%26aufirst%3DF.%2BC.%26aulast%3DJacobsen%26aufirst%3DO.%26aulast%3DHolst%26aufirst%3DJ.%2BJ.%26atitle%3DDipeptidyl%2520Peptidase%2520IV%2520Resistant%2520Analogues%2520of%2520Glucagon-like%2520Peptide-1%2520which%2520Have%2520Extended%2520Metabolic%2520Stability%2520and%2520Improved%2520Biological%2520Activity%26jtitle%3DDiabetologia%26date%3D1998%26volume%3D41%26spage%3D271%26epage%3D278%26doi%3D10.1007%2Fs001250050903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gramm, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Once-weekly Glucagon-like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Grammauthor=S.+M.+Knudsenauthor=N.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+Once-weekly+Glucagon-like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0limzPpkN4Kc7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGramm%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DNielsen%26aufirst%3DN.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Once-weekly%2520Glucagon-like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span> <span> </span><span class="NLM_article-title">Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOgt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=390-402&author=J.+Hanauthor=F.+Zhouauthor=Y.+Feiauthor=X.+Chenauthor=J.+Fuauthor=H.+Qian&title=Preparation+and+Pharmaceutical+Characterizations+of+Lipidated+Dimeric+Xenopus+Glucagon-Like+Peptide-1+Conjugates&doi=10.1021%2Facs.bioconjchem.7b00712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates</span></div><div class="casAuthors">Han, Jing; Zhou, Feng; Fei, Yingying; Chen, Xinyu; Fu, Junjie; Qian, Hai</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">390-402</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pair of glucagon-like peptide-1 (GLP-1) analogs (1 and 2) were synthesized by hybridizing the key sequences of GLP-1, exendin-4, lixisenatide, and xenGLP-1B (Xenopus GLP-1 analog).  To achieve long-acting hypoglycemic effects and to further improve their anti-diabetic potencies, lipidization and dimerization strategies were used to afford two lipidated dimeric conjugates (9 and 11).  Conjugates 9 and 11 showed stronger receptor activation potency than GLP-1 and exendin-4 in vitro.  Moreover, 9 and 11 exhibited superior hypoglycemic and insulinotropic activities to liraglutide in type 2 diabetic C57BL/6J-m+/+ Leprdb (db/db) mice.  Pharmacokinetic studies revealed that the circulating half-lives (t1/2) of 9 and 11 were 2.3- and 1.7-fold longer than that of liraglutide.  The improved pharmacokinetic profiles led to significantly protracted in vivo anti-diabetic effects as confirmed by multiple oral glucose tolerance tests and hypoglycemic duration tests.  Most importantly, chronic treatment studies found that once daily administration of 9 or 11 in db/db mice achieved more beneficial effects on HbA1c redn. and glucose tolerance normalization than liraglutide.  Our research demonstrated lipidization and dimerization as useful tools for the development of novel GLP-1 receptor agonists.  The preclin. studies suggested the potential of 9 and 11 to be developed as novel anti-diabetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvdDcZ6PsWCbVg90H21EOLACvtfcHk0limzPpkN4Kc7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgt7nK&md5=da3d8f26e47d8fc635ebc8436f4e76b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00712%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DH.%26atitle%3DPreparation%2520and%2520Pharmaceutical%2520Characterizations%2520of%2520Lipidated%2520Dimeric%2520Xenopus%2520Glucagon-Like%2520Peptide-1%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D390%26epage%3D402%26doi%3D10.1021%2Facs.bioconjchem.7b00712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span> <span> </span><span class="NLM_article-title">Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-acting Conjugates for Type 2 Anti-diabetes Therapeutics</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1021/bc100404x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100404x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2mu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=625-632&author=T.+H.+Kimauthor=H.+H.+Jiangauthor=S.+Leeauthor=Y.+S.+Younauthor=C.+W.+Parkauthor=Y.+Byunauthor=X.+Chenauthor=K.+C.+Lee&title=Mono-PEGylated+Dimeric+Exendin-4+as+High+Receptor+Binding+and+Long-acting+Conjugates+for+Type+2+Anti-diabetes+Therapeutics&doi=10.1021%2Fbc100404x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics</span></div><div class="casAuthors">Kim, Tae Hyung; Jiang, Hai Hua; Lee, Seulki; Youn, Yu Seok; Park, Chan Woong; Byun, Youngro; Chen, Xiaoyuan; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-632</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dimerization is viewed as the most effective means of increasing receptor binding affinity, and both dimerization and PEGylation effectively prolong the life spans of short-lived peptides and proteins in vivo by delaying excretion via the renal route.  Here, we describe the high binding affinities of two long-acting exendin-4 (Ex4) conjugates, dimerized Ex4 (Di-Ex4) and PEGylated Di-Ex-4 (PEG-Di-Ex4).  Di-Ex4 and PEG-Di-Ex4 were prepd. using cysteine and amine residue specific coupling reactions using Ex4-Cys, bisMal-NH2, and activated PEG.  The Ex4 conjugates produced were of high purity (>98.5%), as detd. by size-exclusion chromatog. and MALDI-TOF mass spectrometry.  The receptor binding affinity of Di-Ex4 on RIN-m5F cells was 3.5-fold higher than that of Ex4, and the in vivo antihyperglycemic efficacy of Di-Ex4 was also greater than that of native Ex4 in type 2 diabetic db/db mice.  Furthermore, Di-Ex4 and PEG-Di-Ex4 were found to have greater blood circulating t1/2 and AUCinf values than native Ex4 by 2.7- and 13.7-fold, and by 4.0- and 17.3-fold, resp.  Accordingly, hypoglycemic durations were greatly increased to 15.0 and 40.1 h, resp., at a dose of 25 nmol/kg (native Ex4 7.3 h).  The results of this study show that combined dimerization and PEGylation are effective when applied to Ex4, and suggest that PEG-Di-Ex4 has considerable potential as a type 2 anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWGsCV-iYfBLVg90H21EOLACvtfcHk0lgA6ymSyKC3IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2mu74%253D&md5=5bb66fffeb0ad1ddb42547053adb80c7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fbc100404x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100404x%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BH.%26aulast%3DJiang%26aufirst%3DH.%2BH.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYoun%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DC.%2BW.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DMono-PEGylated%2520Dimeric%2520Exendin-4%2520as%2520High%2520Receptor%2520Binding%2520and%2520Long-acting%2520Conjugates%2520for%2520Type%25202%2520Anti-diabetes%2520Therapeutics%26jtitle%3DBioconjugate%2520Chem.%26date%3D2011%26volume%3D22%26spage%3D625%26epage%3D632%26doi%3D10.1021%2Fbc100404x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfeld, J. F.</span></span> <span> </span><span class="NLM_article-title">Does Sulfation of Gastrin Influence Gastric Acid Secretion in Man</span>. <i>Scand. J. Gastroenterol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.3109/00365529008997601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.3109%2F00365529008997601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=2396089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVGnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1990&pages=739-745&author=P.+Cantorauthor=M.+B.+Petersenauthor=J.+Christiansenauthor=J.+F.+Rehfeld&title=Does+Sulfation+of+Gastrin+Influence+Gastric+Acid+Secretion+in+Man&doi=10.3109%2F00365529008997601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Does sulfation of gastrin influence gastric acid secretion in man?</span></div><div class="casAuthors">Cantor, Per; Petersen, M. Boye; Christiansen, J.; Rehfeld, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">739-45</span>CODEN:
                <span class="NLM_cas:coden">SJGRA4</span>;
        ISSN:<span class="NLM_cas:issn">0036-5521</span>.
    </div><div class="casAbstract">To assess the physiol. significance of tyrosine O-sulfation of gastrin in humans, the gastric acid stimulatory potencies of sulfated and non-sulfated human gastrin-17 were compared in normal young subjects.  Sulfated and non-sulfated forms of synthetic human gastrin-17 were infused i.v. in doses of 12.7-478 pmol/kg/h.  Similar acid secretory responses were obsd.  The calcd. maximal acid response for sulfated gastrin-17 was 35.7 mmol/h, and that for non-sulfated gastrin-17 was 39.8 mmol/h.  The 50% ED of sulfated gastrin-17 was 22.2 pmol/kg/h, whereas it was 29.3 pmol/kg/h for non-sulfated gastrin-17.  Finally, the 50% effective concn. of gastrin in serum was 34.7 pmol sulfated gastrin-17/L and 4.25 pmol non-sulfated gastrin-17/L.  Thus, tyrosine O-sulfation is without influence on the gastric acid secretory potency of gastrin-17 in man.  Moreover, sulfated and non-sulfated gastrin-17 have similar rates of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplezO5aq8fobVg90H21EOLACvtfcHk0lgA6ymSyKC3IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVGnsbk%253D&md5=40d7e5f0e5ce93d074eea82a5d88f7aa</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3109%2F00365529008997601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00365529008997601%26sid%3Dliteratum%253Aachs%26aulast%3DCantor%26aufirst%3DP.%26aulast%3DPetersen%26aufirst%3DM.%2BB.%26aulast%3DChristiansen%26aufirst%3DJ.%26aulast%3DRehfeld%26aufirst%3DJ.%2BF.%26atitle%3DDoes%2520Sulfation%2520of%2520Gastrin%2520Influence%2520Gastric%2520Acid%2520Secretion%2520in%2520Man%26jtitle%3DScand.%2520J.%2520Gastroenterol.%26date%3D1990%26volume%3D25%26spage%3D739%26epage%3D745%26doi%3D10.3109%2F00365529008997601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Dimeric Lipidated Xenopus Glucagon-like Peptide 1 Analogues as Long-acting Antihyperglycaemic Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejmech.2018.07.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=30096651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=177-187&author=J.+Hanauthor=Y.+Huangauthor=X.+Chenauthor=F.+Zhouauthor=Y.+Feiauthor=J.+Fu&title=Rational+Design+of+Dimeric+Lipidated+Xenopus+Glucagon-like+Peptide+1+Analogues+as+Long-acting+Antihyperglycaemic+Agents&doi=10.1016%2Fj.ejmech.2018.07.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycemic agents</span></div><div class="casAuthors">Han, Jing; Huang, Yue; Chen, Xinyu; Zhou, Feng; Fei, Yingying; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dimerization is viewed as an effective means to enhance the binding affinity and therapeutic potency of peptides.  Both dimerization and lipidation effectively prolong the half-life of peptides in vivo by increasing hydrodynamic size and facilitating phys. interactions with serum albumin.  Here, we report a novel method to discover long-acting glucagon-like peptide 1 (GLP-1) analogs by rational design based on Xenopus GLP-1 through a combined dimerization and lipidization strategy.  On the basis of our previous structure anal. of Xenopus GLP-1, palmitic acid and a C-terminal Cys were firstly introduced into two Xenopus GLP-1 analogs (1 and 2), and the afforded 3 and 4 were further reacted with bis-maleimide amine to afford two dimeric lipidated Xenopus GLP-1 analogs (5 and 6).  The in vitro and in vivo biol. activities of 5 and 6 were significantly improved as compared with their monomers.  Moreover, the selected compd. 6 showed greater hypoglycemic and insulinotropic activities than liraglutide even when the dose of 6 was reduced to half in db/db mice.  Pharmacokinetic test revealed that 6 had a ∼ 3-fold longer half-life than liraglutide in Kunming mice and SD rats, and the longer half-life of 6 led to excellent long-acting hypoglycemic effects as confirmed by two different pharmacol. methods conducted on db/db mice.  Finally, a 7 wk chronic study conducted on db/db mice demonstrated the better therapeutic efficacies of 6 on glucose tolerance normalization, HbA1c redn. and pancreas islets protection than liraglutide.  The present research showed that combined dimerization and lipidization is effective when applied to Xenopus GLP-1 analog to develop novel GLP-1 analog for the treatment of type 2 diabetes.  In addn., the promising preclin. data of 6 suggested the therapeutic potential of 6 as a novel anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu69hLGs6cPLVg90H21EOLACvtfcHk0livfITE8PQF_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO&md5=ae25a20f5222a840602f9bece420e690</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.072%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DRational%2520Design%2520of%2520Dimeric%2520Lipidated%2520Xenopus%2520Glucagon-like%2520Peptide%25201%2520Analogues%2520as%2520Long-acting%2520Antihyperglycaemic%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.ejmech.2018.07.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skarbaliene, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigbolt, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosgerau, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billestrup, N.</span></span> <span> </span><span class="NLM_article-title">In-vitro and In-vivo Studies Supporting the Therapeutic Potential of ZP3022 in Diabetes</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>815</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.09.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.ejphar.2017.09.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=28928089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFems73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=815&publication_year=2017&pages=181-189&author=J.+Skarbalieneauthor=K.+T.+Rigboltauthor=K.+Fosgerauauthor=N.+Billestrup&title=In-vitro+and+In-vivo+Studies+Supporting+the+Therapeutic+Potential+of+ZP3022+in+Diabetes&doi=10.1016%2Fj.ejphar.2017.09.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro and in-vivo studies supporting the therapeutic potential of zp3022 in diabetes</span></div><div class="casAuthors">Skarbaliene, Jolanta; Rigbolt, Kristoffer T.; Fosgerau, Keld; Billestrup, Nils</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">815</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GLP-1-gastrin dual agonist ZP3022 has been shown to increase β-cell mass with a concomitant improvement of glycemic control in diabetic mice and rats.  Here we tested the in-vitro effects of ZP3022 on β-cell proliferation, islet apoptosis and glucose-stimulated insulin secretion (GSIS) in rat islets of Langerhans.  Moreover, gene expression profiling in whole pancreas from Zucker Diabetic Fatty (ZDF) rats was performed to characterize genes differently regulated by short-term treatment with ZP3022.  Treatments with exendin-4, gastrin-17 alone or in combination were included in the studies.  ZP3022 promoted β-cell proliferation, protected from palmitate-, but not from cytokine-induced apoptosis, and induced an increase in GSIS, demonstrating a glucose dependent insulinotropic action of ZP3022 on β-cells.  The combination treatment with exendin-4 and gastrin-17 showed comparable effects on proliferation, apoptosis, and GSIS as did ZP3022.  Microarray anal. revealed that ZP3022 exerted specific effects on pancreatic gene expression not obsd. when treating ZDF rats with either exendin-4 alone or in combination with gastrin-17.  In particular MAPK signaling pathway was obsd. among the highest affected pathways; while also pathways related to insulin signaling and secretion were regulated by ZP3022.  Moreover, rats treated with ZP3022 had a higher expression of genes encoding for the specific β-cell/endocrine cell markers, such as islet amyloid polypeptide (IAPP), protein convertase 1/3 and -2 (PC 1/3 and-2), as well as transmembrane protein 27(TMEM27) compared to vehicle treated rats.  We conclude that ZP3022 may have therapeutic potential in the prevention/delay of β cell dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY1L8Xu974X7Vg90H21EOLACvtfcHk0livfITE8PQF_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFems73M&md5=17d4cd2612edc6ef3e6275b4f1c92bbc</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.09.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.09.026%26sid%3Dliteratum%253Aachs%26aulast%3DSkarbaliene%26aufirst%3DJ.%26aulast%3DRigbolt%26aufirst%3DK.%2BT.%26aulast%3DFosgerau%26aufirst%3DK.%26aulast%3DBillestrup%26aufirst%3DN.%26atitle%3DIn-vitro%2520and%2520In-vivo%2520Studies%2520Supporting%2520the%2520Therapeutic%2520Potential%2520of%2520ZP3022%2520in%2520Diabetes%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D815%26spage%3D181%26epage%3D189%26doi%3D10.1016%2Fj.ejphar.2017.09.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span> <span> </span><span class="NLM_article-title">Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-modified Long-acting Exendin-4 Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6889</span>– <span class="NLM_lpage">6896</span>, <span class="refDoi"> DOI: 10.1021/jm901153x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901153x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kjtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6889-6896&author=S.+Sonauthor=S.+Y.+Chaeauthor=C.+W.+Kimauthor=Y.+G.+Choiauthor=S.+Y.+Jungauthor=S.+Leeauthor=K.+C.+Lee&title=Preparation+and+Structural%2C+Biochemical%2C+and+Pharmaceutical+Characterizations+of+Bile+Acid-modified+Long-acting+Exendin-4+Derivatives&doi=10.1021%2Fjm901153x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-Modified Long-Acting Exendin-4 Derivatives</span></div><div class="casAuthors">Son, Sohee; Chae, Su Young; Kim, Chang Wan; Choi, Yang Gyu; Jung, Sung Youb; Lee, Seulki; Lee, Kang Choon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6889-6896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop an effective long-acting antidiabetic, the GLP-1 analog of exendin-4 was modified with three different bile acids (BAs; cholic, deoxycholic, or lithocholic acid), at its two lysine residues.  The biol., pharmaceutical, and physicochem. characteristics of these exendin-4 analogs were carefully investigated.  Biol. activity tests demonstrated that the monobile acid substitutions of exendin-4 showed well preserved receptor binding efficacy without noticeable insulinotropic or antidiabetic activity loss.  However, physicochem. and pharmacokinetic studies revealed that the albumin-binding properties and in vivo elimination half-lives of BAM1-Ex4s (Lys27-BA-Ex4s) were significantly enhanced by increasing the hydrophobicities of the conjugated BAs.  Furthermore, the protracted antidiabetic effects of the BAM1-Ex4s were also verified by the prolonged restoration of normoglycemia in type 2 diabetic mice.  Accordingly, the present study suggests that the derivatization of exendin-4 with BAs offers a means of producing long-acting GLP-1 receptor agonists for type 2 diabetic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8cucxupDebLVg90H21EOLACvtfcHk0livfITE8PQF_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kjtb7M&md5=f3309b520be1159081e59aac471f7edc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm901153x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901153x%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%26aulast%3DChae%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DChoi%26aufirst%3DY.%2BG.%26aulast%3DJung%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BC.%26atitle%3DPreparation%2520and%2520Structural%252C%2520Biochemical%252C%2520and%2520Pharmaceutical%2520Characterizations%2520of%2520Bile%2520Acid-modified%2520Long-acting%2520Exendin-4%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6889%26epage%3D6896%26doi%3D10.1021%2Fjm901153x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trevaskis, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athanacio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samant, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatarkiewicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkers, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. D.</span></span> <span> </span><span class="NLM_article-title">Synergistic Metabolic Benefits of an Exenatide Analogue and Cholecystokinin in Diet-induced Obese and Leptin-deficient Rodents</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/dom.12390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1111%2Fdom.12390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=25204356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVylurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=61-73&author=J.+L.+Trevaskisauthor=C.+Sunauthor=J.+Athanacioauthor=L.+J.+D%E2%80%99Souzaauthor=M.+P.+Samantauthor=K.+Tatarkiewiczauthor=P.+S.+Griffinauthor=C.+Wittmerauthor=Y.+Wangauthor=C.-H.+Tengauthor=B.+Foroodauthor=D.+G.+Parkersauthor=J.+D.+Roth&title=Synergistic+Metabolic+Benefits+of+an+Exenatide+Analogue+and+Cholecystokinin+in+Diet-induced+Obese+and+Leptin-deficient+Rodents&doi=10.1111%2Fdom.12390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents</span></div><div class="casAuthors">Trevaskis, J. L.; Sun, C.; Athanacio, J.; D'Souza, L.; Samant, M.; Tatarkiewicz, K.; Griffin, P. S.; Wittmer, C.; Wang, Y.; Teng, C.-H.; Forood, B.; Parkes, D. G.; Roth, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-73</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To test the impact of cholecystokinin (CCK) plus either amylin or a glucagon-like peptide-1 receptor (GLP-1R) agonist on metabolic variables in diet-induced obese (DIO) rodents.  Methods : A stabilized acetylated version of CCK-8 (Ac-Y*-CCK-8), selective CCK1 receptor (CCK1R) or CCK2 receptor (CCK2R) agonists, amylin or the GLP-1R agonist and exenatide analog AC3174 were administered in select combinations via continuous s.c. infusion to DIO rats for 14 days, or Lepob/Lepob mice for 28 days, and metabolic variables were assessed.  Results : Combined administration of Ac-Y*-CCK-8 with either amylin or AC3174 induced greater than additive wt. loss in DIO rats, with the overall magnitude of effect being greater with AC3174 + Ac-Y*-CCK-8 treatment.  Co-infusion of AC3174 with a specific CCK1R agonist, but not a CCK2R agonist, recapitulated the wt. loss mediated by AC3174 + Ac-Y*-CCK-8 in DIO rats, suggesting that synergy is mediated by CCK1R activation.  In a 4 × 4 full-factorial response surface methodol. study in DIO rats, a synergistic interaction between AC3174 and the CCK1R-selective agonist on body wt. and food intake was noted.  Co-administration of AC3174 and the CCK1R-selective agonist to obese diabetic Lepob/Lepob mice elicited a significantly greater redn. in percentage of glycated Hb and food intake relative to the sum effects of monotherapy groups.  Conclusions : The anti-obesity and antidiabetic potential of combined GLP-1R and CCK1R agonism is an approach that warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ymduZxipoLVg90H21EOLACvtfcHk0lg-queyfuFTvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVylurvI&md5=c5b8717cd0f03a6eceb8c23a16a770e6</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1111%2Fdom.12390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12390%26sid%3Dliteratum%253Aachs%26aulast%3DTrevaskis%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAthanacio%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DL.%2BJ.%26aulast%3DSamant%26aufirst%3DM.%2BP.%26aulast%3DTatarkiewicz%26aufirst%3DK.%26aulast%3DGriffin%26aufirst%3DP.%2BS.%26aulast%3DWittmer%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTeng%26aufirst%3DC.-H.%26aulast%3DForood%26aufirst%3DB.%26aulast%3DParkers%26aufirst%3DD.%2BG.%26aulast%3DRoth%26aufirst%3DJ.%2BD.%26atitle%3DSynergistic%2520Metabolic%2520Benefits%2520of%2520an%2520Exenatide%2520Analogue%2520and%2520Cholecystokinin%2520in%2520Diet-induced%2520Obese%2520and%2520Leptin-deficient%2520Rodents%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2015%26volume%3D17%26spage%3D61%26epage%3D73%26doi%3D10.1111%2Fdom.12390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Long-lasting GLP-1/anti-GLP-1R Antibody Fusion Protein, Exerts Anti-diabetic Effects Through Targeting Dual Receptor Binding Sites</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.01.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1016%2Fj.bcp.2018.01.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=29355505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVentr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=46-53&author=C.+Liauthor=M.+Yangauthor=X.+Wangauthor=H.+Zhangauthor=C.+Yaoauthor=S.+Sunauthor=Q.+Liuauthor=H.+Panauthor=S.+Liuauthor=Y.+Huanauthor=S.+Liauthor=J.+Caoauthor=X.+Wangauthor=Y.+Guoauthor=N.+Guoauthor=S.+Jingauthor=C.+Zhangauthor=S.+Shen&title=A+Novel+Long-lasting+GLP-1%2Fanti-GLP-1R+Antibody+Fusion+Protein%2C+Exerts+Anti-diabetic+Effects+Through+Targeting+Dual+Receptor+Binding+Sites&doi=10.1016%2Fj.bcp.2018.01.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites</span></div><div class="casAuthors">Li, Caina; Yang, Miaomiao; Wang, Xiaofeng; Zhang, Hua; Yao, Chenjiang; Sun, Sujuan; Liu, Quan; Pan, Hao; Liu, Shuainan; Huan, Yi; Li, Shengnan; Cao, Jun; Wang, Xing; Guo, Yong; Guo, Nan; Jing, Shuqian; Zhang, Cheng; Shen, Zhufang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-53</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glucagon like-peptide-1 (GLP-1)-based drugs have been proposed as mono- or combined therapy for type 2 diabetes mellitus.  Thus we characterized a novel antibody fusion protein engineered by linking the human GLP-1 deriv. to a humanized GLP-1 receptor (GLP-1R) antibody via a peptide linker.  Glutazumab was characterized by receptor binding and reporter activation assays, and its specificity was investigated with the aid of the cognate receptor antagonist exendin (9-39) and antibody Ab1.  Pharmacokinetics was evaluated in Sprague-Dawley (SD) rats and cynomolgus monkeys, and pharmacodynamics was assessed in normal ICR and spontaneous type 2 diabetic KKAy mice.  Hypoglycemic effects were evaluated after acute administration and glucose metab. and β-cell function were assessed with repeated administrations.  Dulaglutide was a pos. control in all expts.  Glutazumab significantly bound and activated GLP-1R, but the receptor antagonist exendin (9-39) did not inhibit the activation except when combined with Ab1.  Single injection of glutazumab reduced the blood glucose in ICR mice and KKAy mice, and the half-lives in SD rats and cynomolgus monkeys were 18 h and 33.6 h.  Repeated injections of glutazumab controlled glycemic fluctuations and improved β-cell function in KKAy mice.  As a novel GLP-1R agonist, glutazumab may be a potential treatment for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKpJTySrEuQLVg90H21EOLACvtfcHk0lg-queyfuFTvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVentr0%253D&md5=539f06ff9f27edc190fb2c7981b16675</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.01.029%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DHuan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DJing%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Long-lasting%2520GLP-1%252Fanti-GLP-1R%2520Antibody%2520Fusion%2520Protein%252C%2520Exerts%2520Anti-diabetic%2520Effects%2520Through%2520Targeting%2520Dual%2520Receptor%2520Binding%2520Sites%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D150%26spage%3D46%26epage%3D53%26doi%3D10.1016%2Fj.bcp.2018.01.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baggio, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">An Albumin-exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2008.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=10.1053%2Fj.gastro.2008.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=18313669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2008&pages=1137-1147&author=L.+L.+Baggioauthor=Q.+Huangauthor=X.+Caoauthor=D.+J.+Drucker&title=An+Albumin-exendin-4+Conjugate+Engages+Central+and+Peripheral+Circuits+Regulating+Murine+Energy+and+Glucose+Homeostasis&doi=10.1053%2Fj.gastro.2008.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis</span></div><div class="casAuthors">Baggio, Laurie L.; Huang, Qingling; Cao, Xiemin; Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1137-1147</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background & Aims: Glucagon-like peptide-1 (GLP-1) regulates glucose homeostasis through multiple mechanisms including direct actions on the endocrine pancreas and indirect activation of central nervous system circuits regulating gastric emptying, satiety, and body wt.  Because native GLP-1 is rapidly degraded, there is considerable interest in development of more potent GLP-1 receptor (GLP-1R) agonists with sustained activity; however, the extent to which much larger GLP-1R agonists will mimic some or all of the actions of smaller peptides remains uncertain.  Methods: We studied the actions of CJC-1134-PC, a recombinant human serum albumin-exendin-4 conjugated protein, at the GLP-1 R using heterologous cells expressing the GLP-1R in vitro and both wild-type and Glp1r-/- mice in vivo.  Results: CJC-1134-PC activated GLP-1R-dependent signaling in baby hamster kidney-GLP-1R cells and acutely lowered blood glucose in wild-type but not in Glp1r-/- mice.  Moreover, acute administration of CJC-1134-PC rapidly activated c-Fos expression in multiple regions of the central nervous system, acutely inhibited gastric emptying, and produced sustained inhibition of food intake in a GLP-1R-dependent manner.  Furthermore, chronic daily treatment of high-fat diet-fed wild-type mice with CJC-1134-PC for 4 wk led to improved glucose tolerance, increased levels of glucose-stimulated insulin, decreased HbA1c, and wt. loss assocd. with decreased hepatic triglyceride content.  Conclusions: These findings illustrate that a high-mol.-wt. exendin-4-albumin conjugate retains the ability to mimic a full spectrum of GLP-1R-dependent actions, including activation of central nervous system circuits regulating gastric emptying, food intake, and body wt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxypVQ2EIAS7Vg90H21EOLACvtfcHk0lh3RxYCSkgTeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1Gls7s%253D&md5=2fb7202fa81db14fe2e83a7baca618e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2008.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2008.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DBaggio%26aufirst%3DL.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DAn%2520Albumin-exendin-4%2520Conjugate%2520Engages%2520Central%2520and%2520Peripheral%2520Circuits%2520Regulating%2520Murine%2520Energy%2520and%2520Glucose%2520Homeostasis%26jtitle%3DGastroenterology%26date%3D2008%26volume%3D134%26spage%3D1137%26epage%3D1147%26doi%3D10.1053%2Fj.gastro.2008.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span> <span> </span><span class="NLM_article-title">Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2840</span>– <span class="NLM_lpage">2856</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSktb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=2840-2856&author=J.+Hanauthor=X.+Chenauthor=L.+Zhaoauthor=J.+Fuauthor=L.+Sunauthor=Y.+Zhangauthor=F.+Zhouauthor=Y.+Fei&title=Lithocholic+Acid-Based+Peptide+Delivery+System+for+an+Enhanced+Pharmacological+and+Pharmacokinetic+Profile+of+Xenopus+GLP-1+Analogs&doi=10.1021%2Facs.molpharmaceut.8b00336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs</span></div><div class="casAuthors">Han, Jing; Chen, Xinyu; Zhao, Liming; Fu, Junjie; Sun, Lidan; Zhang, Ying; Zhou, Feng; Fei, Yingying</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2840-2856</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GLP-1 analogs suffer from the main disadvantage of a short in vivo half-life.  Lithocholic acid (LCA), one of the four main bile acids in the human body, possesses a high albumin binding rate.  We therefore envisioned that a LCA-based peptide delivery system could extend the half-life of GLP-1 analogs by facilitating the noncovalent binding of peptides to human serum albumin.  On the basis of our previously identified Xenopus GLP-1 analogs (1-3), a series of LCA-modified Xenopus GLP-1 conjugates were designed (4a-4r), and the bioactivity studies of these conjugates were performed to identify compds. with balanced in vitro receptor activation potency and plasma stability.  4C, 4i, and 4r were selected, and their LCA side chains were optimized to further increase their stability, affording 5a-5c.  Compd. 5b showed a more increased albumin affinity and prolonged in vitro stability than that of 4i and liraglutide.  In db/db mice, 5b exhibited comparable hypoglycemic and insulinotropic activity to liraglutide and semaglutide.  Importantly, the enhanced albumin affinity of 5b resulted in a prolonged in vivo antidiabetic duration.  Finally, chronic treatment investigations of 5b demonstrated the therapeutic effects of 5b on HbA1c, body wt., blood glucose, and pancreatic endocrine deficiencies on db/db mice.  Our studies revealed 5b as a promising antidiabetic candidate.  Furthermore, our study suggests the derivatization of Xenopus GLP-1 analogs with LCA represents an effective strategy to develop potent long-acting GLP-1 receptor agonists for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg7cAD-Es-7Vg90H21EOLACvtfcHk0lh3RxYCSkgTeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSktb3F&md5=668ebb515707233f7fcc67ca1aee47aa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00336%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26atitle%3DLithocholic%2520Acid-Based%2520Peptide%2520Delivery%2520System%2520for%2520an%2520Enhanced%2520Pharmacological%2520and%2520Pharmacokinetic%2520Profile%2520of%2520Xenopus%2520GLP-1%2520Analogs%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D2840%26epage%3D2856%26doi%3D10.1021%2Facs.molpharmaceut.8b00336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00736">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47720"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00736?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00736</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data and characterizations of <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, <b>4a</b>–<b>4x</b>, <b>5a</b>–<b>5d</b>, <b>6a</b>–<b>6d</b>, <b>7a</b>, and <b>7b</b>; dose–response curves of <b>1</b>, <b>2</b>, <b>3</b>, <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, and <b>4a</b>–<b>4x</b> on GLP-1R; albumin binding capacities of liraglutide, semaglutide, <b>4c</b>, <b>4d</b>, <b>4m</b>, <b>4n</b>, <b>4u</b>, and <b>4x</b>; general synthetic route of <b>5c</b> and <b>5d</b>; dose–response curves of <b>2</b>, Leu<sub>15</sub>-gastrin-17, ZP3022, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> on GLP-1R and CCK-2R; PK profiles of ZP3022, <b>6a</b>, and <b>6b</b> in ICR mice; PK profiles of <b>7a</b> and <b>7b</b> in SD rats; and docking studies of <b>6a′</b> and <b>6b′</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1a</b>–<b>1m</b>, <b>2a</b>–<b>2m</b>, <b>3a</b>–<b>3m</b>, <b>4a</b>–<b>4x</b>, <b>5a</b>–<b>5d</b>, and <b>6a</b>–<b>6d</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_001.pdf">jm0c00736_si_001.pdf (5.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00736/suppl_file/jm0c00736_si_002.csv">jm0c00736_si_002.csv (58.1 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00736&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00736%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00736" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679991715e57d1b3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
